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Abstract
Placental expression of matrix metalloproteinases MMP-2 and MMP-9 in
pregnancy:
The use of villous explants and high altitude pregnancy studies to explore the 
role of oxygen in the pathogenesis of pre-eclampsia.
Successful placental development is essential for the normal progression of 
pregnancy. Pre-eclampsia is a leading complication o f human pregnancy. The 
condition is characterised by a lack o f remodelling of the maternal spiral arteries, 
thought to result from a failure of cytotrophoblast (CTB) invasion during the early 
stages o f pregnancy. The subsequent reduced placental perfusion may cause relative 
placental hypoxia and lead to endothelial activation in the maternal circulation 
through the action of several factors including placental debris. In order to understand 
this condition it is necessary to establish the mechanisms which control normal 
placentation. Studies on placentae as well as in vitro models have proved useful in 
helping to understand these processes.
The matrix metalloproteinases MMP-2 and MMP-9 have been implicated in 
trophoblast invasion in several studies but the in vivo expression patterns of these 
proteins and their inhibitors (tissue inhibitors o f matrix metalloproteinases - TIMPs) 
and regulators o f their transcription (including the transcription factor H IF -la ) are 
unclear. The first aim o f this study was to investigate levels o f MMP-2, MMP-9, 
TIMP-1, TIMP-2 and H IF -la  in placentae throughout pregnancy using various 
techniques.
The study used immunohistochemistiy to detect and quantify MMP-2 and 
MMP-9 expression in placentae from 7-19 and at 40 weeks of gestation, A reduction 
was found in extra villous trophoblast (EVT) expression o f both MMPs as pregnancy 
progressed. In contrast endothelial expression of both MMPs increased. MMP-2 
expression in villous CTB (vCTB) was highest in early pregnancy but decreased with 
gestation, MMP-9 expression in vCTB. ,was.yery low throughout pregnancy.
Zymograpliy studies revealed a significant decrease in pro-MMP-2 but not 
pro-MMP-9 activity through gestation although the latter did decrease during the first 
trimester.
The results of the study suggest a role for MMP-2 and MMP-9 not only in 
early placental development but also in vascular remodelling in the later stages of 
gestation. Moreover it also suggests that the role of MMP-2, often regarded as less 
important than MMP-9 in plaeental development, warrants further study.
Immunohistochemical studies on the same placentae showed that TIMP-1 
expression in muscle suiTounding the villous endothelium and in the villous stroma 
increased with gestation while vCTB expression did not alter and EVT expression 
increased during the second trimester. TIMP-2 staining in vCTB decreased with 
gestation while staining on endothelium, muscle and stroma increased. EVT 
expression of TIMP-2 was negatively correlated with gestation. Thus TIMP-2 
appeared to have a high degree o f co-distribution with MMP-2 both spatially and 
temporally. H IF -la  staining on vCTB and EVT decreased with gestation while 
expression on the endothelium increased.
These results suggest both paracrine and autocrine regulation o f MMPs may 
occur early in pregnancy. Furthermore TIMPs and H IF -la  may have a role in 
regulating the processes in which MMPs are involved in later on in pregnancy.
Pregnant women living at high altitude are exposed to chronic hypoxia 
throughout gestation. It has been reported that high altitude pregnancies show 
physiology intermediate between normal pregnancy and pre-eclampsia and thus may 
provide a useful in vivo model of the disease. This study compared MMP-9 and 
MMP-2 expression in placentae from high, moderate and low altitude. Endothelial 
expression of MMP-9 was lower at high altitude than low altitude while MMP-9 
expression in the villous stroma was higher. This may implicate MMP-9 in adaptive 
responses to hypoxia and villous remodelling in high altitude placentae. There were 
no differences in MMP-2 expression between high and low altitude placentae 
supporting previous studies, which have reported that MMP-2 expression may not be 
subject to regulation by oxygen.
Maternal semm markers o f endothelial cell aetivation were measured 
throughout pregnancy at high and moderate altitude. It was hypothesised that since
circulating VCAM-1 and E-Selectin are increased in pre-eclampsia, they might also 
be elevated in high altitude pregnancy. This hypothesis was not supported and another 
marker o f endothelial activation, ICAM-1, was not found to be increased either. On 
the contrary, levels of VCAM-1 showed an overall tendency to be lower at high 
altitude than at moderate altitude. Thus while some aspects o f high altitude pregnancy 
may be suitable for modelling pre-eclampsia, clearly this is not reflected in 
endothelial cell activation. High altitude pregnancy is useful for determining which 
aspects o f pre-eclampsia may result from hypoxia alone and which are due to more 
complex factors.
Explant studies provide a model to study aspects o f trophoblast invasion 
including MMP secretion. Therefore we set up and validated a model to allow 
examination o f MMP expression during trophoblast invasion at different oxygen 
tensions. A semi-quantitative evaluation o f trophoblast proliferation and invasion at 
different oxygen tensions was carried out. Explants o f human villous tissue (6-9 
weeks o f gestation) cultured on matrigel in both standard culture conditions (18% O2) 
and in a low oxygen environment (2% O2) produced regions of outgrowth of 
cytotrophoblast cells from villous tips and migration o f cells into the matrigel. The 
number o f sites o f outgrowth and migration, area o f outgrowth and extent o f 
migration of cells into the matrigel tended to increase throughout the culture period 
but varied between explants from the same placenta and those from different 
placentae. There were no significant differences in the number o f sites o f outgrowth 
or migration scores in explants cultured in a low oxygen environment compared to 
those cultured in standard conditions. This study highlights the importance o f careful 
validation, design and interpretation o f experiments using in vitro culture systems, 
particularly those investigating the regulatory role o f oxygen.
Understanding normal placentation and developing adequate models for failed 
pregnancy may provide a key to elucidating the fundamental principles o f conditions 
such as pre-eclampsia. This may ultimately lead to improved therapeutic 
interventions.
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Chapter 1: Introduction
' Ai
1.1 The Placenta
1.1.1 The term placenta
The placenta is a unique organ that forms the connection between the mother and 
fetus during pregnancy. The placenta has two main roles -  the physical attachment of 
the embryo to the uterus, and the bringing o f the fetal and maternal circulations into 
close proximity, allowing exchange o f gases, nutrients and waste.
The full term human placenta is a circular disc-like organ of, on average, 
22cm in diameter and 2.5cm thick, weighing around 470g. The umbilical cord 
implants slightly off-centre on the fetal (chorionic) side (figure la). The chorionic 
plate is covered with the avascular glossy amnion, a protective membrane. The 
vessels that can be seen on the surface of this plate are the chorionic vessels. These 
are continuous with those o f the umbilical cord and branch repeatedly. The maternal 
portion of the placenta is called the basal plate (figure lb) and the top layer o f this 
surface adheres to the placenta after separation from the uterus. It consists of 
endometrial and trophoblast cells and fibrinoid (Kaufmann, 1971). The basal surface 
is separated into a series of lobes or placentones, which roughly mark the underlying 
villous trees. The placental bed consists o f endometrial tissue and trophoblast cells 
(Robertson and Warner, 1974).
Fetal growth and development is dependent on successful placentation, a 
process which begins almost immediately after fertilisation and continues throughout 
pregnancy. Many of the vital stages in the development o f the placenta occur in the 
early weeks o f gestation.
1.1.2 Early development of the blastocyst
After fertilization has occurred the nuclei of the ovum and the spei*m combine to form 
a zygote, which is subsequently transported through the fallopian tube to the cavity of 
the uterus, a process taking 3-4 days. The zygote undergoes rapid mitotic division to 
form a ball o f cells called a momla, which develops into a blastocyst soon after entry 
into the uterus. The blastocyst consists o f a fluid filled cavity surrounded by a single 
layer of trophoblast cells (figure 2). At one end o f the blastocyst there lies a cell mass 
that is the precursor o f the embiyo, while the cytotrophoblast (CTB) layer is the
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precursor of the placenta and the membranes sun'ounding the embryo (Boyd and 
Hamilton, 1970; Benirscloke and Kaufmann, 2000; Barnea et al. 1992).
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Figure la The terni placenta -  chorionic plate
Umbilical Cord
Chorionic Vessels
Figure lb The term placenta -  basal plate
Lobes (Placentones)
rdJmbilical Cord
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Reprinted with permission, DSM Path Works, Inc (1998).
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Figure 2 Blastocyst structure
Inner Cell Mass (Embryoblast)
Blastocyst Cavity
O uter Cell Mass (Trophoblast)
Modified from Sadler TW, Langman’s Medical Embryology, 5th edition, Williams & 
Wilkins, 1985, with permission.
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1.1.3 Implantation of the blastocyst
For the successful continuation o f pregnancy, implantation of the blastocyst into the 
uterine wall must occur. Implantation can be divided into several stages. Firstly the 
blastocyst must attach itself to the epithelial surface o f the utems, this can be further 
divided into an apposition stage and an adhesion stage (Schlafke and Enders, 1975). 
The penetration o f the uterine luminal epithelium then occurs as trophoblast 
extensions penetrate between uterine epithelial cells by a mechanism called intrusion 
penetration (Schlafke and Enders, 1975). By day 6-7 the embiyo is completely 
embedded in the uterus and uterine epithelial cells grow over the implantation site 
(Hertig et al. 1956).
1.1.4 Early development o f the placenta
As implantation proceeds, the trophoblast cell layer sun*ounding the blastocyst 
differentiates into two layers, the proliferating inner villous cytotrophoblast (vCTB) 
and the non-dividing outer layer called the syncytiotrophoblast (STB). vCTB cells are 
the precursor cells that differentiate into the STB layer (Carter, 1964). By day 8 post 
conception, a series o f fluid filled spaces known as lacunae begin to develop within 
the STB mass (figure 3). These lacunae are the early intervillous space. Cords o f CTB 
that surround the spaces start to penetrate into the lacunae. Side branches of these 
finger-like projections appear by day 13 (Kingdom et al. 2000).
During this early stage o f placental formation, some trophoblasts migrate into 
the endometrial stroma, between the uterine glands and around the uterine spiral 
arteries (Pijnenborg, 1990). Initially maternal blood escaping from the spiral arteries 
passes into the lacunae (figure 4) before the mouths of the spiral arteries become 
blocked with trophoblast plugs. These prevent maternal blood from entering the 
lacunae or intervillous space for the first 10 weeks of pregnancy (Schaaps and Hustin, 
1988; Hustin et al. 1988).
As a result o f the prevention o f blood flow into the lacunae, the oxygen 
concentration in the intervillous space remains relatively low (Rodesch et al. 1992) 
until the trophoblast plugs are loosened allowing blood to flow freely. W hen there is 
no blood flow in the intervillous space the placenta and fetus consequentially 
experience no oxidative stress. As the plugs dissolve oxygen tension increases and
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hence oxidative stress increase, as does the production o f protective anti-oxidant 
enzymes by the placenta (Jaffe et al. 1997; Burton et al. 1999). During the low oxygen 
period, nutrients necessary for fetal development are obtained from glandular 
secretions and plasma filtrate in the inteiwillous space. Important changes also occur 
in the endometrial lining o f the uterus during these early stages o f pregnancy, 
including cellular growth and accumulation of glycogen in a process termed 
decidualisation (reviewed in Dunn et al. 2003).
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Figure 3 Differentiation of trophoblasts and formation of lacunae
Uterine Epithelial Cells growing over implanted blastocyst
llnner Cell Mass (Embryoblast)
‘ :*v^;.^'(^^^lastocyst Cavity
Lacunae
vCTB 
Syncytiotrophoblast
aternal Blood Vessels
Endometrial Stroma
Modified from Sadler TW, Langman’s Medical Embryology, 5th edition, Williams & 
Wilkins, 1985, with permission.
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Figure 4 Blood flow into lacunae
Blastocyst Cavity
Lacunae 
(Blood Filled)
Endometrial Stroma
vCTB
Syncytiotrophoblast
Maternal Blood Vessels
Modified from Sadler TW, Langman’s Medical Embryology, 5th edition, Williams & 
Wilkins, 1985, with permission.
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1.2 Development of the placenta and the utero-placental circulation
1.2.1 Villous structure and development
As placentation continues, the cords o f trophoblasts (trabeculae) that had begun to 
penetrate the lacunae become increasingly branched as the trophoblasts proliferate. 
The lacunae are the precursors o f the intervillous space, the site o f exchange between 
maternal and fetal circulations, and the trabeculae are the precursors o f the chorionic 
villi. At this early stage they are known as primary villi. The primary villi become 
secondary villi as extraembiyonic mesoderm fi'om the primaiy chorionic plate invades 
the trabeculae. The villous core is known as the stroma and is composed of a loose 
network o f fibroblast cells with Hofbauer cells (fetal macrophages) dispersed 
throughout (Kaufmann et al. 1977). At day 19 o f development fetal capillaries begin 
to develop within the villi by the differentiation o f hemangioblastic progenitor cells 
(Demir et al. 1989). This ti'ansfomis the secondary villi into tertiary villi. During the 
second and third trimesters tertiary villi are predominant and branches o f the villi 
continue to form until tenn (Moore and Persaud, 1998). In early pregnancy, the vCTB 
form a continual layer below the STB surrounding the villi whereas at term very few 
vCTB are observed. Thus at term only the syncytial layer separates the endothelium 
o f the villous capillaries from the maternal circulation.
As villi develop throughout the placenta a complex network called the villous 
tree, is established (figure 5) allowing the growing fetus to be supported by the 
maternal circulation. The placenta contains 60-70 main stem villi each o f which is at 
the centre o f a villous tree. These main stem villi subdivide into 2-5 branches, which 
further subdivide (Page, 1993). Final stem villi are 80-100 pm in diameter, have a 
single arteriole and venule and contain up to ten capillaries. The area o f exchange of 
the villi is about 14m^ by term and the capillaries within the villi have a length of 
50km (Martal and Cedard, 1993).
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Figure 5 Development of the villous tree
Vitrine t'esseU Ulerine glatuis
Sj/ncj/lioirophoblast 
-  Ct/UHrvphablaat
yîenoderm InlerviUmut space
a) Primary chorionic villi
Reprinted with permission Bartleby.com, Inc.
Ulerine veeselsUterine glande
Syncytiol
Cyiotrophoblasl
Care of mesoderm with fetal vesseU
Mesoderm Intervillous space
b) Secondary chorionic villi
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1.2.2 Trophoblast invasion
Two types o f villi are present in the placenta, known as floating and anchoring villi, 
Floating villi are not connected to the maternal uterus and float freely in the 
intervillous space allowing exchange between maternal and fetal circulations to occur. 
Anchoring villi attach the placenta to the uterus. Cell columns form at the tips of these 
villi where CTB cells proliferate and then break through the syncytium and invade the 
uterus and its spiral arteries. These migratory invasive cells are extra-villous CTB 
(EVT). Their invasion is one o f the most important processes in placentation. EVT 
that migrate into the spiral arteries cause an important physiological change in these 
vessels - the loss o f the endothelial and muscular layer (Brosens et al. 1967; DeW olf 
et al. 1973; Sheppard and Bonnar, 1974), the endothelial layer being restored later in 
pregnancy. As a result, the blood flow through the spiral arteries changes from a low 
flow-high resistance to a high flow-low resistance circuit, allowing the needs o f the 
growing fetus to be met. Maternal vasomotor control over the intervillous circulation 
is also lost through the loss o f contractility o f the vessels (Moll et al. 1988).
Invasion by metastatic tumour cells has been defined as “the disruption of 
extracellular matrix boundaries (ECM, basement membrane, interstitial stroma), 
followed by mixing o f the tumour cells with cell types o f a different origin to those in 
the primary tumour" (Liotta and Rao, 1986). This definition is also appropriate in 
describing trophoblast invasion o f the uterus (figure 6).
Although some invasion o f trophoblasts into the spiral arteries is observed 
very early in gestation as described previously (section 1.1.4), the principal wave of 
trophoblast invasion does not occur until several weeks later. Two pathways of 
invasion have been described, the interstitial and the endovascular (Pijnenborg et al. 
1980; Pijnenborg et al. 1981a; Pijnenborg et al. 1981b; Pijnenborg et al. 1983; 
Pijnenborg, 1990; Pijnenborg et al. 1996; Benirschke and Kaufmann, 2000). In the 
interstitial pathway the cells invade the placental bed to the endometrium and the first 
third o f the myometrium. In the endovascular pathway, EVT also invade the lumen of 
arteries and the distal parts of some veins. In vitro studies have never been able to 
differentiate between the two cell populations (Lyall and Kaufmann, 2000).
There is some debate regarding the origin of endovascular trophoblast and 
about the “two wave theory” -  the concept that endovascular invasion occurs in two 
waves, the first at 8-10 weeks and the second at 16-18 weeks (Pijnenborg et al. 1980).
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In this model, the first wave of invasion is into the decidual segments o f spiral arteries 
and the second wave extends into the myométrial segments.
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Figure 6 (b) The utero-placental circulation
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1.2.3 Mechanisms of control of trophoblast invasion
1.2.3.1 Control of invading trophoblast
The invasive phenotype acquired by the migrating EVT clearly requires dramatic 
molecular changes in the cells. Immunohistochemical studies on placental bed 
biopsies from trimester placentae which contain both basal plate decidua and parts 
o f the underlying myometrium and its spiral arteries, in conjunction with in vitro 
studies have suggested that changes in various factors may be involved. These factors 
include cell adhesion molecules (CAMs), Matrix Metalloproteinases (MMPs) and 
their inhibitors Tissue Inhibitors of Metalloproteinases (TIMPs), nitric oxide (NO), 
the carbon monoxide (CO)/hemeoxygenase (HO) pathway, transforming growth 
factor-ps (TGF-Ps) and Human leukocyte antigen-G (HLA-G). In addition, it is 
thought that oxygen may have a regulatory role. Some of these factors are outlined 
below while MMPs and TIMPs are discussed separately in section 1.4 and oxygen 
tension is considered in section 1.5.
It is thought that trophoblast invasion is compromised in pre-eclampsia 
(section 1.7). Much remains unknown about both normal and abnormal trophoblast 
invasion but it is likely that some o f the regulators o f invasion discussed below are 
aberrant in pre-eclampsia (section 1.7).
1.2.3.2 Cell adhesion molecules
Cell adhesion molecules (CAMs) are expressed on the surface o f invading CTB, and 
their ligands, and regulate the adhesion o f cells to each other and to other cell types. 
They are involved in interactions with the extracellular matrix (ECM) and thus may 
be important in controlling invasion. There are four major families o f CAMs -  the 
immunoglobulin superfamily, integrins, selectins and cadherins, each with differing 
functions in cell adhesion. All highly invasive cells have alterations in CAM 
expression (Alexander and Werb, 1989) thus it is not surprising that for invasive CTB 
this also seems to occur.
Integrins bind to ECM proteins e.g. collagen, laminin and fibronectin. 
Villous trophoblasts express integrins found on many polarized epithelial cells,
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previous reports.
1.2.3.3 Transforming growth factor-ps
Transforming Growth Factor-ps (TGF-ps) are part o f a large family o f cytokines that 
comprises three related 25 kilodalton (kDa) proteins TG F-pl, TGF-p2, and TGF-p3. 
Several studies have suggested that decidual production o f TBF-ps may act as a 
negative regulator o f trophoblast invasion (Lala and Hamilton, 1996; Caniggia et al.
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primarily a6/p4, and to a lesser extent a 3 /p i (Korhonen et al. 1991; Damsky et al.
1992; Bun'ows et al. 1993; Aplin, 1993; Damsky et al. 1994). The basement 
membrane to which the CTB are attached in the first trimester expresses collagen, 
laminins and heparin sulphate (Ohno et al. 1986; Levio et al. 1989; Rukosuev, 1992; | |
Tryggvason, 1993; Castellucci et al. 1993; Church et al. 1998) but only weakly 
expresses fibronectin and collagen IV (Damsky et al. 1992). When trophoblasts in cell 
columns are studied there appears to be a gradual modulation of adhesion molecules 
as distance from the villi increases. a6/p4 staining remains strong on CTB close to the 
villi, although a3  is no longer detectable (Damsky et al. 1992). CTB furthest from the 
villi increase the production o f a 5 /p i subunits o f the fibronectin receptor while a6/p4 
expression deceases to very low levels (Damsky et al. 1992; Aplin, 1993). Single 
CTB or cell clusters within the placental bed have been shown to express a l / p i  and I
a 5 /p i integrins (Damsky et al. 1992). During the differentiation o f CTB into EVT, 
changes in the distribution o f laminin and fibronectin isoforms have also been noted 
(Levio et al. 1989; Castellucci et al. 1993; Frank et al. 1994; Korhonen et al. 1997;
Church et al. 1998). Several in vitro studies have shown similar findings (Yagel et al.
1989; Librach et al. 1991; Damsky et al. 1994; Librach et al. 1994; Irving et al. 1995; ;f
Vicovac et al. 1996; Zhou et al. 1997a). Some studies have suggested that as CTB 
invade spiral arteries, they undergo a switch in adhesion molecules to mimic the 
endothelial cells they are replacing (Zhou et al. 1997a; Damsky and Fisher, 1998).
However these studies failed to take into account the fact that spiral arteries are re- 
endothelialised in the third trimester (DeW olf et al. 1973; Khong et al. 1992) and that ythe vessel lumen is not replaced with a lining of CTB. Lyall et al. (2001b) reported no 1
I
expression of PECAM-1, an endothelial CAM, on EVT in either normal or abnoimal
pregnancy at any stage o f gestation illustrating that care must be taken in interpreting ig
1999). It was reported that TGF-(33 expression in the placenta was low until seven 
weeks o f gestation, rose during the following two weeks then fell dramatically at nine 
weeks o f gestation, thus corresponding with the proposed first wave o f invasion. 
Furthermore the same study reported overexpression o f TGF-P3 in pre-eclamptic 
pregnancies during the third trimester. Another study reported TGF-(32 but not TGF- 
p3 expression in the placenta and placental bed (Simpson et al. 2002). The data may 
be inconsistent due to use o f different antibodies, and methods of reporting placental 
age must also be taken into consideration. There is some evidence that TGF-^s can 
regulate trophoblast invasion in vitro although the data is again inconsistent (Graham 
et al. 1992; Bass et al. 1994; Caniggia et al. 1998) Lyall et al. (2001a) found no 
difference in expression o f any o f the TGF-Ps in the complications o f pregnancy pre­
eclampsia or intra-uterine growth restriction (lUGR) compared to noitnal pregnancy 
suggesting that they may not have a pathological role in either o f these conditions.
1.2.3.4 Nitric Oxide Synthase pathway
The production o f endothelial nitric oxide synthase (eNOS) by human placental 
syncytiotrophoblast and villous endothelial cells and studies in guinea pig led to the 
speculation that nitric oxide expression by CTB may be partly responsible for dilation 
of the spiral arteries during human placentation (Nanaev et al. 1995). Studies by Lyall 
et al. (1999b), however, showed that invasive CTB did not express eNOS or inducible 
nitrous oxide Synthase (iNOS) and suggested that CTB-derived nitric oxide was not 
responsible for dilation o f spiral arteries. Furthermore no differences were obseiwed 
between normal pregnancy and cases o f pre-eclampsia and lUGR where trophoblast 
invasion was compromised.
1.2.3.5 Carbon Monoxide/Hemeoxygenase pathway
Carbon Monoxide (CO) is produced by the enzyme hemeoxygenase (HO) which 
exists in two forms; HO-1 (inducible) and HO-2 (constitutive). The similarities 
between the effects o f NO and CO led to speculation that CO may contribute to spiral 
artery dilation during placentation. Significant differences were found in HO-2 
immunostaining between 2"^ and 3'^ trimester placenta on villous trophoblast and
48
endothelium (Lyall et al. 2000a). In placental and placental bed biopsies from 
pregnancies complicated by pre-eclampsia endothelial HO-2 expression was 
significantly reduced, perhaps contributing to the reduced blood flow seen in this 
condition. Within the placental bed all EVT were positive for HO-2 and no 
differences were seen in pre-eclampsia (Lyall et al. 2000). It is thus possible that the 
expression o f HO-2 and hence production o f CO contributes to spiral artery dilation.
1.2.3.6 Human leucocyte antigen-G (HLA-G)
HLA-G is a class IB major histocompatability antigen expressed by EVT that may 
protect cells from natural killer cell lysis (Chumbly et al. 1994). It is upregulated in 
culture as cells invade and is only expressed in vivo on cells which invade the decidua 
(McMaster et al. 1995). It has also been suggested that HLA-G expression enables 
trophoblasts to evade damage by interleukin-2 which is a cytotoxic cytokine found in 
decidual tissue (Hamai et al. 1999). Other HLA’s may have specific interactions with 
uterine natural killer cells and much current research is focussed in this area. The 
subject is reviewed in King et al. (2000b) and Moffett and Loke (2004).
1.2.4 Spatial and temporal regulation of trophoblast invasion
Ensuring that invasion occurs at the right stage o f gestation and the limiting o f 
invasion to the endometrium and first third o f the myometrium is clearly critical. 
Where invasion does not occur properly blood flow to the developing fetus is 
compromised and this may result in loss o f the pregnancy, lead to pre-eclampsia or 
lUGR (Kingdom, 1998). Alternatively, if  invasion is unrestrained choriocarcinoma, a 
very metastatic cancer, may develop.
While many o f the factors required for trophoblast invasion such as integrin 
expression modulation and the secretion o f proteases to degrade the ECM have been 
studied, the underlying mechanisms controlling these are less well understood. It is 
possible that the transition from the invasive to the non-invasive phenotype results 
from an intrinsic control mechanism within the trophoblast cells themselves that 
allows invasion to cease 4-5 months after implantation. Another possibility is that 
exposure to the myometrium during the late stages o f invasion acts as a signal to halt 
the process. Alternatively the maternal decidua may physically act as a barrier to
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intrinsically invasive trophoblasts (Billington, 1971; Aplin, 1991; Bischof et al. 2000).
Much recent work has focussed on the role o f oxygen in controlling trophoblast 
invasion and this will be considered separately (section 1.5).
1.2.5 Syncytiotrophoblast and the consequences of the development of the 
maternal-fetal circulation
X.2.5.1 Syncytiotrophoblast
The syncytiotrophoblast (STB) is the continual cell layer fonning the outer surface o f 
the placental villi. It is formed by fusion o f the underlying vCTB layer. The STB is 
bathed in maternal blood and has many microvilli on its surface increasing the surface 
area available for exchange o f substances between the mother and fetus. The syncytial 
surface also expresses receptors for molecules to be transported into the placenta from 
maternal blood. Conversely the syncytial layer acts as a barrier against substances 
which would be harmful were they to pass into the fetal circulation. Lyall et al 
reported expression o f nitric oxide synthase by the STB suggesting it may have a role 
in regulating blood flow and as an anticoagulant (Lyall et al. 1999a). STB is also the 
principal site o f various hormones vital for pregnancy including human chorionic 
gonadotrophin (hCG) and human placental lactogen (hPL) (section 1.2.5.3). By term 
the underlying vCTB layer is sparse (Jones and Fox, 1991) and STB dominates.
1.2.5.2 Transport of metabolites and nutrients
Once the utero-placental circulation is established fetal blood, which is low in oxygen i
and nutrients, flows through two umbilical arteries to the capillaries o f the villi and 
then returns through the single umbilical vein to the fetus. Maternal blood (rich in 
oxygen and nutrients) flows from the uterine arteries into large blood sinuses 
surrounding the villi then back into the uterine veins o f the mother. Since the villous 
capillaries are lined with a thin endothelium and surrounded by a layer o f 
mesenchymal tissue, which is covered on the outside of the villi by a layer o f ;
trophoblast cells, a very short distance separates the maternal and fetal circulations. It 
is thought that placental exchange mainly occurs across the vasculosyncytial 
membranes, formed by insertion of capillary loops within the syncytiotrophoblast
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layer. In such areas no mesenchymal layer is present between fetal endothelium and 
the veiy thin nucleus-free region o f the syncytiotrophoblast. This allows for diffusion 
of various substances while ensuring that the individual circulations never actually 
come into direct contact (figure 7). As pregnancy progresses the permeability o f the 
placenta increases, allowing greater diffusion. Oxygen and metabolic substrates (eg 
glucose, fatty acids, ionic substances) diffuse readily into fetal blood by concentration 
gradients, while other products such as amino acids are transfencd via active transport 
processes. Waste products from the fetus also pass through the placenta into the 
maternal circulation for disposal by the liver (Moore and Persaud, 1998). Matemo- 
fetal exchange across the placenta is reviewed in Sibley and Boyd, (1988) and Sibley 
etal. (1998).
1.2.5.3 Endocrine secretion
During pregnancy the placenta is an important endocrine organ which releases the 
steroid hormones progesterone and oestrogens into the fetal and maternal circulations 
(Conley and Mason, 1990). Towards the end o f pregnancy the placenta produces up to 
30 times the normal amount o f oestrogen that the body produces in the non-pregnant 
state and ten times the normal levels of progesterone. These honnones are vital both 
in fetal development and in preparing the mother’s body for parturition. The placenta 
also secretes peptide hormones including hCG and hPL into the maternal circulation 
from very early stages ensuring the persistence o f the corpus luteum and preventing 
menstruation which would result in the loss o f pregnancy (Jones, 1989). A review of 
placental growth hormones is found in Lacroix et al. (2002).
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Figure 7 Transport of metabolites from maternal to fetal blood
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1.3 Methods for studying trophoblast invasion
1.3.1 The study of trophoblast invasion
Morphological studies of placenta and placental bed biopsies from first and second 
trimester hysterectomies have provided important information on the timing of 
trophoblast invasion of the maternal spiral arteries. (Brosens et al. 1964; Brosens et al. 
1967; Brosens et al. 1978; De Wolf et al. 1980; Pijnenborg et al. 1980; Pijnenborg et 
al. 1981a; Pijnenborg et al. 1981b; Pijnenborg et al. 1982; Pijnenborg et al. 1983;
Robertson et al. 1986; Khong et al. 1986; Wells and Bulmer, 1988; Loke, 1990;
Pijnenborg, 1990). However, because of practical and ethical considerations, dynamic 
studies of implantation and trophoblast invasion are generally limited to in vitro 
models. Hence the gaps in the understanding of the processes that occur during early 
placentation result partially from a lack of adequate experimental models although the 
past decade has seen significant advances in this area.
Two main in vitro systems have been used to study trophoblast invasion. CTB 
isolated from placentae have been cultured extensively to determine characteristics of 
the cells and to examine invasion of artificial basement membranes. More recently, 
culture of placental villous explants has been used to model differentiation of CTB 
cells whilst maintaining the tissue integrity and simulating an environment as close to 
the in vivo situation as possible.
1.3.2 Primary trophoblast cell culture
For many years the principal in vitro system for studying trophoblast behaviour has 
been the isolation and culture of dispersed mononuclear CTB from 2"  ^ and 
trimester placentae. Many studies have described methods for culturing CTB (Kliman 
et al. 1986; Bax et al. 1989; Bloxam, 1991; Bloxam et al. 1997a; Bloxam et al. 1997b; 
Frank et al. 2000; Frank et al. 2001). Dissection and mincing of the placental tissue 
followed by enzymatic digestion provides an initial means of isolating CTB from the 
placentae. The digestion is followed with further purification steps using, for example, 
density gradient centrifugation or HLA-Class I antibody-coated beads to remove 
contaminating cells (Kawata et al. 1984; Butterworth and Loke, 1985). First trimester 
CTB always require further purification due to the high level of contamination and
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term CTB may also require purification, depending on experimental requirements. 
Possible contaminating cells include fibroblasts, myofibroblasts, pericytes, endothelial 
and blood cells and remnants of the syncytium (Loke, 1982; Butterworth and Loke, 
1985; Loke et al. 1988; Douglas et al. 1989; Shorter et al. 1990; Bischof et al. 1991; 
Douglas et al. 1993) There has been much debate over purification procedures 
(Blaschitz et al. 2000). The CTB obtained at the end of the purification are a mixture 
of non-invasive villous and invasive EVT. EVT can only be recovered from the tips of 
anchoring villi since the cells that have invaded will remain in the placental bed after 
delivery of the placenta. Care must be taken when choosing the antibody for 
purification as some commonly used HLA-Class I antibodies bind to EVT due to its 
expression of HLA-G and HLA-C (Hutter et al. 1996; King et al. 2000a).
Studies of CTB behaviour during differentiation into a continuous syncytial 
layer can be undertaken on cells cultured on plastic surfaces. In order to study cell 
behaviour during invasion, CTB are cultured on ECM-llke matrices. The cells can 
also be co-cultured with decidual extract from human endometrial tissue, endometrial 
explants or endothelial cells in order to study paracrine interactions (Babawale et al. 
1996; Gallery et al. 2001).
1.3.3 Invasive properties of CTB cultured on extra cellular matrix
Matrigel is an ECM material containing type IV collagen, laminin, heparan sulfate, 
proteoglycan derived cells and enactin. Trophoblast cells seeded onto a filter coated in 
this substance (or with collagen) tend to aggregate then move through the gel and the 
pores to the opposite side of the filter. The ability of cells to penetrate matrigel and 
migrate to the underside of the filter has been associated with invasive potential in 
several studies (Fisher et al.1985; Fisher et al. 1989; Yagel et al. 1988; Librach et al.
1991). Matrix degrading proteolytic activity has also been correlated with invasive 
potential (Yagel et al. 1988; Fisher et al. 1989; Feinberg et al. 1989; Emonard et al. 
1990b; Librach et al. 1991).
CTB cells isolated from placentae at term have been reported to be less 
invasive than those isolated from early gestation placentae in several studies (Fisher et 
al. 1989; Librach et al. 1991) although Klîman et al. (1990) reported that both first 
and third trimester CTB cause degradation of matrigel. It is possible that during the
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isolation protocol, the third trimester trophoblasts undergo some degree o f de­
differentiation that allows them to exhibit invasive properties.
It is also important to note that the composition o f the ECM can affect the 
profile o f proteolytic enzymes produced by first trimester CTB (Emonard et al. 1990a; 
Kliman and Feinberg, 1990). Since matrigel contains endogenous proteolytic activity 
as well as growth factors, results based on models such as those described must be 
treated with caution (Vukicevic et al. 1992; Mackay et al. 1993; Vicovac and Aplin, 
1996). B ischof et al. (1991) identified 4 enzymes secreted into the medium of cultured 
CTB, and showed that a 59kDa gelatinase was specific to cells cultured on matrigel.
1.3.4 Trophoblast cell lines
In addition to primary cell culture o f CTB isolated from placentae, numerous 
trophoblast cell lines have been used for studying invasion. The most commonly used 
cell lines are BeWo, JEG and JAR, all three being derived from choriocarcinomas. 
Other cell lines have been generated from viral transformation or from fusion of 
normal CTB with choriocarcinoma cells (White et al. 1989; White et al. 1990; King et 
al. 2000c).
There are several advantages in using transfonned cell lines in invasion studies. 
No lengthy isolation from placentae is required, there is no limit on cell yield, the 
cells replicate rapidly in culture, and they retain some similarities to non-transformed 
CTB. The main drawback is that transformed cells have little control over their 
invasiveness and growth, in contrast to EVT cells in which proliferation and invasive 
behaviour are tightly regulated. Therefore transformed cells have limited applications 
in modelling trophoblast invasion.
A replicating CTB cell line from trimester placentae has also been produced 
by spontaneous detachment of cells from villous placental tissue that had been 
cultured for several days. The cells were able to migrate through epithelium free 
human amnion composed o f basement membrane and connective tissue, indicating 
that they had retained their invasive potential (Yagel, 1989).
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1.3.5 Limitations of trophoblast cell culture
Despite the numerous uses of primary cultures in modelling CTB invasion, currently 
available cell isolation protocols produce a heterogeneous mixture of cells and the 
effect of contaminants is hard to appreciate fully. The structure of the villous tissue is 
not maintained resulting in the removal of locally produced factors that may have a 
role in regulating CTB behaviour. Moreover, isolated CTB may suffer from 
alterations in phenotype in vitro, which could lead to errors in interpreting their 
behaviour. As an alternative, explant culture offers the potential to maintain the basic 
architecture of placental tissue in a culture system that can be readily manipulated.
1.3.6 Villous explant culture
Explant culture of anchoring villi from early in gestation provides a system in which 
to study the differentiation, proliferation and invasion of EVT cells (Genbacev et al.
1992). EVT are present in the remains of the cell columns on the tips of anchoring 
villi, which have detached from the uterine wall. In vivo, these are the sites of 
differentiation of invasive CTB (Fisher and Damsky, 1993).
To set up placental explant culture, placental tissue is obtained from the 
termination of clinically normal pregnancies, and dissected to provide villous tissue. 
Villous explants are cultured on the surface of matrigel, which supports EVT cell 
differentiation, proliferation and invasion. Cell culture chambers have been used to 
give a three-dimensional culture that allows access of media to both the upper and 
lower cell surfaees. The explants are cultured under standard conditions and remain 
viable for 6-8 days.
EVT differentiation, proliferation and invasion can be observed by examination 
of the cultures using an inverted microscope. Villous tips flatten and attach to the 
substrate within 12 hours, and outgrowth commonly occurs after 24 hours of culture. 
Cell migration into the matrix is seen after 48-72 hours. After the period of study the 
explants can be flash frozen and serial sections cut through the explant and underlying 
matrigel. Immunohistochemical characterisation o f invasive cells can then be 
performed.
Genbacev et al. (1993a; 1993b and 1993c) evaluated metabolic activity and 
morphological characteristics of villous tissue explants. The study showed that villous
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expiants of first trimester placentas (5 to 10 weeks of gestation) readily attached to 
matrigel and decidual extract containing collagen 1 within 12 hours of culture. 
Proliferation of CTB was seen in all expiants and these sites of proliferation gave rise 
to migrating EVT cells within 24 hours of culture. Proliferative (Ki67 and 
Proliferating cell nuclear antigen positive) cells were identified amongst both villous 
and extravillous CTB.
EVT cells that differentiated in vitro were cytokeratln and HLA-A, B, C class 1 
antigen positive and hCG negative, correlating with EVT cell properties in vivo. 
Villous explants of 2"  ^ trimester placentas attached to the matrix but no proliferating 
CTB cells or EVT cells were seen.
In several other explant studies it has been observed that the pattern of CTB 
differentiation in vitro closely resembles differentiation of the CTB cells described at 
the sites of invasion in vivo (Aplin, 1993; Vicovac et al. 1995; Aplin et al. 1999). In 
both in vitro and in vivo studies a decrease in lipid and glycogen stores during cell 
migration and a gradual expression of EVT cell proteolytic activity and hPL synthesis 
and accumulation were noted.
Various groups have utilised the explant culture model to study the effects of 
oxygen on explant behaviour in culture. These will be discussed in section 1.5
1.3.7 Summary
In summary, both primary cell culture and villous explant in vitro models have been 
important in studying CTB invasion at the molecular level. While primary culture is 
widely applicable for testing the invasiveness of already differentiated cells and 
assessing the effects of various factors on invasion itself, villous explants provide a 
more comprehensive system for studying the differentiation of CTB and their 
detachment and migration outside the villi.
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1 .4  Matrix Metalloproteinases
1.4.1 Introduction to Matrix Metalloproteinases
As discussed in section 1.2, trophoblast invasion is thought to involve many factors 
including matrix metalloproteinases. The matrix metalloproteinases (MMPs) are a 
family of zinc dependent endopeptidases, capable of degrading components of the 
ECM. They are a family of enzymes belonging to the broader class of 
Metalloproteinases, which comprises over 200 members. Over 25 MMPs have been 
discovered (table 1). Most MMPs are extracellular enzymes, secreted as inactive 
zymogens that require cleavage of a pro peptide sequence for activation. They can be 
subdivided according to their principle substrate into 4 groups; collagenases, 
gelatinases, stromelysins and enamelysins. Several membrane inserted MMPs (MT- 
MMPs) have also been described.
Of particular interest with regard to trophoblast invasion are MMP-2 and 
MMP-9. MMP-2 (72kDa gelatinase A) activity was first noted in rheumatoid synovial 
tissue (Harris and Krane, 1972) and was separated from collagenase-1 and 
stromelysin-1 several years later in medium from rabbit bone eulture (Sellers et al. 
1978). The complete sequence for the human enzyme, excluding the signal peptide, 
was reported by Collier et al. (1988).
MMP-9 (Gelatinase B), the largest of the known MMPs at a molecular weight 
(Mw) of 92kDa, was isolated from human polymorphonuclear leukocytes (Sopata and 
Dancewicz, 1974; Sopata and Wize, 1979) and was later purified and characterized 
(Rantala-Ryhanen et al. 1983). The sequencing of the cDNA followed this (Wilhelm 
et al. 1989).
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Table 1 Matrix Metalloproteinases
MMP-No. Name Mw(kDa) latent/active
MMP-1 Collagenase 1 52000/43000
MMP-2 Gelatinase A 71000/62000
MMP-3 Stromelysin 1 52000/43000
MMP-7 Matrilysin 28000/19000
MMP-8 Collagenase 2 51000/42000
MMP-9 Gelatinase B 76000/67000
MMP-10 Stromelysin 2 52000/44000
MMP-11 Stromelysin 3 51000/46000
MMP-12 Macrophage Elastase 52000/20000
MMP-13 Collagenase 3 52000/42000
MMP-14 MT-MMP-1 64000/54000
MMP-15 MT MMP- 2 71000/61000
MMP-16 MX MMP-3 66000/56000
MMP-17 MT MMP-4 62000/51000
MMP-18 Collagenase 4 53000/42000
MMP-19 No trivial name 54000/45000
MMP-20 Enamelysin 54000/22000
MMP-21 MMP-23a 70000/53000
MMP-22 MMP-23b 51000/43000
MMP-23 Cysteine array MMP 44000/43000
MMP-24 MT-MMP-5 71000/61000
MMP-25 MT-MMP-6 59000/38000
MMP-26 No trivial name 28000/19000
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1.4.2 Physiological roles
MMPs have a broad spectrum of involvement in biological activity since the 
breakdown of connective tissue collagen is important in various physiological 
processes. These include bone remodelling, embryogenesis, wound healing and 
postpartum involution of the uterus (Woessner, 1991; Woessner, 1998). They have 
also been implicated in several pathological processes including tissue destruction, 
fibrotic diseases and weakening of the matrix, with relevance to diseases such as 
arthritis, oral pathology, arteriosclerosis and liver/renal fibrosis. A major field of 
interest in MMPs is regarding their role in invasion and metastasis in cancer and many 
reviews have been written on this subject (Basset et al. 1997; Chambers and 
Matrisian. 1997).
It is difficult to elucidate the roles of individual MMPs in specific processes 
and pathologies and most conclusions are drawn from relative activity levels in 
specific situations. Individual gene knockout experiments o f specific MMPs are 
reviewed in Shapiro, (1997).
1.4.3 MMP structure
All MMPs have an N-terminal signal peptide of variable length which is removed 
during transit to the extracellular environment. This is followed by the propeptide 
domain, consisting of around 80 amino acids including a highly conserved cysteine 
switch sequence. The purpose o f this sequence is to block the active site; the cysteine 
residue is positioned opposite the zinc atom in the active centre (Springman et al.
1990).
The catalytic domain o f around 160 residues follows the propeptide and 
contains a highly conserved sequence in its C-terniinal portion. This m otif binds the 
catalytic zinc atom by three His residues.
Following the catalytic domain there is a hinge region, o f variable length of 
between 2-72 residues. Lastly there is a hemopexin-like domain (Hunt et al. 1987), 
thought to be involved in binding to the ECM (Clark et al. 1989).
Several o f the MMPs have additional variations on this basic theme. In the 
membrane inserted MMPs such as MMP-14, a transmembrane domain follows the 
hemopexin domain (Takino et al. 1995) MMP-2 & 9 (figure 8) contain fibronectin
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repeats - three tandem repeats of about 58 residues related to fibronectin type II 
domains. These repeats occur within the catalytic domain and assist binding to the 
I substrate (Banyai and Patthy, 1991). Finally a Type V collagen insert is found only in
MMP-9, between the active centre and the hemopexin domain (Wilhelm et al. 1989). 
It is 54 residues long, rich in proline and is an extension of the hinge region.
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Figure 8 MMP-2 and MMP-9 structure
MMP-2
Propeptide Catalytic Domain
t
Signal Peptide
MMP-9
I I I 1+ ü I I I I
Linker legion 
Hemopexin-like Domain
Fibronectin Type II Domain
Collagen-like Domain
Propeptide
i
Catalytic Domain
I I 1 t- r~ T ~ rt
Signal Peptide î
Fibronectin Linker Region 
Type II Domain Hemopexin-like Domain
62
1.4.4 Activation of the zymogen and catalytic action
Since MMPs are secreted as inactive zymogens they must be activated by cleavage of 
the inhibitoiy propeptide before they can digest their substrates. One o f the distinct 
features of the MMPs is their ability to be activated from the pro-form not only by 
proteinases but by a wide variety of non-proteolytic agents including mercurial 
compounds, other thiol reactive reagents, iodoactetate, N-ethyleimide, oxidized 
glutathione, SDS, NaSCN, Nal, reactive oxygens such as HOCl, NO 2 , heat treatment 
and by exposure to acidic pH (Springman et al. 1990).
A hypothesis for activation o f the zymogen was proposed based on the 
idea o f a cysteine switch mechanism (Van Wart et al. 1990), which attempts to 
explain the activation by various reagents. In this model, the cysteine residue found in 
the conserved sequence o f the pro-peptide interacts with the catalytic Zn^ "^ . This 
prevents the zinc ion associating with a molecule o f water required for the hydrolysis 
o f the propeptide. Thus the enzyme is maintained in the latent state. This Cys-Zn^"^ 
bond must be disrupted for activation to occur. The term ‘Velcro’ mechanism is also 
used to describe this activation (Vallee and Auld, 1990). Proteolytic agents destabilise 
the zinc-cysteine bond by interacting with the proteinase at a ‘bait’ region. Non- 
proteolytic agents essentially achieve the same result by interacting with the 
transiently dissociated cysteine. The final stage in activation is the complete removal 
of the pro-peptide by the action o f an active MMP or an MMP intermediate.
The mechanism hy which MMPs catalyse hydrolysis o f the peptide bond 
o f their substrates has been modelled on the mechanism deduced for thermolysin due 
to similarities in 3-D structure (Spurlino et al. 1994, Becker et al. 1995). The glutamic 
residues in the catalytic m otif play an active role in catalysis, along with the Zif^ ion.
1.4.5 The substrates of MMPs: The ECM
As previously mentioned, MMPs are responsible in vivo for the breakdown of the 
ECM. The ECM surrounds and supports the cells within mammalian tissues. It is 
composed o f 3 major classes o f biomolecules: a) Structural proteins collagen and 
elastin; b) Specialized proteins such as fibrillin, fibronectin, and laminin; c) 
Proteoglycans: a protein core attached to long chains o f repeating disaccharide units 
called glycosaminoglycans (GAGs). In order for cells to migrate though the ECM, as
63 i ï
happens in trophoblast invasion or in tumour cell metastasis, degradation must occur. 
The large number o f MMPs and their specificity is accounted for by the different 
components o f the ECM degraded.
MMPs have been named in accordance with the substrate they were originally 
observed to digest. In some cases this can be misleading. Despite being known as 
gelatinases, MMP-2 and -9 are also capable o f degrading native Type I collagen, 
elastin and several other proteins.
1.4.6 Inhibitors of MMPs
1.4.6.1 Levels of control
It is obviously important that the activation of MMPs is tightly controlled to avoid 
tissue damage and this is achieved at several levels. The release o f MMPs into the 
extracellular space occurs only in response to well defined signals at times when 
degradation is appropriate. Many MMPs remain near to the cell from which they were 
released, bound either to the cell surface or to matrix components. The latent pro-form 
must be cleaved to give the active form, providing another level o f control. Lastly 
there are several inhibitors o f MMPs, both general and specific, often produced by the 
same cell as secreted the MMP itself in an autocrine regulatory loop.
1.4.6.2 Tissue Inhibitors of Metalloproteinases
In vivo, once MMPs have been released into the extracellular space, their control is 
largely the responsibility o f a family o f inhibitors known as the tissue inhibitors of 
metalloproteinases (TIMPs). Four TIMPs have been described (table 2). They are 
important in the processes that MMPs are involved in and have been studied in a 
variety o f pathologies including malignancy, regulation o f cell morphology, inhibition 
o f angiogenesis and tissue remodelling (Gomez et al. 1997).
1.4.6.3 TIMP function
Inhibition o f the proteolytic activity o f MMPs is the principal role o f TIMPs in vivo 
(Woessner, 2000), The four members of the TIMP family each comprise 200-210
64
amino acid residues, aiTanged in three domains; a signal peptide, an N-terminal 
domain which is responsible for the inhibition o f MMPs (Murphy, 1991; DeCierck et 
al. 1993) and a C-terminal domain which enhances binding to the MMP and helps to 
orient the TIMP to the MMP active centre (Willenbrock, 1993). The C-terminal 
domain o f the TIMP interacts with the C-teraiinal domain o f the MMP to orient the 
inhibitoiy end o f the TIMP towards the active centi'e o f the MMP. Due to this 
interaction, the active centre o f the MMP is not free to interact with its substrates, and 
therefore ECM breakdown is controlled (Gomis-Ruth et al. 1997).
1.4.6.4 TIMP interaction with pro-MMPs
In addition to the general mode o f inhibition, there are two known cases o f TIMP 
interaction with pro-MMPs; the pro-form o f MMP-9 with TIMP-1 (Murphy et al. 
1989) and the pro-form o f MMP-2 with TIMP-2 (Goldberg et al. 1989; Stetler- 
Stevenson et al. 1989). Interestingly, whilst these interactions reduce the activation of 
the pro-enzymes, the pro-MMP-2 / TIMP-2 complex interacts with the cell surface, 
anchoring the pro-enzyme in a position where it can be activated by the membrane 
type metalloproteinase MMP-14 (Emmert-Buck et al. 1995; Corcoran et al. 1996).
1.4.6.5 Other inhibitors
A variety o f other compounds have also been found to inhibit MMP activity 
(Woessner, 2000). The principal means of inhibition is the chelation or replacement of 
zinc at the active centre. This is the method of inhibition by ethylenediamine 
tetraacetic acid (EDTA), cysteine (chelation) and DTT & gold compounds used to 
treat arthritis (replacement). Several natural antibiotics also act by chelation.
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Table 2 Properties of Tissue Inhibitors of Matrix Metalloproteinases
Mw (kDa) MMPs Inhibited
TIMP-1 20.6 All
TIMP-2 21.5 All
TIMP-3 21.6 All
TIMP-4 22.3 MMP-1,2,3,7,9
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1.4.7 Genetics
MMP-2 maps to chromosome 16ql3. The gene is 17 kb long with 13 exons varying in 
size from 110 to 901 base pairs (bp) and 12 introns ranging from 175 to 4,350 bp. 
Alignment of introns showed that introns 1 to 4 and 8 to 12 of the type IV collagenase 
gene coincide with intron locations in the MMP-1 and MMP-3 genes, indicating a 
close structural relationship of these metalloproteinase genes. Analysis of the 0.4-kb 
5'-flanking region of the MMP-2 gene showed that, in contrast to the genes of 
interstitial collagenase and stromelysin, there was no TATA box or 12-0- 
tetradecanoylphorbol-13-acetate-responsive element present in the promoter region, 
whereas there were two GC boxes. There is no CAAT box, but a potential binding site 
(CCCCAGGC) for the transcription factor AP-2 is located in the first exon (Huhtala et 
al. 1990; Tryggvason et al. 1990).
MMP-9 maps to 20ql 1.2-ql3.1. Both MMP-2 and MMP-9 have 13 exons and 
similar intron locations (Huhtala et al. 1991). The number of exons is 3 more than has 
been found in other members of the gene family. The extra exons encode the amino 
acids of the fibronectin-like domain which has been found only in MMP-2 and MMP- 
9.
There have been many studies on the gene regulation o f the metalloproteinases 
(Benbow and Brinckerhoff, 1997). The promoter region of MMP-9 more closely 
resembles those of the interstitial collagenase and stromelysin genes than MMP-2. It 
contains a TATA-like sequence and has TPA (Phorbol) response element like 
sequences. The regulatory processes for transcription of MMP-9 appear to be 
sensitive to oxygen through Hypoxia inducible factor l a  (HIF-1 a) transcription 
factor which is degraded at normal oxygen levels, but not in hypoxic conditions 
(Caniggia et al. 2000b). MMP-2 on the other hand is not thought to be responsive to 
HIF la . This is discussed in section 1.5. Thus whilst MMP-2 and MMP-9 share many 
common features and have identical substrate specificity, the regulation of their genes 
appears to be quite distinct.
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1.4.8 Methods of studying MMPs
Several methods have been used in the study of MMPs in physiology and pathology, 
each method having both advantages and disadvantages. A combination o f various 
overlapping approaches is often the best strategy in deducing roles o f MMPs in any 
system.
The inhibition o f MMPs by sodium dodecyl sulphate (SDS) is a property that 
has been exploited in zymography, a popular method o f studying MMP activity. After 
SDS-polyacrylamide gel electrophoresis (PAGE) on a gel containing a relevant 
protein substrate e.g. gelatin, the gel is washed to remove SDS, and incubated in a 
buffer containing Zn^^ and Ca^^; the pro-enzyme is renatured and degrades the 
substrate e.g. gelatin in the gel. This method detects both pro and activated forms of 
MMPs.
Immunohistochemistry (IHC) o f tissue sections can be used to precisely 
localize specific MMP expression to particular regions although it can be hard to 
ensure no cross reactivity between MMPs occurs and many antibodies do not 
distinguish between pro and active forms o f MMPs. Semi quantitative analysis is 
possible however and this method has been widely used in studies o f MMP 
expression in the placenta.
If  fairly large quantities of MMPs are present in a sample, western blotting can 
be used as a semi-quantitative method for comparing amounts o f MMPs between 
samples. As with IHC, the quality of the results will depend heavily on the choice of 
antibody, and often will not distinguish between pro and active forms o f the enzyme.
The use o f MMP assays has increased dramatically over the past few years 
with the growth in the number of commercially available kits. They have the 
advantage o f being MMP specific, can be very sensitive and have a high throughput 
o f samples. Unfortunately cross-reaction with other MMPs is fairly common. 
Moreover, in addition to detecting free MMPs, unquantifiable levels of MMP- 
inhibitor complexes may also be detected.
Quantitative PCR (polymerase chain reaction) has the advantage o f being 
MMP specific and has the ability to measure changes in mRNA for multiple MMPs in 
small samples relatively quickly. However, because only mRNA levels are measured 
neither protein or activity levels can be accurately quantified. In conjunction with
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iother methods, however, it can provide useful insights into control at a transcriptional 
level.
1.4.9 MMPs and placental development
1.4.9.1 Trophoblast outgrowth models
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The study o f the secretion o f proteolytic enzymes by invasive trophoblasts has its '"Broots in studies performed during the 1970s and 80s. Experiments studying 
trophoblast outgrowth on radiolabelled extracellular matrices and cell monolayers 
found that outgrowing cells can invade and migrate through uterine stromal cells 
(Salomon and Sherman, 1975; Sherman and Salamon, 1975; Sherman, 1975a;
Shemian, 1975b; Glass et al. 1979) and ECMs (Glass et al. 1983). It was proposed 
that the clear halo that fonned slightly ahead of the outgrowth o f the trophoblasts was 
the result o f cytolytie enzymes.
1.4.9.2 The role of plasminogen activator in trophoblast invasion
I
Plasminogen activator (PA) is an enzyme that converts inactive plasminogen into the 
proteolytic enzyme plasmin. In addition to having a direct role in tissue digestion, 
plasmin may act as an upstream activator o f MMPs. Trophoblast outgrowth models 
demonstrated that outgrowth in both humans and mice required urokinase like 
plasminogen activator (uPA) (Sherman et al. 1976; Strickland et al. 1976; Martin and 
Alias, 1982; Queenan et al. 1987). Studies suggesting that exogenous proteinase 
inhibitors can prevent blastocyst attachment in vitro (Blackwood et al. 1968) 
supported this interpretation. Blastocyst attachment in the mouse required a trypsin­
like activity and the process o f trophoblast outgrowth required both plasminogen §
activator and trypsin like activity (Kubo et al. 1981). Plasminogen activator inhibitor 
(PAI) type 1 is also associated with invading trophoblasts suggesting it may have a 
role as a regulator o f uPA activity (Feinberg et ai. 1989).
■i
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1.4.9.3 The role of gelatinases in trophoblast invasion
However, studies by Denker, (1977) and Denker and Fritz, (1979) found no inhibition 
o f rabbit blastocyst attachment by epsilon amino caproic acid, an inhibitor of plasmin 
activity. The degradation observed by Glass et al. (1983) was not uPA dependent. The 
authors hypothesised that the degmdative activity could be due to either secreted or 
cell bound proteinases or to endocytosis by the trophoblast cells. A later study 
(Behrendtsen et al. 1992) demonstrated that MMPs mediated the ECM degradation by 
cells from mouse blastocyst outgrowths.
It is generally accepted that CTB isolated from V \  but not 2"^ or 3'"’ trimester 
placenta, degrade and invade the ECM, corresponding with their invasive potential in 
vivo. The suggestion that trophoblasts mediate the developmentally regulated 
degradative properties o f human chorionic villi was supported by evidence provided 
by Fisher et al. (1989) who used the method o f Kliman et al. (1986) to isolate and 
compare the gelatin degrading proteinases produced by early gestation, invasive CTB 
with those produced by non invasive later gestation CTB and with placental 
fibroblasts. There were several proteinases uniquely produced by the invasive 
trophoblasts including a group of gelatinases ranging in Mwt from 68-200 kDa.
In support of the role of both MMPs and uPA in invasion, Yagel et al. (1988) 
showed that both inhibitors of plasminogen activator, and inhibitors o f MMPs had the 
effect o f blocking the invasion o f a basement membrane by human trophoblast. It is 
possible that uPA acts upstream o f MMPs by activating the zymogen.
The work o f Librach et al. (1991) was pivotal in the study o f metalloproteinases 
during trophoblast invasion. First trimester trophoblasts were shown to secrete the 
92kDa type IV collagen-degrading metalloproteinase (MMP-9) and this was required 
for invasiveness in vitro. Its synthesis and activation peaked in the first trimester and 
correlated well with the invasive period in vivo. Inhibitors o f the plasminogen 
activator system reduced but did not completely abolish invasion.
1.4.9.4 Temporal regulation of gelatinase expression -  studies of cultured 
CTB
Several studies have cultured CTB from EV2"*^ /3'"^  trimester and analysed MMP 
secretion profiles in the culture medium. After implantation and before placental
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development is complete in the 1 st trimester, both MMP-9 and M M P-2 are secreted 
(Fisher et al. 1985; Shimonovitz et al. 1994; Librach et al. 1994). By the 3rd trimester 
it has been reported that MMP-9 is predominant, although levels are significantly less 
than in trimester, and MMP-2 is secreted in only small amounts (Fisher et al. 1989; 
Shimonovitz et al. 1994).
Niu et al. (2000) found that trimester villous tissue cultured alone secreted 
around I Ox more pro-MMP-2 than pro-MMP-9, and that pro-MMP-2 levels decreased 
dramatically in the 2"^ trimester. Conversely, E ‘ trimester CTB cultured in the 
absence o f stromal cells had pro-MMP-9 levels lOx those o f pro-MMP-2. Levels o f 
TIMP-1 and TIM P-2 remained constant. Active MMP-2 was also secreted from 
villous tissue in the first trimester. This study illustrates the importance o f the villous 
environment for influencing gelatinase production.
The first study to examine dynamics of MMP secretion during the first 
trimester was undertaken by Xu et al. (2000) who found a gradual increase in MMP-9 
secretion by cultured CTB between week 7-11 and a corresponding decline in MMP- 
2 secretion. TIMP-1 secretion increased with gestation and no TIMP-2 was detected.
In contrast to previous studies Sawicki et al. (2000) found expression of 
MMP-2 and M M P-9 in 3"^*^ trimester CTB culture.
1.4.9.5 MMP distribution patterns in the placenta
Several studies have been published examining the in vivo distribution patterns of 
MMPs and TIMPs in the placenta throughout gestation. Different protocols for tissue 
preparation and fixation were used in each of these and as such the data are difficult to 
compare. Several early studies on trophoblast invasion were carried out on primate 
placentae rather than human, which must also be taken into account when considering 
the data.
To determine the collagenase secreting cell type in first trimester human 
placenta. Moll and Lane (1990) cultured CTB from 8-12 weeks o f gestation. 
Interstitial collagenase was localized to villous and EVT by light microscopy (paraffin 
embedded tissue) and immunogold labelling on cultures. The enzyme was present in 
the cytoplasm as well as on the cell surface of the trophoblast.
MMP-2 distribution at both protein and mRNA level has been studied in 
human placenta by Autio-Harmainen et al. (1992); Fernandez et al. (1992); Follette et
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al. (1994); Huppertz et al. (1998); Sawicki et al. (2000) and Isaka et al. (2003). A 
summary of these studies is given in table 3. The expression o f MMP-2 in trophoblast 
cell columns of early pregnancy is a predominant finding of these studies. Huppertz et 
al. (1998) suggested that expression does not alter considerably in the later stages of 
pregnancy. In addition to a role in trophoblast invasion, Sawicki et al. (2000) 
suggested that basolateral polarised release of the gelatinases may be important in the 
villous tissue remodelling that occurs late in gestation.
MMP-9 localisation has also been studied by immunohistochemistiy and in 
situ hybridization (Polette et al. 1994; Hurskainen et al. 1996; Huppertz et al. 1998; 
Sawicki et al. 2000 and Isaka et al. 2003). From these studies it has been reported that 
MMP-9 is expressed by EVT in early pregnancy but is downregulated towards term.
Most data published on the expression o f TIMPs describe their expression as 
being restricted to the decidual cells at the maternal/fetal interface. (Graham and Lala, 
1991; Damsky et al. 1993; Polette et al. 1994). Contradictory findings of EVT 
secretion of TIMPs were reported by Hurskainen et al. (1996) and Ruck et al. (1996). 
The data from these two studies supports the hypothesis that invasion may be 
controlled in an autocrine manner by the trophoblast cells themselves in addition to 
paracrine control by maternal decidua.
' I
f
72
I■sII aI
I a,I 1
Ê'M
è* s5 -q(/} otwO .£2OJ Æla osH sg
(S
I
aP4
I
1PQ I Iex ic
1II
ÎI
I
y
Dm
I
W3
c53 T3
I
1P u
!•
g
ffi
iI
Du
I
Du
Ê-
1 II
O n
OÎ
rol>
1 E 1 a1 R 1
R U f )
Dm
a "O
t
I'a
I (DI cdrtjI
Dm
I
II II Î
Î
cS
OI
E
a.
a
I I
Io 4h fNa Oo V) G■H D d O<D% c3t obJO OO &
I
■g
N .aI I-I
NO
O s
ON
!cJ
III4-1O 'O I 1 1 11 > wc 1 .sw •S % (Ü,Ou oa Pm .s §
i
Ï
1
J iI
NO
NO CO
O n ONO n O n
O <D.s NS b
t i Ou<u Ou
> œ
IT3
I S)
NO
<N
o
O n
00m1
gI
£■
II
II
•§I Ü
I Pm y I
i
Pm
Ii
E
o II 03E
H> a
.Sa ps •Bex
% H
.hpM
J oro
III I
S 'Io
1
cd
I Ia
P m
o mo oo oCN <N
cd
0
1CO
0>I
1.4.9.6 Regulation of MMP expression
Many studies have examined the influence o f various hormones, cytokines and other 
chemicals on MMP expression in trophoblast invasion. Studies include the effect o f 
progesterone (Shimonovitz et al. 1998), Interleukin-10 (Roth and Fisher, 1999), 
Interleukin-Ip (Librach et al. 1994), hCG (Yagel et al. 1993), 8-Iso-Prostaglandin F^a 
(Staff et al. 2000) on MMP production. However, much of the data published are 
confined to a single study and thus await further investigation. The studies by 
Caniggia et al on oxygen tension and regulation of MMP-9 are discussed in section 
1.5.
1.4.9.7 MMPs and abnormal placentation
This subject will be discussed in Section 1.7. It suffices to state that MMP activity 
may be aberrant in several placental abnormalities including pre-eclampsia, lUGR, 
certain causes o f miscaniage and choriocarcinoma, possibly being downregulated in 
the first three conditions and upregulated in the latter.
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1.5 Placental development and oxygen tension
1.5.1 Oxygen tension in the placenta
Throughout pregnancy the placenta is exposed to changing levels of oxygen. Oxygen 
levels in the endometrial and trophoblast tissues can be measured using oxygen 
electrodes. Yedwab et al. (1976) showed that the oxygen tension (PO2) in the lumen 
of the uterine body during the secretory phase is around 10 to 15 mmHg. In the first 
study to examine oxygen levels in trimester pregnancies Rodesch et al. (1992) 
found that PO2 values in the intervillous space increased from around ISmmHg at 8 
weeks of gestation to about 60mmHg at 13 weeks of gestation. The oxygen tension in 
the endometrial stroma remained constant at around 40mmHg throughout pregnancy. 
In all cases between 8-10 weeks of gestation PO2 values in the endometrium were 
higher than in the placenta, whereas between 10-12 weeks of gestation there was no 
difference between placental and endometrial values.
1.5.2 Intervillous blood flow and oxygen tension
It was thus established that early placentation occurs in a relatively hypoxic 
environment before the flow of blood into the intervillous space results in the CTB 
being exposed to increased oxygen tension. The presence of trophoblast plugs in the 
uterine spiral arteries (Hamilton and Boyd, 1960) is thought to prevent blood flow 
into the intervillous space in early pregnancy. The plugs are dispersed around the end 
of the first trimester at the same time that uteroplacental blood flow increases and 
oxygen tension in the placenta rises (Hustin and Schaaps, 1987). Injection of 
radiopaque dye into the aorta of pregnant women and the tracing of the dye in the 
intervillous space showed that at 6 weeks of gestation little dye entered the 
intervillous space, while at 12 weeks of gestation diffusion of the dye was observed 
throughout the intervillous space and continuous maternal blood flow was present 
(Burchell, 1967). Thus it has been speculated that the rise of oxygen tension in the 
intervillous space may be linked to the differentiation of CTB from the proliferative to 
the invasive state. In recent years in vitro experimentation has begun to unravel the 
effects of oxygen tension on CTB behaviour during early pregnancy. However 
interpretation of the data is not straightforward since proliferation and migration both
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occur before and after the oxygen change and a simple theory is unlikely to be correct 
(Pijnenborg, 1980).
1.5.3 Oxygen tension and trophoblast invasion
Isolated CTB from the first trimester cultured on an ECM in 20% oxygen will invade 
the matrix on which they are cultured (Fisher et al. 1989). First trimester villi which 
have been explanted onto matrigel and cultured in 20% oxygen form new invasive 
sites at the tips of the explants (Vicovac and Aplin, 1996; Genbacev et al. 1997; Aplin 
et al. 1999) while those cultured in 2 or 3% oxygen are maintained in a proliferative, 
non-invasive immature state (Genbacev et al. 1997; Zhou et al. 1998; Caniggia et al. 
2000a; Caniggia et al. 2000b). It has been accepted for some time that CTB 
proliferation is higher in hypoxia (Fox, 1964). CTB cultured in low oxygen do not 
undergo the switch in integrin receptors normally found as the invasive phenotype is 
acquired (Genbacev et al. 1997).
Several studies have examined other responses of trophoblasts to low oxygen 
including increased production of inflammatory cytokines, vascular endothelial 
growth factor (VEGF), PAI-1 and inhibition of differentiation to the syncytium (Alsat 
et al. 1996; Benyo et al. 1997; Taylor et al. 1997).
1.5.4 Oxygen concentration and regulation of transcription -  the role of
H IF-la
The question of how oxygen tension regulates invasive behaviour centres on the 
transcription factor hypoxia inducible factor 1 (HIF-1). Low oxygen increases 
transcription of many genes in various cell types e.g. VEGF, erythropoietin and 
various glycolytic enzymes and transcription factors (Semenza and Wang, 1992; 
Forsythe et al. 1996; Semenza et al. 1994). In mammalian cells regulation of genes 
through oxygen tension is reliant on the transcription factor HÏF-1 (Wang and 
Semenza, 1993a, 1993b). HIF-1 is a basic helix-loop-helix protein which binds to a 
short DNA motif in the 3'-flanking regions of hypoxia-inducible genes. HIF-1 is a 
heteromeric complex that is composed of two subunits, HIF-1 [3 which is 
constitutively expressed and HIF-1 a  which is inducible. Although HIF-1 a  is present
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at low oxygen tensions it is rapidly ubiquitinated and degraded by the proteasome 
under normoxic conditions (Salceda and Caro, 1997). The degradation occurs via an 
interaction with the tumour suppressor protein Von-Hippel-Lindau (Maxwell et al. 
1999).
1.5.5 HIF-la and trophoblast invasion
In a recent study, high expression of H IF-la mRNA was shown in placental 
trophoblasts between 7-10 weeks of gestation. The levels then fell dramatically by 12- 
14 weeks (Cannigia et al. 2000b). The same study showed that incubation of villous 
explants from 7-10 weeks of gestation cultured in 3% oxygen with antisense H IF-la 
inhibited proliferation and induced invasion.
Weiner et al. (1996) showed by northern blotting that both H IF-la and HIF- 
Ip are present in term placenta and others have shown the presence of HIF-1 DNA 
binding activity in isolated CTB cells at term (Seligman et al. 1997). mRNA activity 
of various transcription factors including HIF-1 in CTB was also recently reported 
(Janatpour et al. 1999).
In a comprehensive study, Rajakumar and Conrad, (2000) investigated the 
expression of H IF-la and HIF-2a in normal human placenta from trimester to 
term. They found that both proteins were localised to the STB, villous CTB and 
fetoplacental vasculature. Both proteins but not the corresponding mRNAs decreased 
significantly with gestation and both proteins could be induced by hypoxia in cultured 
placental villous explants. In addition the DNA binding activity of H IF-la was 
increased by hypoxia. Caniggia et al. (2000b) reported that H IF-la mRNA decreased 
with increasing gestation during the first trimester, but did not quantify H IF-la 
protein expression.
1.5.6 Mechanisms of regulation of trophoblast invasion by HIF-la
The evidence that MMPs are important in the degradation of the ECM during 
trophoblast invasion has led to speculation that oxygen tension may regulate MMP 
expression through HIF-la. Caniggia et al. (1999a) reported that as oxygen tension 
increased, secretion of proteins that are induced in hypoxia such as TGF-|33 decreased
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in villous expiants. Caniggia et al. (2000a) also reported that TGF-p3 levels declined 
when H IF-la mRNA was reduced by antisense treatment. In the same study, TGF-P 
was also reported to have an inhibitory effect on MMP-9 and integrin al(31. Caniggia 
et al suggested that H IF-la and TGF-|33 may act together to mediate the effects of 
oxygen on CTB invasion by modulating MMP-9 and integrin levels. Despite the 
findings of Caniggia et al, others have not been able to substantiate these results 
(section 1.2; Lyall et al. 2001a). However another study reported that CTB cultured in 
20% O2 dramatically up-regulated H IF-la expression compared with those cultured 
in 2% O2 (Jantapour et al. 1999), highlighting the need for caution in interpreting in 
vitro studies.
1.5.7 Defective trophoblast invasion and oxygen tension
Optimal perfusion of the plaeenta is achieved only if EVT invade deep into the 
decidua and remodel the spiral arteries. If exposure to increased oxygen does not 
occur at the critical stage, CTB differentiation into fully invasive cells could be 
impaired, a scenario which has been implicated in complications such as pre- 
eclampsia (section 1.7). Placental hypoxia has been implicated in abnormal CTB 
differentiation and placental development in pre-eclampsia (Conrad et al. 1997; Lim 
et al. 1997; Lindheimer et al. 1999; Caniggia et al. 1999b). This is discussed further 
in section 1.7.6. It has also been observed that CTB from pregnancies complicated by 
pre-eclampsia show defects in integrin switching, a process which may be regulated 
by oxygen (Zhou et al. 1993). If CTB invasion does not proceed normally then this 
would result in a lack of remodelling of the spiral arteries and impaired uteroplacental 
blood flow.
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1.6 High altitude pregnancy
1.6.1 Physiological impact of living at high altitude
With increasing altitude the barometric pressure and hence partial oxygen pressure, 
falls linearly. Arterial P02 at sea level is around 95mmHg while at 4000m arterial 
P02 is around 50mmHg. Haemoglobin oxygen saturation decreases from 95-100% to 
around 80% with the same increase in altitude (Ward et al. 1995). High altitude 
hypoxia leads to several well documented cardiovascular, respiratory and electrolyte 
changes in the body (reviewed in Sarkar et al. 2003).
1.6.2 Increased incidence of pregnancy complications at high altitude
Pregnancy at high altitude has interested researchers for many years. Studies of 
pregnancy and fetal growth at altitudes of >2700m were undertaken as many as 45 
years ago when Lichty et al. (1957) demonstrated that babies born to mothers living at 
3100m were significantly smaller than those born at 1600m, irrespective of 
gestational age. Numerous studies since that time have confirmed that fetal growth is 
reduced at high altitude throughout the world (Moore et al. 1998). This lowered birth 
weight is independent of other characteristics such as gestational age, maternal weight 
gain, parity, smoking and hypertension (Jensen and Moore, 1997). Altitude related 
growth restriction frequency is negatively correlated with the length of time a 
population has resided at high altitude, suggesting an evolutionary shift towards sea 
level birth weight (Moore et al. 2000). Other than pre-term delivery, altitude reduces 
birth weight more than any other known factor; a decrease in birth weight of 
lOOg/lOOOm has been reported (Yip, 1987; Jensen and Moore, 1997).
An increased rate of spontaneous pre-term birth has also been noted in some 
high altitude populations and there is also evidence that newborns at high altitudes 
have a higher mortality risk. Neonatal mortality is increased three-fold with increased 
altitude in urban and rural communities in Peru and Bolivia (PAH, 1994).
Perhaps most interestingly in relation to the current study, a dramatic increase 
ill pre-eclampsia has been noted in populations living at >2800m (Palmer et al. 1999). 
This study reported a four-fold incidence in the prevalence of pre-eclampsia at an 
altitude of 3100m.
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1.6.3 Types of placental hypoxia
Evidence o f fetal hypoxia is suggested from the discovery that cord blood samples 
from high altitude newborns have a higher haemocrit and fetal haemoglobin than 
those at sea level (Ballew et al. 1986).
Women who are pregnant at high altitude experience hypobaric hypoxia 
(Espinoza et al. 2001; McAuliffe et al. 2001) and this results in pre-placental hypoxia 
(Kingdom and Kaufmann, 1997). Fetal hypoxia can be classified as one o f three types 
(Kingdom and Kaufmann, 1997). In pre-placental hypoxia the maternal blood 
entering the intervillous space is hypoxic resulting in the mother, fetus and placenta 
being affected. Both high altitude pregnancies and pregnancies where the mother is 
anaemic fall into this category. Utero-placental hypoxia occurs when the maternal 
blood has normal oxygen levels but the inteiwillous space is compromised resulting in 
placental villi being exposed to lower oxygen, such as occurs in pre-eclampsia and 
some cases of lUGR. Finally, in post-placental hypoxia both the mother and the 
intervillous blood flow are normal but the fetal vascular perfusion is abnormal 
resulting in a reduced ability to obtain adequate oxygen. The various types of hypoxia 
affect placental villous development in different ways hence care must be taken in 
studies which attempt to relate one type o f placental hypoxia to another.
1.6.4 Physiological parameters
Ultrasound studies have shown around a third reduction in uterine blood flow during 
the last trimester in high altitude, corresponding with a 30% reduction in oxygen 
delivery to the uterus (Zamudio et al. 1995). Impedance to uterine artery blood flow 
was lower at high altitude than at sea level suggesting a possible compensatory 
mechanism to this (Zamudio et al. 1995; Krampl et al. 2001). Recent studies have 
demonstrated a reduction in the invasion o f the maternal spiral arteries by placental 
CTB at high altitude and have also shown a reduction in growth factors necessary for 
placental and fetal growth in these women (Zamudio et al. 2000; Tissot et al. 2000).
The normal pregnancy-associated fall in blood pressure during the second 
trimester is not seen in pregnant women at 3100m, even in those who remained 
normotensive throughout pregnancy (Palmer et al. 1999). This suggests failure of the 
normal cardiovascular adaptations to pregnancy since the fall in blood pressure seen
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in normal pregnancy is possibly caused by primaiy peripheral vasodilation. The study 
also found a higher incidence o f pre-eclampsia at 3100m (16% versus 3%), 
supporting an earlier study which had found that mean arterial blood pressures were 
increased late in the third trimester in women residing at the same altitude as was the 
prevalence o f proteinuria, leading to an increase in diagnosis o f pre-eclampsia (Moore 
et al. 1982).
1.6.5 Placental morphology and pathophysiology in high altitude pregnancy
The increases in complications o f pregnancy found at high altitude are associated with 
increased markers o f placental hypoxia such as formation o f syncytial knots, 
persistence o f vCTB at term and hypercapillarisation (Ali, 1997). The placenta is 
thought to adjust to some extent to the hypoxia by maintaining total oxygen diffusive 
conductance (Mayhew et al. 1990; Reshetnikova et al. 1994) even when growth in 
villous surface area is compromised (Jackson et al. 1987b). To compensate for this, it 
has been suggested that diffusion distances across the intravascular barrier might 
decrease, particularly across the trophoblast layer which may be sparser (Jackson et 
al. 1988). A decrease in perivascular cells around many o f the villous capillaries has 
also been noted (Zhang et al. 2002) perhaps adding to the thinning of the maternal 
fetal interface.
Other compensatory mechanisms thought to occur include increased 
vasculosyncytial membrane formation and alterations in villous capillaiy diameter. 
Although the majority o f studies have found an increase in diameter, others have 
found a decrease thus the situation is unclear (reviewed in Mayhew, 2003). At 
moderate altitudes (up to 2800m) growth of the villous tree and structure are 
maintained (Reshetnikova et al. 1994) but above 3600m surface area is reduced and to 
compensate, there is an enlargement of the intem llous space. Under hypoxic 
conditions, increased branching o f fetal capillaries is thought to occur (Kaufmann et 
al. 1985; Kaufmann, Luckhardt and Leiser, 1988), possibly contributing to the altered 
configuration of the villous tree seen at altitude (Ali et al. 1996).
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1.6.6 Maternal markers
Hypoxia is known to upregulate VEGF production and total VEGF has been shown to 
be increased in the maternal circulation at high altitude (Wheeler at al. 2002). 
Circulating levels of total VEGF are also increased in pre-eclampsia (Baker et al.
1995) again suggesting that maternal physiology at high altitude may be intermediate 
between normal pregnancy and pre-eclampsia. Women residing at high altitude also 
have elevated levels of pro-inflammatory cytokines and catecholamines during 
pregnancy suggesting that the maternal neural-immune axis may be altered, 
predisposing these women to complications (Coussons-Read et al. 2002).
1.6.7 Rationale for studying pregnancy at high altitude as a model for pre­
eclampsia
The effects of altitude on pregnancy are relatively difficult to study due to the lack of 
communities residing at >2500m and the remote location of these in the US. In 
Europe no permanent communities reside at >2500m and studies on high altitude 
communities in South America and Asia are confounded by various factors relating to 
sub-standard maternal care.
It has been suggested that women living at high altitude may adapt to 
pregnancy in a way which is intermediate between that seen in normal versus pre­
eclamptic pregnancy (Palmer et al. 1999). The fact that pre-eclampsia and other 
pregnancy complications occur more frequently at high altitude (Palmer et al. 1999; 
Mahfouz et al. 1994) supports this theory.
Pregnancy at high altitude may thus provide a natural experiment for 
studying the effects of hypoxia on maternal physiology and on placental and fetal 
development. It may thereby provide a model for the development of conditions such 
as pre-eclampsia.
84
1.7 Pre-eclampsia
1.7.1 Pre-eclampsia -  epidemiology and clinical features
Pre-eclampsia is a disorder o f late pregnancy, diagnosed by blood pressure 
>140/90mmHg and proteinuria (>300mg in 24 hours) after twenty weeks o f gestation 
in women who were previously normotensive (Davey and MacGillivray, 1988). 
Widespread endothelial dysfunction is found in the maternal circulation (Roberts and 
Redman, 1993). The disease progresses from mild to severe in an unpredictable 
manner and is associated with maternal cerebral oedema, renal failure, liver capsule 
distension, pulmonary oedema, neurological manifestations, thromobocytopenia, 
coagulopathy and HELLP syndrome (hemolysis elevated liver enzymes low platelets) 
(reviewed in Lyall and Greer, 1994b). Pre-eclampsia when left untreated may 
progress to eclampsia, a life-threatening condition characterised by convulsions. By 
the stage that the clinical symptoms are evident, the pathology o f the disease is 
advanced and no reliable predictors o f pre-eclampsia have been found (Dekker and 
Sibai, 1991). Magnesium sulphate is currently the drug of choice for the management 
and treatment of the condition, to prevent development o f eclampsia (Duley et al. 
1995; Duley et al. 2002). Delivery o f the fetus and placenta are the only way to 
relieve the symptoms reinforcing the role o f the placenta in this condition.
Pre-eclampsia affects between 5-10% o f pregnancies in the developed world 
(Zeeman et al. 1992) and is one o f the leading causes of maternal mortality in the UK 
(Department o f Health, 1999). It also results in a fivefold increase in perinatal 
mortality compared with normal pregnancy (Roberts, 1998). In the developing world 
pre-eclampsia accounts for 10-15% o f all deaths connected with pregnancy (-50000 
per year) (Duley, 1992). It is also associated with several complications o f pregnancy 
including placental abruption, increased risk o f premature delivery and an increase in 
the requirement o f a caesarean section. Additionally, infants born to pre-eclamptic 
mothers have a higher incidence o f lUGR (Witlin et al. 2000).
Various studies have implicated many different factors in the development of 
pre-eclampsia. These include maternal; nulliparity (Long et al. 1979), obesity 
(reviewed in O ’Brien et al. 2003), age (Ziadeh et al. 2001) and new paternity 
(Trogstad et al. 2001), fetal e.g. multiple pregnancy (Long and Oats, 1987) and 
environmental factors (Neela and Raman, 1993). A correlation between several
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maternal genes and pre-eclampsia has also been found (reviewed in Cooper et al. 
1993).
1.7.2 Placental bed morphology in pre-eclampsia
There is much evidence that the placenta has a central role in the development of pre­
eclampsia. The condition is relieved only after deliveiy of both fetus and placenta and 
pre-eclampsia has been observed in cases where there is no fetus present e.g. 
hydatidiform mole (Scott, 1958; Chun et al. 1964).
It has been known for many years that the placentae o f pre-eclampsia women 
are poorly perfused (Page, 1939). In normal pregnancies, the lining o f the maternal 
spiral arteries is replaced and remodelled by invading EVT from the placenta (section 
1.1.7). This remodelling results in a four to six fold increase in the diameter o f these 
arteries, transforming the vascular supply to a high-flow low-pressure system which 
can meet the demands of the developing fetus (section 1.2). It is widely recognised 
that invasion of trophoblasts into the maternal tissue is abnormal in pre-eclampsia. 
This observation was first made over thirty years ago in placental bed biopsies from 
pre-eclampsia patients and has been substantiated in several other studies (Brosens et 
al. 1972; Robertson et al. 1975; Sheppard and Bonnar, 1981; Gerretsen et al. 1981; 
Pijnenborg et al. 1991; Meekins et al. 1994). The morphological evidence to date 
suggests that the principal defect in invasion occurs in the endovascular invasive 
pathway and that interstitial invasion is relatively normal (Pijnenborg et al. 1996). In 
pre-eclamptic pregnancies the conversion of spiral arteries by invading EVT occurs 
only in the decidual segments (Brosens et al. 1972; Pijnenborg et al. 1991) and only a 
proportion of these are actually remodelled (Khong et al. 1986; Meekins et al. 1994).
As a result of impaired invasion the spiral arteries do not undergo full 
physiological change and hence blood flow to the placenta is reduced. Impaired 
invasion is also observed in some cases o f lUGR (Gerretsen et al. 1981, Khong et al. 
1986), miscaiTiage (Khong et al. 1987), premature labour (Salafia et al. 1995) and 
other complications of pregnancy. It is possible that the clinical syndi'ome o f pre­
eclampsia is the maternal response to the poorly perfused placenta (Friedman et al.
1991).
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1.7.3 MMPs/TIMPs in pre-eclampsia
If  trophoblast invasion is partially deficient in pre-eclampsia, it seems logical that one 
or more o f the normal mechanisms governing invasion must be dysfunctional in the 
disease. MMPs and their regulators TIMPs are possible candidates.
Several studies have highlighted the importance o f MMP-2 and MMP-9 in 
regulating normal CTB invasion (section 1.4.9). It was reported that MMP-9 was 
reduced in term placental extracts from women with pre-eclampsia (Kolben et al.
1996). Subsequent studies suggested that terni trophoblast cell cultures from nonnal 
pregnancies secreted high levels o f active MMP-9 while teim trophoblast cultures 
from pre-eclamptic pregnancies secreted higher levels o f inactive pro-MMP-9 
(Graham and McCrae, 1996; Lim et al. 1997).
One study found that decidual microvascular endothelial cells obtained from 
cases complicated by pre-eclampsia expressed lower levels o f MMP-1 than control 
cases but no difference in either MMP-9 or TIMP-1 was found (Gallery et al. 1999), 
suggesting that MMP-1 may have a role in regulating invasion into the maternal blood 
vessels.
There is a lack o f in vivo information regarding MMP expression in pre­
eclampsia. Since pre-eclampsia does not develop until mid-late gestation, levels of 
MMP-9 and MMP-2 in placentae from early gestations cannot be easily correlated 
with future disease, It is thus difficult to establish any connection between MMP 
expression early in gestation and the later development of pre-eclampsia. A veiy 
recent study (Huisman et al. 2004) found no relation between MMP expression in 
early chorion villous samples and the eventual occurrence of the disease.
1.7.4 Cell adhesion molecules in pre-eclampsia
Cell adhesion molecules and their ligands regulate the adhesion o f cells to each other, 
to other cell types and to the ECM (section 1.2). Invasion of the maternal uterus and 
arteries by trophoblast cells requires modification of the adhesion molecule repertoire, 
a process which is thought to be deficient in several disorders including pre-eclampsia 
and lUGR (reviewed in Lyall, 1998).
Some immunohistochemical studies on placentae from cases complicated by 
pre-eclampsia have shown abnormal CAM expression by invasive CTB particularly
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with regard to integrin switching. Cell adhesion molecule expression in normal 
pregnancy is discussed in section 1.2.3. Zhou et al. (1993) reported that cultured CTB 
from placentae from pre-eclamptic pregnancies failed to downregulate a6p4  and to 
upregulate a l p l  in distal cells columns and in the uterine wall. The expression 
patterns o f a 3 p l and a 5 p l were not different in pre-eclampsia compared with normal 
pregnancy. The same study showed an increase in laminins A and B2 in pre­
eclampsia pregnancies compared to uncomplicated pregnancies. Zhou et al later 
reported changes in CTB expression of endothelial CAMs in pre-eclampsia compared 
with normal pregnancy with differences in all three a v  family members. Pre­
eclampsia was also associated with differences in cadherin expression and in CAMs 
associated with leukocyte trafficking. (Zhou et al. 1997a; Zhou et al, 1997b). 
However these findings are hard to reconcile with the fact that in the third trimester 
spiral arteries are re-endothelialised and therefore not lined with CTB. In contrast, 
Divers et al. (1995) reported no differences in integrin expression in either the 
amniochorion or the basal plate in pre-eclampsia compared to normal pregnancy. 
Pijnenborg et al. (1998) and Lyall et al. (2001b) did not identify any PECAM-1 
expression on CTB in placental bed biopsies in either pre-eclampsia, lUGR or in 
normal pregnancy suggesting they may not adopt endothelial cell properties. Thus 
aberrant cell adhesion in pre-eclampsia has not been firmly linked with abnormal 
CAM expression and further studies are required.
1.7.5 Cell adhesion molecules and the maternal inflammatory response in 
pre-eclampsia
Cell adhesion molecules are associated with leukocyte trafficking, a process which 
has significance in the inflammatory response seen in pre-eclampsia. Platelets and 
neutrophils are thought to be mediators o f maternal endothelial dysfunction in the 
condition and both are activated in pre-eclamptic pregnancies (Greer et al. 1989). 
Platelets cause vascular damage and obstruction, resulting in tissue ischaemia and 
damage (Greer, 1992). Neutrophils, once activated, release a variety of 
vasoconstrictive agents and other mediators o f vascular damage (Harlan, 1987).
The recruitment and activation of platelets and neutrophils is partly 
controlled by the expression of cell adhesion molecules on the surface of the
endothelium of the maternal blood vessels and on the surface o f circulating cells 
(Harlan and Liu, 1992). The major CAMs expressed on the endothelial surface which 
are involved in platelet and neutrophil activation are platelet endothelial cell adhesion 
molecule (PECAM), E-Selectin, intracellular adhesion molecule-1 and 2 (ICAM-1 
and 2) and vascular cell adhesion molecule-1 (VCAM-1). Increased concentrations of 
soluble VCAM-1 and E-Selectin have been described in the maternal circulation in 
pre-eclampsia (Lyall, 1994a; Lyall et al. 1995).
1.7.6 The role of O2 in pre-eclampsia
Oxygen tension is reported to be vital in regulating CTB proliferation and invasion in 
the early stages o f pregnancy (section 1.5). Both pre-eclampsia and lUGR have been 
associated with placental hypoxia although this is controversial (Kingdom and 
Kaufmann, 1997). Several recent studies have focussed on the role o f oxygen in 
modulating CTB proliferation and invasion. One study reported that CTB cells 
cultured under hypoxic conditions (2% O2) failed to upregulate the integrin a l p l  in a 
similar manner to CTB from pre-eclamptic pregnancies (Genbacev et al. 1996). 
Hypoxic Inducible Factor (H IF -la) may be a key mediator o f this response to 
hypoxia. Placentae from pre-eclamptic pregnancies overexpress both HIF-1 a  and 
HIF-2 a  proteins (Rajakumar et al. 2001). Additionally, Rajakumar et al showed by 
western blotting that cells in placentae from normal pregnancies upregulate H IF -la  
and HIF-2 a . in response to low oxygen and that the proteins are degraded when 
oxygen levels are increased. In contrast, explanted villous tissue from pre-eclamptic 
pregnancies failed to degrade HIF-1 a  and HIF- 2 a  when transferred from a low to a 
high oxygen environment (Rajakumar et al. 2003).
Caniggia et al also found abnormal elevation o f HIF-1 mRNA and protein 
expression in placental tissue from pre-eclamptic pregnancies compared to normal 
placental tissue (Caniggia and Winter, 2001). The same group had previously shown 
an association between the expression o f TGF-p3 and HIF-1 a  and demonstrated that 
inhibition o f the later reduced TGF- (33 mRNA levels, reduced trophoblast 
proliferation and triggered both MMP-9 and a l  integrin expression (Cannigia et al. 
1999). Moreover, inhibition o f TGF-P has been reported to restore the invasive 
capability o f CTB from explants from patients with pre-eclampsia and it was
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suggested this may act through HIF (Caniggia et al. 2000b). The implications o f these 
studies are that if  oxygen levels fail to increase in pre-eclampsia, or if  any increase is 
not detected, then levels o f both H IF -la  and TGF-p3 remain high, impairing 
trophoblast invasion. The authors reported that TGF-(33 was increased in pre­
eclampsia placentae. However, other studies do not support an involvement o f TGF-(3 
in the development o f pre-eclampsia (Lyall et al. 1998; Lyall et al. 2001a).
1.7.7 Two-stage model of pre-eclampsia
It has been suggested that pre-eclampsia could be explained by a two-stage model in 
which a poorly perfused placenta releases factor(s) into the maternal circulation which 
result in generalised endothelial dysfunction (Redman, 1991). Poor perfusion of the 
placenta, resulting from insufficient trophoblast invasion and placental bed vascular 
remodelling, may cause the placenta to secrete cytokines or growth factors in 
response to decreased oxygen (Benyo et al. 1997). Alternatively the reduced perfusion 
may cause an increase in trophoblast apoptosis/necrosis, leading to an increase of 
particulate material in the maternal circulation and subsequent endothelial activation 
(DiFederico et al. 1999; Redman and Sargent, 2000). Another possibility is that 
oxidative stress caused by the decreased oxygen flow to the placenta creates free 
radicals, which then cause an inflammatory response in the maternal circulation 
(Hubei et al. 1989; Hubei, 1999). This pathway could involve the activated leukocytes 
present in the maternal circulation in pre-eclampsia (Sacks et al. 1998; Redman et al. 
1999). This is discussed further in section 1.7.8. Indeed since a maternal inflammatory 
response occurs in normal pregnancy, the extent o f endothelial activation seen in pre­
eclampsia may represent an over-exaggeration o f the normal maternal response to 
pregnancy.
1.7.8 The role of oxidative stress in the development of pre-eclampsia
As discussed previously, in pre-eclampsia a heightened maternal inflammatoiy 
response to pregnancy occurs as evidenced by an increase in several maternal markers 
(section 1.7.5). Accumulating evidence suggests that the link between the maternal 
syndrome and the compromised placenta may be found in placental synthesis of
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reactive oxygen species (ROS) and the consequent free-radical associated dysfunction 
o f the maternal vasculature. There is considerable evidence of oxidative stress in 
women with pre-eclampsia (reviewed in Hubei, 1999).
Hypoxia can affect cells through increased generation o f free radicals 
(Halliwell and Gutteridge, 1999). While metabolism is aerobic electrons passed along 
the mitochondrial respiratory chain are combined with oxygen to form water. At times 
electrons are leaked and combine with molecular oxygen to form the superoxide anion 
O2 or other ROS. In hypoxia the formation o f ROS is increased. ROS attack all types 
of biological molecules resulting in damage to DNA strand breakage, alteration o f 
DNA bases, lipid peroxidation and protein misfolding. Furthermore ROS also 
increase cellular calcium concentrations leading increased apoptosis and necrosis 
(Halliwell, 1996). Ischaemia-reperfusion where tissue is subjected to a period of 
hypoxia followed by perfusion with blood and hence oxygen is an even more potent 
inducer of free-radical formation than hypoxia alone. Interestingly, generation o f 
oxygen free radicals is also increased under hyperoxic conditions (Freeman and 
Crapo, 1981).
It was reported many years ago that mitochondria in the placenta o f women 
with pre-eclampsia are both more abundant and of abnormal appearance (Jones and 
Fox, 1980) and show signs o f oxidative damage (Wang and Walsh, 1998). This could 
lead to increased electron leakage and so increase the formation o f free radicals. ROS 
are likely to be generated through the xanthine oxidase/dehydrogenase pathway and 
this may also be stimulated by ischaemia/reperfusion iiijuiy as described above. 
Failure to detoxify ROS because of a lack o f antioxidant defences may also contribute 
to oxidative stress in pre-eclampsia. Alternatively or additionally, ROS may be 
generated by leucocytes, which are activated in pre-eclampsia or by the endothelium 
(reviewed in Poston, 2003).
In uncomplicated pregnancies it is likely that blood flow to the placenta is 
generally adequate for fetal and placental development, although some intermittent 
perfusion may occur, resulting in low levels o f ischaemia/reperfusion injury. This 
may explain the low levels o f oxidative stress seen in normal placentae (Hung, 
Skepper and Burton, 2001). In cases of pre-eclampsia with lUGR, chronic hypoxia in 
the placenta is likely to occur, as a result o f incomplete transformation o f the spiral 
arteries due to reduced trophoblast invasion (section 1.7.6). Furthermore, the lack of 
transfoimation o f the spiral arteries may lead to increased intermittent
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vasoconstriction of the proximal segments o f these arteries as a result o f maternal 
vasomotor control being maintained. Narrowing of the spiral arteries through acute 
atherosis is also observed. Both o f these situations could result in ischaemia- 
reperfusion type injury and initiate oxidative stress within the placenta at an early 
stage. In late onset pre-eclampsia with normal biithweight, there is evidence o f 
increased oxidative stress (Hubei, 1999) in the placenta but little evidence to support 
chronic intraplacental hypoxia. In this scenario there may be an exaggeration of the 
situation in normal pregnancy, perhaps with greater fluctuations in oxygen 
concentrations due to incomplete conversion o f the spiral arteries or deficiencies in 
antioxidant defences in the placental tissue.
In normal pregnancy it has been reported that the production o f protective 
antioxidant molecules is upregulated at the same gestational age as maternal blood 
begins to perfuse the placenta (Jauniaux et al. 2000). This may protect against the 
potential increase in oxidative stress that would accompany the rise in oxygen tension 
in the placenta. Thus antioxidant therapy using vitamins C and E may offer 
protection against pre-eclampsia by reducing oxidative stress (Chappell et al. 1999) 
and clinical trials are currently underway.
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1.8 Aims of the current study
As outlined in this chapter, successful trophoblast invasion is critical to the outcome 
of pregnancy. Failure of this process has been implicated in several complications of 
pregnancy including pre-eclampsia.
MMPs and their regulators may be of critical importance in regulating 
trophoblast invasion. In order to determine the role of these proteins in pre-eclampsia 
it is first important to understand their expression and activity in normal pregnancy. 
As previously discussed, there is no consensus of opinion at which stage in gestation 
and where in the placenta these molecules are expressed. The aims of the current 
study were initially to investigate placental MMP expression and activity throughout 
gestation and thereafter to study various regulators of MMP activity, specifically 
TIMP-1, TIMP-2 and H lF-la. Although several studies have investigated these 
molecules, it was hoped to carry out a more comprehensive analysis than had been 
previously undertaken. Integral to achieving this aim would be determining which 
methods of studying MMP expression were most suited to placental tissue.
In addition to obtaining a comprehensive understanding of placentation in 
normal pregnancy and relating this to placentation in pre-eclampsia, in vivo and in 
vitro models of pre-eclampsia may be useful in elucidating the underlying pathology 
in the disease. Since oxygen has been implicated as a critical regulator of trophoblast 
invasion high altitude pregnancy where the mother is subjected to chronic hypoxia has 
been suggested as one such model.
MMP expression is decreased in pre-eclampsia and in low oxygen tension, 
hence it was hypothesised that placenta at high altitude may show alterations in MMP 
expression. Thus an aim of the study was to quantify MMP-9 and MMP-2 expression 
in term placentae from various altitudes in order to determine whether MMP 
expression was altered in placentae at high altitude compared to low altitude.
Maternal circulating concentrations of CAMs are markers of endothelial 
activation and are elevated in pre-eclampsia. Hence the subsequent objective of the 
study was to measure concentrations of circulating CAMs in the maternal serum from 
placentae at various altitudes.
Placental villous explant culture in low oxygen tension has also been used in 
many previously published studies as a model for pre-eclampsia. The current study
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aimed to set up this model in a laboratory where it had not previously been used and 
to initially examine explant behaviour at normal and low oxygen tensions before 
I studying MMP expression in both conditions. The model would then be extended to
utilise villous tissue from chorionic villous samples (CVS), as this had not previously 
been attempted.
In summary the aims of the thesis were to determine the expression and 
activity of MMP-9 and -2 and their regulators in normal pregnancy and to investigate 
two different models of pre-eclampsia.
I
A :
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► Chapter 2: Materials and Methods
This chapter describes the methodology used in this thesis and the source of reagents 
and relevant equipment.
2.1 Buffers
Water (dHzO) used in buffer preparation was Milli-Q RG Ultrapure.
2.1.1 General buffers
PBS Phosphate buffered saline: A solution of one PBS tablet per 100ml dHiO, 
stored at 4°C.
PBST PBS with 0.4% polyoxyethylene sorbiton monolaurate (tween-20), stored 
at 4 T .
TBS Tris buffered saline: 20mM tris, 0.5M NaCl, pH 7.5, stored at 4°C.
TBST TBS with 0.4% tween-20, stored at 4°C.
TBSTB TBST with 0.25% Bovine serum albumin (BSA), stored at 4”C.
2.1.2 Cell culture reagents 
Culture medium for explant culture
.-.j'
1: 1 ratio of Dulbecco’s Modified Eagle’s Medium (DMEM): Hams F12 culture 
medium, supplemented with 10% fetal bovine serum (FBS), 1% lOOx L-glutamine, 
1% lOOx fungizone and 1% lOOx penicillin/streptomycin.
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2.1.3 Tissue homogenisation buffer
25mM tris, pH 7.6, 250mM sucrose. The buffer was sterilized by autoclaving and 
stored at 4°C. 12.5pl/ml protease inhibitor cocktail designed for use with mammalian 
tissue was added on the day o f use.
2.1.4 Western blotting and zymography buffers
Resolving gel buffer 
1.5M tris, 0.4% SDS, pH 8.8.
Stacking buffer
IM  tris, 0.4% SDS, pH 6.8.
5x running buffer
25mM tris, 190mM glycine, diluted 1:5 in dH20 on the day o f use.
2x loading buffer
1.2ml o f IM  tris, pH 6.8, 2ml glycerol, 4ml of 10% SDS, 0.8ml dH20 and a few 
bromophenol blue crystals. IM  dithiolthreitol (DTT) was frozen at -20°C in 1ml 
aliquots and on the day o f use was added to loading buffer at a ratio of 1:4. For non­
reducing gels DTT was omitted.
Transfer buffer
2mM tris, 190mM glycine, 20% methanol.
Zymography wash buffer
50mM tris, pH 7 .4 ,150mM NaCl, 2.5% triton X-100.
Zymography reaction buffer
50mM tris, pH 7.4, 5mM CaCh, 0.02% NaNs.
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MMP activation buffer
50mM tris, pH 7.5, 0.15M NaCl, 5mM CaCb.
2.2 Antibodies used in western blotting and immunohistochemistry
MMP-9
Anti-MMP-9 (gelatinase B), sheep polyclonal Immunoglobulin G (IgG) (Biogenesis, 
catalogue no. 5980-0911).
Anti-MMP-9 mouse monoclonal, IgGl, directed against the carboxy-terminal domain 
(residues 626-644) of human MMP-9 (Chemicon, catalogue no. MAB 3309).
MMP-2 (Biogenesis)
Anti-MMP-2 (gelatinase A), sheep polyclonal IgG (Biogenesis, catalogue no. 5980- 
0211).
LP34 (Novocastra)
Anti-Cytokeratin 5/6 and 18 intermediate filament proteins, mouse monoclonal IgGl, 
clone LP34 (Novacastra, catalogue no. NCL-L-LP34).
TIMP-1 (Biogenesis)
Anti-TIMP-1, rabbit polyclonal purified Ig (Biogenesis, catalogue no. 9013-1108). 
TIMP-2 (Biogenesis)
Anti-TIMP-2, sheep polyclonal, purified Ig, raised against loop 6 of synthetic human 
TIMP-2 (Biogenesis, catalogue no, 9013-2609).
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HIF"la (Serotec)
Anti-HIF“la , goat polyclonal, purified IgG, Raised against peptide mapping near the 
carboxy-terminus of HIF-Ia of human origin (Serotec catalogue no. Sc-8711).
Ki67 (Novacastra)
Anti-Ki67 Liquid mouse monoclonal antibody IgGl. Raised against prokaryotic 
recombinant fusion protein corresponding to a 1086bp Ki67 motif-containing cDNA 
fragment (Novacastra catalogue no. NCL-L-Ki67-MM1).
Table 4 Antibody dilutions
Antibody Immunohistochemistry
dilution
ABC kit 
used for 
ICC
Western
blotting
dilution
MMP-9
(Biogenesis)
1/500 Sheep 1/1000
MMP-9
(Chemicon)
N/A* N/A* 1/1000
MMP-2
(Biogenesis)
1/250 Sheep 1/1000
TIMP-1 1/250 Universal N/A
TIMP-2 1/300 Sheep N/A
H IF-la 1/250 Goat N/A
LP34 1/200 Universal N/A
Ki67 1/250 Universal N/A
*N/A = Not applicable
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The primary antibody was omitted and substituted with either PBS or the relevant Ig 
fraction o f non-immune serum from sheep, goat, rabbit or mouse at the same 
concentration as the primary antibody as a negative control in each experiment 
performed. No staining was present on any o f the controls. A representative control 
for each antibody is shown in figure 9.
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Figure 9 Representative negative control for primary antibodies used in 
immunohistochemistry (Relevant Ig fraction substituted for 
primary antibody)
MMP-9 MMP-2
TIMP-1 TIMP-2
HIF-Ia LP34
Ki67
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2.3 Purified MMP proteins used as controls in western blotting and
zymography
2.3.1 Purified MMPs 
MMP-9 (Biogenesis)
Purified human pro-MMP-9 (gelatinase B), 0.4mg/ml, >95% purity, 92kDa single 
band which upon activation exhibits a relatively stable band at 84kDa (Biogenesis 
Catalogue no. 5980-0957).
MMP-2 (Biogenesis)
Purified human pro-MMP-2 (gelatinase A), 0.202mg/ml, >98% purity, 72kDa single 
band whieh upon activation produces a band at 68kDa. However this 68kDa form is 
readily degraded to smaller species (Biogenesis Catalogue no. 5980-0257).
2.3.2 Activation of purified MMPs
Method 1 : APMA activation of MMP-9
0.021 g 4-aminophenylmercuric acetate (APMA) was dissolved in 210pl 
dimethylsulphoxide (DMSO) by vortexing. 211 pi o f dH20 was added to the solution 
resulting in a 142mM solution o f APMA and 50% DMSO. A working concentration 
was prepared by adding lOpl o f the 142mM APMA solution to 345pi o f H 2 O to give 
a final concentration of 4mM APMA. 20pg MMP-9 was added in a 1:1 ratio (2pi + 
2pi) to 4mM APMA, the eppendorf was vortexed and incubated at 37°C for 18 hrs. 
The activated MMP-9 was then diluted with dH20 to the required concentration for 
loading onto the gel.
Method 2: Trypsin activation of MMP-9
500pg TPCK-trypsin was diluted in 1ml activation buffer (section 2.1.4) and stored in 
aliquots at -20“C. 20pl o f this solution was added to a 10pi aliquot of 0.4mg/ml 
MMP-9, and the total volume made up to lOOpl with activation buffer. The reaction
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mixture was incubated at 1>TC for 20 min. Following this, lOpl of a Img/ml solution 
of aprotinin in activation buffer was added to stop the reaction. For varying 
concentrations of MMP-9, the trypsin and aprotinin concentrations were scaled 
accordingly.
2.4 Placental sample collection
2.4.1 Gestational study samples
First and second trimester placentae (20 of each) were obtained from women 
undergoing termination of apparently normal pregnancies at the Royal Victoria 
Infirmary, Newcastle-upon-Tyne. Informed consent was obtained from each woman. 
The samples were collected and stored for a previous study and full details of the 
samples are given in previous publications (Lyall et al. 1998; Lyall et al. 1999a; Lyall 
et al. 2000a; Lyall et al. 2001a; Robson et al. 2002; Simpson et al. 2002). An initia! 
ultrasound scan was performed to confirm fetal viability and determine gestational 
age. After evacuation of the uterine contents, placental villous samples were collected 
from all cases. 30 term placenta were obtained from women undergoing elective 
caesarean sections (ELCS).
All samples were collected directly into liquid nitrogen-cooled isopentane and 
stored sealed at -70°C. These samples were transported to Glasgow on dry ice and 
stored immediately upon arrival at -70°C.
2.4.2 High altitude study samples
2.4.2.1 Placental collection
The study comprised 6 women residing at 1600m (Denver, Colorado), 10 women 
residing at 3100m (Leadville, Colorado) and 10 women residing at sea level 
(Glasgow, Scotland). Inclusion criteria were that subjects were healthy non-smokers 
and without chronic conditions predisposing to pre-eclampsia such as renal disease, 
diabetes or obesity. Subjects resided at their respective altitudes of residence from 
conception to birth. All Denver and Leadville specimens were collected and supplied
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by Dr Stacy Zamudio, Dept of Obstetrics, Gynecology and Women’s Health, Newark, 
USA. Informed consent was obtained from each patient, according to the procedures 
approved by the Institutional Review Board of the University of Colorado or by the 
Ethics Committee of Yorkhill Hospital, Glasgow as appropriate. Placentae were 
collected immediately following birth by ELCS. Gross examination was performed to 
exclude any major abnormalities and the placenta was weighed. After removing 2cm 
around the cord insertion and 2cm of the perimeter, the placenta was cut 
longitudinally into 5 strips. The placental strips were dissected to produce Icm^ 
blocks and a random 5 of these were chosen to process further.
2.4.2.2 OCT/Iiquid nitrogen freezing
One full thickness block from each placenta to be included in the high altitude study 
was snap frozen directly in liquid nitrogen. The blocks received from Leadville and 
Denver had been processed according to the OCT method described below, thus it 
was necessary to treat the blocks from Glasgow (low altitude) placentae in the same 
way to exclude any differences due to experimental method.
For OCT processing full thickness placental blocks were rinsed three times in 
PBS until the blood was washed away. The blocks were then dehydrated in a stepwise 
manner through a series of sucrose solutions in PBS (2, 4, 6, 8, 10, 12%) for one 
minute in each, before being placed into a universal container on ice containing 1ml 
of a 1:1 ratio of OCT: 15% sucrose in PBS, After 30 min the blocks were removed 
from the universal container, and placed in a bed of OCT in plastic holders. The 
holder was wrapped securely in tinfoil and placed in liquid nitrogen. After snap 
freezing the samples were placed onto dry ice and stored at -70”C.
2.4.2.3 Maternal serum collection
Fifteen women from Denver, Colorado (moderate altitude group, 1600m) and 19 
women from Leadville, Colorado (high altitude group, 3100m) gave informed consent 
to the study procedures, approved by the University of Colorado Health Science 
Institutional Review Board. Healthy primipara were identified by referral or by 
response to approved flyers placed in waiting rooms. Interested women were recruited 
to participate as early in pregnancy as possible. Approximately 10ml of blood was
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withdrawn from the antecubital vein once per month throughout pregnancy and at 3 
months postpartum. Blood was drawn into a serum separator vacutainer. Blood was 
allowed to clot for 1 hour, serum was separated by centrifugation for 5 min at 
lOjOOOrpm and placed in liquid nitrogen or a minus 70°C freezer. After the birth of 
the baby, gestational ages at the time of the blood draws were back-calculated from 
the clinically assessed gestational age and these dates are reported here as the 
gestational age at which the blood samples were obtained.
2.4.3 Termination of pregnancy (TOP) collection for explant culture
TOPs (6 to 12 weeks of gestation) were carried out at Gartnaval General Hospital, 
Glasgow. Ethical approval to use the placentae obtained from TOPs was granted by 
Yorkhill ethics committee. Terminations were performed by vacuum suction and the 
evacuation products were transferred immediately, on ice, to the laboratory.
2.4.4 Chorionic villous sample (CVS) collection for explant culture
CVS samples were obtained from women undergoing cytogenetic investigation in the 
Institute of Medical Genetics, Yorkhill Hospital. Each sample was transported in 
transport medium to the cytogenetics diagnostic laboratory. Once tissue had been 
removed for diagnosis, any remaining tissue was available for research purposes. 
CVS tissue was always processed on the same day the sample was taken. Ethical 
approval to use the placental tissue obtained from CVS was granted by Yorkhill ethics 
committee.
2.5 Expiant culture methods
2.5.1 Tissue dissection
The method used was based on the method described by Genbacev et al. (1992). 
Villous tissue was obtained from CVS performed in the Queen Mother’s Hospital or 
from TOPs obtained from Gartnaval General Hospital (section 2.4.372.4.4).
CVS contained only very small pieces of villi and were rinsed in PBS and not 
dissected further. TOP tissue was rinsed with PBS and any fetal tissue removed.
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Villous tissue, identified under a dissecting microscope by its attachment to the 
chorionic membrane and by its white fingerlike fluffy projections, was transferred to a 
separate 35mm dish. Following a further rinse, the tissue was dissected to give small 
(5-20mg wet weight) pieces of villi. Each piece of villi, from CVS and TOPs to be 
used was weighed in a sterile petri dish.
2.5.2 Culture of explants on matrigel
All explant culture was carried out in a Class II laminar flow cabinet. Frozen aliquots 
of matrigel were thawed on ice for Ihr, and 150pl of matrigel was added to each 
insert (Millicell 12mm culture plate inserts (pore size 4pm)) using pre cooled pipette 
tips. Each insert was placed in a well of a 24-well plate. The incubators used were 
Forma Scientific water-jacketed incubators. The low oxygen incubator was set at 2% 
02/5%C02/93%N2 and the normal oxygen incubator was set at 
18%02/5%C02/77%N2. The oxygen and carbon dioxide tension in the incubators was 
checked regularly using a Fyrite calibrator. Dissolved oxygen levels 125ml of test 
culture medium in a T75 vented lid flask was measured using a Jenway Model 970 
dissolved oxygen meter and electrode (Jencons, UK) (discussed in chapter 8).
The 24-well plate with inserts was incubated for 30 min at 37°C in 18% O2 
until the matrigel had polymerised. Thereafter one piece of villous tissue was 
carefully placed centrally on each insert using a pipette tip and teased until it was 
lying as uncurled as possible. Any excess liquid medium was removed and the plate 
was incubated for 60 min at 37“C in 18% O2 . 400pl of culture medium was added to 
the lower chamber of the culture plate and the plate was incubated overnight at 37®C 
in 18% O2 . The following morning, 200pl of culture medium was added to the upper 
surface of the insert to submerge the explant. The explant was incubated for 96/144 
hrs at 37°C in either the normal or low oxygen incubator and the culture medium was 
collected and changed every 24/48 hrs. All culture medium was stored at -20°C until 
assayed.
Photographs were taken of the explant at each culture medium change using 
an Olympus S2H microscope with an Olympus C35DA2 camera attachment. The 
number of sites of outgrowth of CTB cells in each explant were recorded and 
migration of cells into or through the matrigel was scored on a scale of 0 -  5 (0 -  no
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migration, 1 -  one or two sites of localised migration, 2 -  several sites of localised 
migration, 3 -  moderate migration, 4 - moderate to extensive migration, 5 - extensive 
migration from several sites around the explant). Cells migrating into the matrigel 
were easier to identify and score when viewed directly under the microscope than in 
the final photographic images.
2.5.3 Expiant freezing
The matrigel was carefully dissected out of the insert using a surgical blade and gently 
blown onto a cork disk. Subsequently the disk was placed upside down in liquid 
nitrogen cooled-isopentane for 30 sec to freeze the tissue. The corks were transferred 
to pre-cooled pots for storage at -70 °C.
2.6 Immunohistochemistry
2.6.1 Preparation of frozen tissue sections
2.6.1.1 Silane coating of slides
Double frosted microscope slides were silane coated (all procedures were carried out 
in a fume hood). Slides were arranged in racks so that both sides of the slide were 
treated. The rack was dipped in acetone for 5 min, followed by 2% 
dimethylchlorosilane solution in acetone for 5 min. The slides were rinsed twice in 
acetone followed by a 30 min rinse in running distilled water. The slides were then 
air-dried in the racks overnight in a Hybaid hybridisation oven at 37°C.
2.6.1.2 Ciyosectioning
6pm sections of all samples were cut on a cryostat. The internal temperature of the 
cryostat was -25”C. Placental blocks or corks containing explants on matrigel were 
mounted onto a chuck using OCT and successive sections were cut using a disposable 
microtome blade. Any section that appeared to fold on cutting was rejected. One
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section of a tissue block or six sections of an explant were mounted onto each slide. 
The slides were air-dried overnight before being placed in a -70”C freezer for storage.
2.6.2 Avidiii/Biotin immunoperoxidase staining of frozen tissue sections
The slides were brought to room temperature in a pre-cooled container, and a ring was 
marked round the placental section using a DAKO pen. The sections were fixed in 
acetone for 5 min followed by ethanol for 5 min and rinsed several times in dH20. 
Sections were blocked with the appropriate serum from a Vectastain ABC kit (lOOpl 
serum in 5ml PBS) for 30 min at 37“C, then washed in PBS for 5 min.
Primary antibody was diluted appropriately (table 4) in the blocker, 50pl was 
pipetted onto each section, followed by incubation for 90 min at 37°C, and 2 x 5  min 
washes in PBS.
The secondary antibody was diluted 1/50 in the blocker. 50pl was placed on 
the sections followed by incubation for 30 min at 37‘^ C, and 2 x 5  min washes in PBS. 
The slides were soaked in 1% hydrogen peroxide in methanol for 15 min at room 
temperature in order to quench any endogenous peroxide activity present, then 
washed for 2 x 5  min in PBS.
Avidin Biotin complex (ABC) was prepared by adding lOOpl reagent A and 
100pi reagent B from the kit to 5ml PBS, This was incubated at room temperature for 
30 min. lOOpl was placed on each section and left for 30 min at room temperature, 
followed by 2 X 5 min washes in PBS. 3,3 diaminobenzidine (DAB) was prepared by 
adding one DAB tablet and one urea tablet to 5m 1 dH20. The resultant solution was 
filtered and lOOpl placed on each section for 10 min.
The slides were washed in running water for 10 min, counterstained with 
Harris’ haemotoxylin, progressively dehydrated in ethanol (30%, 50%, 70%, 100% 
each for 1 min, then 100% for 5 min) and soaked in histoclear for 5 min. Coverslips 
were mounted using DePeX mounting medium and the slides were air dried 
overnight. Slides were viewed using an Olympus BH2 microscope and images were 
captured using an Olympus DP 10 camera and Flashpath software. The staining was 
scored by an observer blinded to the tissue identity on a semi-quantitative scale where 
0 = no staining, 1 -  very mild staining, 2 = mild staining, 3 = moderate staining and 4 
= strong staining.
108
2.7 Placenta homogenisation
Tissue homogenisation buffer (4ml) (section 2.1.3) was aliquoted into a universal 
container and kept on ice. The frozen placental block to be homogenised was 
weighed, then ground in liquid nitrogen with a mortar and pestle to a fine powder. 
The liquid nitrogen was allowed to evaporate before the powder was placed in the 
buffer. Homogenisation buffer was added to the tissue at a final ratio of 4:1 (v:w).
The tissue was homogenized in 6 bursts of 10 sec at full speed, with cooling 
on ice between bursts using a Polytron homogeniser. The homogenate was then 
aliquoted into eppendorfs and spun at 5000g for 10 min at 4°C. The supernatant was 
aliquoted into fresh tubes and spun again at 50,000g for 20 min at 4®C. The 
supernatant was removed and kept as the cytosol fraction and the pellet was 
resuspended in 400ul of 25raM tris, pH 7.6. The amount of protein in the sample was 
quantified by the method of Bradford (section 2.10.1).
2.8 Western Blotting
2.8.1 Denaturing polyacrylamide gel electrophoresis (PAGE) and protein 
transfer
A Mini Protean II western blotting apparatus was used in all experiments except for 
the experiment in which a large gel was required when a Protean II xi cell tank was 
used. A 7.5% SDS polyacrylamide resolving gel was poured (4.5ml of 30% 
acrylamide, 1.2ml of 50% glycerol, 4.5ml resolving gel buffer (section 2.1.4), 7.7ml 
dH20, 90pl of 10% ammonium persulfate (APS) and 9 pi N,N,N’,N’ 
tetramethylethylenediamine (TEMED)). The gel was overlayered with isopropanol 
and left to set for 45 min at room temperature, after which the isopropanol was 
washed out with distilled water.
The stacking gel was poured (2.7ml of 30% acrylamide, 5ml stacking gel 
buffer (section 2.1.4), 12.2ml dH20, lOOpl 10% APS and 20pl TEMED) and a 10 
well comb with 0.75mm spacers was inserted. The gel was left to set for 30 min, the 
comb was removed and the wells were washed out with dH20. Samples were mixed 
1:1 with 2x loading buffer (section 2.1.4). The samples were boiled for 5 min at 95°C
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before loading. The total amount of sample loaded per well was variable depending 
on the protein concentration required but did not exceed 20pl or lOOpg protein. Pre­
stained SDS-PAGE low range molecular weight (Mwt) markers range 20,000-
113,000 kDa were loaded on each gel.
The gel tank was assembled, running buffer (section 2.1.4) was added to the 
tank and the gels were run at a constant current of 15mA and at maximum voltage 
(400V) until the dye front had reached the bottom of the gel (Electrophoresis power 
supply 400L). Protein was transferred overnight in transfer buffer (section 2.1.4) at a 
constant voltage of 30V and at maximum current (250mV), to nitrocellulose 
membranes. The transfer was carried out at 4°C. Immunoblotting was then carried out 
as described in section 2.8.3
2.8.2 Spotting of purified MMP proteins on nitrocellulose membrane for 
antibody comparison
Purified MMP-9 and MMP-2 purified proteins (2.3) were spotted at varying 
concentrations using a pipette onto nitrocellulose membrane. The membrane was left 
to dry until the spots could no longer be detected by eye (about 90 sec). 
Immunoblotting was then carried out as described in section 2.8.3.
2.8.3 Immunoblotting
Filters were blocked for 1 hr at room temperature in 5% non-fat dried milk (Marvel) 
in PB ST (section 2.1.1) or in 5% donkey serum in PBST.
The filters were incubated with the primary antibody at an appropriate dilution 
which was predetermined for 1 hr at room temperature (table 2.2) after which they 
were washed 3 x 5  min in PBST. The secondary antibody (horseradish peroxide 
conjugated donkey anti sheep/goat IgG) was diluted 1/1000 in 1% marvel in PBST, 
and ineubated with the filters for 1 hr at room temperature. The filters were then 
washed 3 x 5  min in PBST.
Proteins were detected using the Amersham Enhanced Chemiluminescence 
(ECL) detection system and the filters were exposed to hyperfilm ECL for various 
times under safety illumination. The film was developed in an X-ray film processor.
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The positions of the molecular weight markers were recorded, a graph was plotted on 
semi log scale and the molecular weights of any visible bands were calculated.
2.9 Zymography
2.9.1 Denaturing polyacrylamide gel electrophoresis (PAGE)
The method used was based on the method described by Herron et al. 1986. The same 
apparatus was used as for western blotting (section 2.8.1). Samples were separated on 
a 7.5% SDS polyacrylamide resolving gel containing varying concentrations of 
gelatin. A 3% solution of gelatin in dH20 was prepared and stored in aliquots at -  
20°C. Table 5 shows the composition of gels with varying final gelatin concentrations. 
Buffer A and B were the same as used in western blotting.
Table 5 Composition of zymography gels
Final % 
gelatin
30%
acrylamide
Buffer
A
dHzO 3%
gelatin
10%
APS
TEMED
0.1% 4.5ml 4.5ml 8.3ml 0.6ml 90pl 9pl
0.05% 4.5ml 4.5ml 8.6ml 0.3ml 90pl 9pl
0.025% 4.5ml 4.5ml 8.75ml 0.15ml 90pl 9pl
The gel was poured and layered with isopropanol and left to set for 45 min at 
room temperature, after which the isopropanol was washed out with dH20. The 
stacking gel was then poured (2.7ml of 30% acrylamide, 5ml stacking gel buffer, 
12.2ml dHzO, lOOpl 10% APS and 20pl TEMED) and a 10 well comb with 0.75mm 
spacers was inserted.
The gel was left to set for 30 min, the comb was removed and the wells were 
washed out with dH20. Molecular weight markers were the same as for western 
blotting (section 2.8.1). Samples were loaded and then the gels were run at a constant 
current of 15mA and maximum voltage (400V) until the dye front had reached the 
bottom of the gel.
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2.9.2 Zymographic detection of gelatinases
The gel was subsequently washed in zymography wash buffer (section 2.1.4) for 3x 
30 min to wash out SDS and incubated in reaction buffer (section 2.1.4) for 18 hrs at 
4°C. The gel was then stained in 0.3% coomassie brilliant blue stain (BDH) in dH20 
for 30 min and destained for 1 x 5  min, 2 x 30 min, 1 x 5 min in destain buffer (20% 
methanol, 10% acetic acid). The bands on the gel were analysed by scanning 
densitometry using a GS-700 imaging densitometer in conjunction with Multianalyst 
software and optical density (OD) was determined for each band.
2.10 Assays
2.10.1 Bradford protein assay
The method is that described by Bradford, (1976). BSA stock standard solution was 
stored at -20°C in lOOql aliquots o f 1.4mg/ml. On the day o f use ISOql H 2O was 
added to give a total volume of 280ql and a concentration o f 500pg/ml. A series of 
standard solutions (0-500pg/ml) using the dilutions below was prepared.
Concentration of standards Volume of standards Volume dHzO
plates followed by 200pl o f bradford’s reagent and the plate was placed on a plate
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(pg/ml) (Bl) m
0 50
100 10 40
200 20 30
300 30 20
400 40 10
500 50 -
Procedure
10pi of standard solutions and samples were added to duplicate wells on microtitre
shaker for 10 sec to ensure thorough mixing. After a period of 5 min to 1 hr, the 
absorbance (Abs) at 595nm was read using a biochromatic plate reader and analysed 
using Genesis software. A standard curve was automatically plotted and total protein 
values calculated from the standard curve.
2.10.2 MMP-9 activity assay (Amersham Pharmacia)
The reagents were prepared as described in the reagent preparation protocol, as were 
the working standards (0, 0.5, 1, 2, 4, 8, 16 ng) for the normal standard curve. For the 
lower range standard curve the values were 0, 0.125, 0.25, 0.5, 1, 2 and 4ng.
Assay buffer (1 lOpl) was added to the zero wells, and lOOpl of each standard 
to the appropriate wells, lOOpl of the samples was then added to the appropriate 
wells. The plate was covered with the plate lid and incubated at 4“C overnight.
The following morning each of the wells was aspirated, washed 4 times with 
wash buffer, and blotted on tissue paper. 50pl of APMA (ImM in DMSO) was added 
to each well containing the standards and those wells where total (i.e. activated and 
pro) MMP-9 was to be measured and 50pi of assay buffer was added to each well 
where active MMP-9 was to be measured. The plate was shaken for 20 sec, covered 
with the plate lid and incubated at 37°C for 90 min.
The detection reagent was prepared just before the end of this incubation 
period as described in the reagent preparation section. 50pl of the detection reagent 
was added to each well and the plate was shaken for 20 sec. The plate was read at 
405nm to obtain a zero time reference value. The plate was then covered and 
incubated at 37“C. At Ihr intervals thereafter the plate was shaken for 20 sec and 
optical density (OD) at 405nm determined and absorbance calculated. This was 
continued until saturation point was reached. A standard curve was plotted for each of 
the time-points, and the values of MMP-9 in the samples calculated from the best 
standard curve.
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2.10.3 Vascular Cell Adhesion Molecule-1 (VCAM-1), Intracellular Cell 
Adhesion Molecule-1 (lCAM-1) and Endothelial Selectin (E-Selectin) 
assays (Parameter Assays, R&D Systems)
Samples and reagents were prepared as described on page 5 of the instruction 
manuals. The serum samples to be assayed were diluted 1:50 in sample diluent for the 
VCAM-1 assay and 1:20 for the ICAM-1 and E-Selectin assays. Standards were 
assayed in duplicate.
lOOpl diluted conjugate was added to each well followed by lOOpl of 
standards, samples, and control, with thorough mixing. The plate was covered and 
incubated at 37“C for 90 min. The wells were then emptied by aspiration and washed 
6 times with 300pl wash buffer. On the final wash, the plate was tapped on paper 
towels to ensure all liquid was removed.
100pi substrate was then added to each well followed by incubation at room 
temperature for 20 min. Finally lOOpl of stop solution was added to each well.
The OD was determined after 5 min at 405nm with correction at 620nm. The 
standards, from which a standard curve was plotted, were in the range 0-75.78ng/ml, 
0-49.55 ng/ml and 0-10.52 ng/ml for each of the assays respectively and the control 
samples were well within the required range. Levels of VCAM-1, ICAM-1 or E- 
Selectin in the serum samples were computed automatically from the standard curve. 
The inter and intra-assay precision coefficient of variance (% CV) values are shown 
for each assay.
VCAM-1: Inter-assay precision CV = 8.5-10.2%, Intra-assay precision CV = 4.3- 
5.9%
ICAM-1: Inter-assay precision CV = 6.0-10.1%, Intra-assay precision CV = 3.3- 
4.8%
E-Selectin:Inter-assay precision CV = 5.7-8.8%, Intra-assay precision CV = 4.7-5%
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2.11 Statistical methods
All data analysis was performed on the statistical analysis package SPSS for 
Windows. Below is an outline o f the tests used in this thesis.
2.11.1 Descriptive statistics
2.11.1.1 Mean
The mean o f a group of data was calculated by dividing the sum of all the cases by the 
number o f cases. This gives a central value o f the data and can only be used reliably 
when the data is not skewed i.e. there is an even or normal distribution,
2.11.1.2 Median
The median o f a group of data refers to the middle value when the information is 
sorted in ascending order. This can also be the average of the two middle cases if 
there is an even number o f data. As it measures central tendency the median is a 
useful descriptive parameter to use when data is skewed since it is not disrupted by 
outlying values.
2.11.1.3 Standard deviation
Standard deviation (SD) refers to the dispersion of the data around the mean and was 
calculated using the equation
SD= V Ev^ -fEvf/N (N-1)
y = individual case values 
N = number o f eases
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2.11.1.4 Standard error of the mean
This figure is a measure of the variance of the mean from sample to sample from the 
same distribution. The standard error (SE) of the mean was calculated by dividing the 
standard deviation by the square root of the number of cases.
2.11.2 Analysis of distribution of data
Before statistical comparison of different groups could be carried out, it was 
necessary to determine whether the distribution of the data was parametric. For this 
purpose Shapiro-Wilk testing was carried out. The Shapiro-Wilk test detects 
departures from normality, without requiring that the mean or variance of the 
hypothesized normal distribution be specified in advance. If the probability (p) value 
for the test >0.05 the data has a normal distribution and parametric testing may be 
carried out. If the p-vaiue <0.05 then the data has a non-normal distribution and non- 
parametic testing should be used. The test result does not indicate the type of non­
normality. Examination of the calculated skewness and kurtosis, and of the histogram, 
boxplot, and normal probability plot for the data may provide clues as to why the data 
failed the Shapiro-Wilk test.
2.11.3 Correlation analysis
2.11.3.1 Pearson’s correlation coefficient
The correlation coefficient provides a measure of the degree of linear association 
between two variables. The Pearson’s correlation analysis is used on data whieh has a 
normal distribution. A correlation coefficient (R) is obtained in addition to a p-value. 
R-values range from -1 to +1 with -1 indicating a high negative correlation and +1 
indicating a high positive correlation. A p-value is also given -  if this <0.05, a 
significant association between the variable is assumed.
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2.11.3.2 Spearman’s correlation coefficient
The Spearman’s correlation analysis is the non-parametric equivalent of the Pearson’s 
correlation.
2.11.4 Analysis of variation between groups
2.11.4.1 Independent samples t-test
The parametric t test is used for the comparison of means in two samples. The test 
gives a p-value which indicates the probability that the samples come from different 
populations. A p-value < 0.05 is taken as significant and indicates that there is a less 
than 5% chance that the samples are from the same population.
2.11.4.2 Mann-Whitney U test
This non-parametrie test is equivalent to the parametric t-test. It measures whether 
two independent samples are likely to have come from the same population. Both 
groups are combined and placed in ascending order and a calculation is made of how 
many times a value in one group precedes the value in the other group (U). If one of 
the groups has a larger proportion of higher rankings the groups are likely to have 
different distributions. A value of p<0.05 is taken as indicating significance.
2.11.4.3 Wilcoxon-signed ranks test
This test is used to determine whether the median difference in paired data is zero. It 
consists of sorting the absolute values of the differences from smallest to largest, 
assigning ranks to the absolute values and then finding the sum of the ranks of the 
positive differences. A value of p<0.05 is taken as indicating significance.
2.11.4.4 Two-way ANOVA
Analysis of Variance (ANOVA) is used to test the hypothesis that samples from more 
than two independent groups have equal means. A two way ANOVA produces a two­
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way analysis of variance of the effect of a dependant variable (eg altitude) on an 
independent variable (e.g. antibody staining). This test is basically an elaborated 
version of the t-test. A value of p<0.05 is taken as indicating significance.
2.11.4.5 Fisher’s PLSD
Once a two-way ANOVA has been carried out, post hoc analysis shows where the 
differences are amongst several means.
2.11.4.6 Kruskal-Wallis
The Kruskal-Wallis test is a non-parametric method of testing the hypothesis that 
samples from more than two independent groups have the same continuous 
distribution versus the alternative that measurements tend to be higher in one or more 
of the populations and has some similarity to an ANOVA. A value of p<0.05 is taken 
as indicating significance.
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2.12 List of suppliers of chemicals and apparatus 
Amersham Pharmacia, Biotechnologies, UK
ECL western blotting detection reagent, hybond ECL, hyperfilm ECL, MMP-9 
activity assay
Bacharacli Instruments, Denmark
Fyrite gas analyser 
Bayer (Germany)
Bayer 288 blood gas analyser 
BD Biosciences, Bedford, UK
Matrigel
BDH laboratory Supplies, Poole, UK
Acetone, APS, coomassie brilliant blue, dimethyldichlorosilate, DPX mounting
reagent, DTT, ethanol, hands’ haematoxylin, isopentane, methanol, NaCl, NaOH,
OCT compound, SDS, sucrose, trichloroacetic acid, triton-XlOO
Biochem Immunosystems, UK
MAI A Clone HCG assay
Biogenesis
MMP-2 protein, MMP-9 protein, anti-MMP-2 antibody, anti-MMP-9 antibody, anti- 
TIMP-1 antibody, anti-TIMP-2 antibody 
Biorad Laboratories Ltd, UK
Protean II xi western blotting apparatus, and mini protean II xi western blotting 
apparatus, low range molecular weight markers, GS-700 imaging densitometer and 
multianalyst software 
Bioquell
Microflow biological safety cabinet BSCl/LGOl 
Boeliringer Mannheim, Germany 
Tris base 
Chemicon
Anti-MMP-9 antibody 
Cryoservice, UK 
Nitrogen gas
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Diagnostics Scotland, Carluke, UK
Normal donkey, horse and human serum, horseradish peroxide conjugated donkey 
anti sheep/goat IgG
Fisher Scientific UK Loughborough, UK
Acetic acid, isopropanol 
Forma Scientific Inc, UK 
CO2 water jacketed incubator model no. 3141 
Gibco-BRL, UK
FES, lOOx L-glutamine, lOOx fungizone, lOOx penicillin/streptomyein, DMEM,
Hams F12 cell culture medium 
Glasgow University Central Stores 
Ethanol
Greineir Labortechnik
Microtitre plates 
Heidolph 
Plate mixer 
Heraeus, UK 
Biofuge centrifuge 
Hybaid, UK 
Hybridisation oven 
Jeiicon Scientific Ltd, UK 
Jenway 970 portable dissolved 02/°C meter and electrode ;
Kinematica AG, Switzerland 
Polytron homogeniser 
Labsystems, UK
Multiskan biochromatic plate reader and Genesis software 
Life Technology Ltd, Paisley, UK
Electrophoresis power supply 400L I
Millipore, UK
Millicell culture plate inserts (12mm diameter, pore size 40m)
Multi RO Plus water purification system i
National Diagnostics, Hull, UK
Histoclear I
Novocastra
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Anti-Cytokeratin LP34 antibody, Ki67 antibody 
Nunc, UK
Sterelin 24-well plates 
Olympus, UK
S2H microscope and C35DA2 camera attachment 
Oxoid Ltd, Basingstoke, UK 
PBS (Dulbecco A)
Premier Beverages, Stafford, UK 
Marvel powdered milk 
Raymond Lamb Ltd, UK 
1cm cork discs
Rectangular 2cm^ plastic holders 
R&D
Parameter assays -  VCAM-1, ICAM-1 and E-Selectin 
Santacruz Biotechnology 
Goat control Ig, catalogue number: sc-2028 
Mouse control Ig, catalogue number: sc-2025 
Rabbit control Ig, catalogue number: sc-2027 
Sheep control Ig, catalogue number: sc-2717 
Sigma-Aldrich Company, Poole, UK
30% acrylamide/bis-acrylamide (ratio 37:5:1), APMA, aprotinin, bradford reagent,
bromophenol blue, BSA, CaCb, Fast 3,3’ diaminobenzide tablets, DMSO, EDTA,
gelatin, glycerol, glycine, hydrogen peroxide 30% solution, NaNs, protease inhibitor
cocktail (P8340 for use with mammalian cell and tissue extracts), TEMED, TPCK-
trypsin, tween-20
Shaiidon,UK
Cryostat microtome
Swann Norton, UK
Surgical blades
Thermashandon, UK
Double frosted microscope slides
Vector Laboratories
DAKO pen
Vectastain ABC kits (universal, sheep and goat)
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Chapter 3: Evaluation of various methods 
for detecting and quantifying MMP-9 and 
MMP-2 in placental homogenates
One key aim of the current study was to quantify MMP-2 and MMP-9 expression and 
activity in normal placenta throughout gestation. These MMPs have been implicated 
in CTB invasion in many studies yet widely differing conclusions on when and where 
they are expressed have been reported (section 1.4). One likely source of these 
differences lies in the methodology used to examine MMP expression.
Therefore it was necessary to evaluate potential methods that could be used to 
study MMP expression. Initially it was decided to attempt to quantify MMP-9 and 
MMP-2 expression and activity in placental homogenates. The overall aim of this 
section was to determine which methods would be most appropriate for detecting and 
quantifying MMP-9 and MMP-2 in placental homogenates. Initially western blotting 
was tested as a potential method of MMP quantification as it was a technique already 
in common use in our laboratory. Secondly zymography, a method widely used in 
determining MMP activity in cell culture medium was investigated. Finally an MMP- 
9 activity assay was evaluated.
3.1 Western blotting
3.1.1 Validation of commercially available MMP antibodies
The purpose of this experiment was to determine which MMP antibodies were most 
sensitive and specific for MMP-2 and MMP-9 detection in studies herein.
The properties and availability of MMP-9 and MMP-2 antibodies on the 
market were investigated. Two MMP-9 antibodies were purchased, one from 
Biogenesis and one from Chemicon (section 2.2). One MMP-2 antibody was 
purchased from Biogenesis (section 2.2) for initial studies.
The antibodies selected were then tested on western blots (section 2.8). Three 
gels were run, each with 50pg total protein homogenates (section 2.7) from a term 
and from a 10 weeks of gestation normal placenta.
For MMP-9 (Chemicon Antibody) after initial washing and detection (30 sec 
exposure) there appeared to be some bands present (figure 10a). However after an 
overnight wash these bands were not present (10 min exposure), suggesting they were 
non-specific (figure 10b).
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For MMP-9 (Biogenesis Antibody), high background initially obscured any 
bands (30 sec exposure) (figure 10c). After overnight washing, clean bands were 
evident but this was not at the correct molecular weight of 92kDa (10 min exposure) 
(figure lOd).
For MMP-2 (Biogenesis Antibody), high background initially obscured any 
bands (30 sec exposure) (figure 1 la). After overnight washing, clean bands were 
evident (10 min exposure) (figure lib) but these seemed to be in a very similar 
position to the bands detected with the MMP-9 Biogenesis antibody. This heightened 
the suspicion that these bands may be nonspecific.
Figure 10 Detection of MMP-9 in placental homogenates under reducing 
conditions using two different antibodies
Chemicon MMP-9 Ab
a) Initial detection b) Detection after overnight wash
mm 113kDa92kDa"^ 82kDa
52.4kDa
36.2kDa
T E T E
T = Term placental homogenate 
E = 10 weeks of gestation placental homogenate
124
Biogenesis MMP-9 Ab
c) Initial detection d) Detection after overnight wash
92kDa 113kDa
82kDa
52.4kDa
36.2kDa
T E T E
T = Term placental homogenate 
E = 10 weeks of gestation placental homogenate
Figure 11 Detection of MMP-2 in placental homogenates using Biogenesis 
MMP-2 antibody under reducing conditions
a) Initial Detection b) Detection After Overnight Wash
72kD
T E ET
113kDa
82kDa
—^  72kD 
52.4kDa
36.2kDa
T = Term placental homogenate 
E = 10 weeks of gestation placental homogenate
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3.1.2 Detection of MMP-9 and MMP-2 purified proteins with commercially 
available antibodies using a ‘spot’ method.
Since the western blotting in section 3.1.1 did not confirm that the antibodies were 
successfully detecting MMP-9 and MMP-2 in placental homogenates, it was decided 
to test their ability to detect purified MMPs which were commercially available. The 
‘spotting’ method (section 2.8.2) was chosen as it is less time consuming than western 
blotting.
MMP-2 and MMP-9 purified protein (Biogenesis, section 2.3.1) were spotted 
at various concentrations onto nitrocellulose and the ability of the antibodies used in
3.1.1 to detect the MMPs was tested. A comparison was also made between using 5% 
Marvel in PBST (section 2.1.1) compared to 5% donkey serum in PBST as the 
blocking reagent.
Detection of the MMP-9 purified protein was successful using both the 
Chemicon and Biogenesis MMP-9 antibodies, however the Biogenesis antibody 
produced slightly better detection sensitivity - 6.5ng of protein was easily detectable 
after a 5 min exposure (figure 12a) while the Chemicon antibody only just detected 
this amount (figure 12b). Since the Biogenesis antibody was four times cheaper than 
the Chemicon antibody, and detection of purified MMP-9 seemed to be slightly better 
with Biogenesis, it was decided to use the Biogenesis antibody in further studies.
For MMP-9, blocking with 5% serum (figure 12c and 12d) gave a clearer 
background particularly with the Biogenesis antibody; therefore this was used in all 
subsequent blots.
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Figure 12 Detection of purified MMP-9 protein spotted onto nitrocellulose 
using Biogenesis and Chemicon antibodies (5 min exposure)
6.5ng 12.5 ng 25ng 50ng
6.5ng 12.5 ng 25ng 50ng
C)
MMP-9 (Biogenesis) Marvel blocker
MMP-9 (Chemicon) Marvel blocker
MMP-9 (Biogenesis) Serum blocker
6.5ng 12.5 ng 25ng 50ng
MMP-9 (Chemicon) Serum blocker
6.5ng 12.5ng 25ng 50ng
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MMP-2 detection was initially weak with the Biogenesis antibody after 5 min 
(figure 13a), however the 50ng spot of MMP-2 was clearly visible after 30 min 
exposure to film (figure 13b). Since the antibody was able to detect MMP-2, it was 
decided to use it in further studies.
For MMP-2, blocking with 5% serum also gave a much clearer background; 
therefore this was used in all subsequent blots.
Figure 13 Detection of purified MMP-2 protein spotted onto nitrocellulose 
using Biogenesis antibody
a) 5 min exposure
MMP-2 (Biogenesis) Marvel blocker
6.5ng 12.5 ng 25ng 50ng
6.5ng 12.5 ng 25ng 50ng
b) 30 min exposure
6.5ng 12.5 ng 25ng 50ng
MMP-2 (Biogenesis) Serum blocker
MMP-2 (Biogenesis) Marvel Blocker
MMP-2 (Biogenesis) Serum blocker
6.5ng 12.5 ng 25ng 50ng
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3.1.3 Detection of purified MMP-9 and MMP-2 by western blotting
In experiments in 3.1.1 it had proved difficult to detect MMPs in placental 
homogenate samples using western blotting. However the subsequent spotting 
experiments in 3.1.2 showed that the antibodies were capable of detecting purified 
MMP-2 and MMP-9. Therefore the next set of experiments was designed to test 
whether the purified MMPs could also be detected using western blotting. For MMP- 
9 this was tested using control proteins loaded at a concentration of 25 to lOOng. In 
addition, early and term placental homogenates were loaded for comparison on the 
same gel.
Control protein (25ng) was readily detectable as one clear band at an estimated 
molecular weight of 92kDa (the known molecular weight of pro-MMP-9) after an 
exposure of 5 min. The lanes in which the placental homogenates were loaded also 
had bands at the same molecular weight as the control protein, although these were 
not particularly strong (figure 14).
Figure 14 Detection of purified MMP-9 protein by western blotting (reducing 
conditions)
MMP-9
113kDa
^ -------- 92 kDa
52.4kD a
36.2kD *
T E 25ng SOnglOOng
T = Term placental homogenate 
E = 10 weeks of gestation placental homogenate
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For MMP-2, detection of the purified protein was tested using protein loaded 
at a concentration of 50 to 200ng, since the antibody had been shown in section 3.1.2 
to be less sensitive than the MMP-9 antibody. Early and term placental homogenates 
were also loaded for comparison on the same gel. 50ng of control protein was just 
detectable after an exposure of 5 min and 100 and 200ng were readily detectable. The 
lanes in which the placental homogenates were loaded also had bands at the same 
molecular weight as the purified protein, although other bands were also present 
(figure 15).
Interestingly in the control protein lanes two bands were observed - one band 
at 72kDa and one at 68kDa. Since the activated form of MMP-2 has a molecular 
weight of 68kDa this additional band probably represents the activated from. Since 
the MMP-2 protein had not been purposely activated, only one band (72kDa) was 
expected to be present. The protein had been aliquoted on arrival and frozen at -70°C 
until used as advised by the manufacturers. The manufacturers (Biogenesis) were 
consulted and advised that the lower band was probably the activated form of MMP- 
2. They also advised that the activation had probably occurred as a result of 
unavoidable autocatalytic cleavage of the enzyme during transit and storage.
Figure 15 Detection of purified MMP-2 protein by western blotting (reducing 
conditions)
72 kDa 
68 kDa
200 too 50 E T 
ng ng ng
T = Term placental homogenate 
E = 10 weeks of gestation placental homogenate
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3.1.4 Does the MMP-9 antibody detect both activated and pro forms of 
MMP-9?
The previous experiment in section 3.1.3 showed that the MMP-9 antibody 
successfully detected non-activated forms of MMP-9. However in tissues both non­
activated and activated forms of MMP-9 are present. It was therefore important to 
establish whether this antibody could also detect the activated form. The following 
experiment was performed.
A Western blot (section 2.8) was run to examine detection of activated and 
pro-MMP-9. MMP-9 can be activated in vitro by incubation with 2mM Amino Phenyl 
Mercuric Acetate (AMPA) for 18 hrs (section 2.3.2). The APMA cleaves the pro 
sequence from the MMP-9 in a similar way to activation in vivo. MMP-9, which had 
been subjected to the activation procedure minus the addition of APMA, was also run 
as a control. lOOng of protein was loaded in each lane. The results are shown in figure 
16.
Figure 16 Detection of pro and APMA activated purified MMP-9 protein by 
the Biogenesis antibody under reducing conditions
92kDa
Activated Control Pro
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No band was present in the lane containing MMP-9 which was treated with 
APMA. In the lanes containing the control and untreated MMP-9, a large band 
conesponding to a molecular weight of 92kDa was seen.
It was clear that this antibody did not detect the activated form o f MMP-9. 
However the gels were run under reducing conditions. It is known that some 
antibodies are sensitive to whether the conditions are reducing or non-reducing. 
Alternatively it was possible that the activation had failed and the protein had been 
completely degraded and was not detected.
Therefore it was decided to test whether the activated form could be detected 
under non-reducing conditions.
3.1.5 Detection of activated and pro-MMP-9 under non-reducing conditions
Since Western Blots are time consuming, it was decided to do a preliminary 
investigation o f non-reducing conditions using spotting (section 2.8.2) before going 
on to carry out a full western blot. 200ng spots o f pro, activated and control MMP-9 
were spotted onto nitrocellulose and incubated with the antibody (figure 17).
A large spot was detected where non-activated MMP-9 was spotted. The 
control spot was smaller and lighter and the activated spot was even lighter. The 
antibody thus seemed to detect the pro form more readily than the activated form. 
Alternatively it was possible that the small spot in the activated sample represented a 
small amount o f pro form which had not been activated, if  the antibody was not 
capable o f detecting the active form. Since MMP-9 can be cleaved to smaller 
fragments than the predominant 84kDa from, it was also possible that incubation with 
AMPA had resulted in smaller fragments which were not detected by the antibody. 
Interestingly, the control seemed to show some spontaneous activation even in the 
absence o f APMA.
In summary, it was still unclear whether the antibody could detect the 
activated form o f MMP-9. Although APMA was the recommended activating agent 
for the purified MMP-9 protein, the manufacturers advised that in certain 
circumstances this activation protocol may be too harsh leading to over activation.
Trypsin is an in vivo activator o f MMP-9 (section 1.4.4) and is without the 
biological hazards associated with APMA. The protocol to activate MMP-9 with
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trypsin is also less time consuming (section 2.3.2). Therefore it was decided to 
activate MMP-9 protein with trypsin to determine whether or not the antibody could 
detect MMP-9 activated in this way.
Figure 17 Detection of pro and APMA activated purified MMP-9 protein 
under non-reducing conditions
t #
A c tivated pro control
3.1.6 Detection of MMP-9 activated by trypsin
Since trypsin activation of MMP-9 is both less hazardous and requires a shorter 
activation time than AMPA, this was attempted (section 2.3.2). The spotting 
procedure was carried out as before (section 2.8.2). The results are shown for a 90 sec 
(a) and 5 min (b) exposure to film (figure 18).
Almost exactly the same results were obtained as with activation by APMA. 
The pro-form and control were detectable at lOOng after a 90 sec exposure and the 
activated form at 200ng after a 90 sec exposure. After a 5 min exposure the pro-form 
was detectable at 25ng, the control at 50ng and the activated at lOOng.
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Figure 18 Detection of pro and trypsin activated purified MMP-9 protein
a) 90 sec exposure
50ng lOOng 200ng25ng
Unactivated
Activated
Control
b) 5 min exposure
25ng 50ng lOOng 200ng
Unactivated
Activated
Control
Since the molecular weight of the MMP-9 protein could not be determined 
from these blots it was impossible to determine whether the antibody detected 
activated MMP-9 in the middle spots or whether it simply detected the remaining 
unactivated form. It was clearly necessary to carry out a full western blot to determine 
the molecular weight of each of the activated, non-activated and control forms of 
MMP-9.
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3.1.7 Western blot of AMPA and trypsin activated MMP-9 and pro-MMP-9 
under non-reducing conditions
Western blotting was performed in order to determine the molecular weights of the 
MMP-9 activated with trypsin and its control, and the MMP-9 activated with APMA, 
and its control. It was hoped this would determine which forms of MMP-9 the 
antibody detected under non-reducing conditions.
Since under reducing conditions no activated MMP-9 was detected, a western 
blot was run under non-reducing conditions with APMA activated MMP-9 (Al) and 
control MMP-9 (Cl) and trypsin activated MMP-9 (A2) and control MMP-9 (C2) 
(figure 19). 200ng of each was loaded. This western blot was carried out exactly as 
described previously with the exception that the loading buffer was non-reducing 
(section 2.1.4).
Figure 19 Western blot of AMPA and trypsin activated purified MMP-9 and 
pro-MMP-9 protein under non-reducing conditions
84kDa
72kDa —► Ife
30kDa
92kDa
Al Cl A2 C2 U
Al
Cl
A2
C2
U:
APMA activated MMP-9 
Control for APMA activated MMP-9 
Trypsin activated MMP-9 
Control for trypsin activated MMP-9 
Pro-MMP-9
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The trypsin activation produced an 84kDa activated form of MMP-9 and a 
72kDa form whereas APMA activation released 72 and 30kDa forms. Neither of the 
controls were activated under these conditions. Since the 84kDa form is the 
predominant active species in vivo trypsin activation was used from this stage 
onwards. These results have clearly shown that the Biogenesis antibody detects both 
active and pro forms of MMP-9 under non-reducing conditions. This is important not 
only for Western Blotting but also for immiinohistochemistry, which is carried out 
under non-reducing conditions.
The next step was to revisit the experiments performed in section 3.1.1 but this 
time using non-reducing conditions.
3.1.8 Detection of MMP-9 in term placental homogenates by non-reducing
western blotting
As the western blots carried out on placental homogenates prior to this stage had all 
been carried out under reducing conditions, it was decided to investigate if detection 
of MMP-9 would be improved if the gel was run under non-reducing conditions.
A block of frozen term placenta was homogenised (section 2.7) using various 
conditions. The conditions used were:
1) Homogenisation buffer containing 5mM PMSF and 12.5 jul/ml Sigma protease 
cocktail inhibitor.
2) Homogenisation buffer containing 12.5 pl/ml Sigma protease cocktail
inhibitor.
3) Homogenisation buffer containing 5mM PMSF.
4) Homogenisation buffer containing neither inhibitor.
The cytosolic fraction (75 pg) was loaded from each of these different experimental 
conditions and a western blot carried out with the MMP-9 Ab (figure 20).
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Figure 20 Detection of MMP-9 in term placental homogenates by non­
reducing western blotting
a) 5 min exposure
92kDa
4 3 2 1
Term Placenta tt
12.5ng 12.5ng 
Pro Active 
MMP-9
b) 30 min exposure
92kDa
84kDa
4 3 2 1
Term Placenta Î Î
12.5ng 12.Sng 
Pro Active 
MMP-9
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When the blot was exposed to film for 5 min, a band was present in the 
placental homogenates (4,3,2,1) at 92kDa. However there were also several other 
bands present making it difficult to identify pro and active MMP-9 separately. It was 
not possible to detect the control pro and activated MMP-9 until the blot had been 
exposed to the film for 30 min. By this stage the bands present in the homogenate 
were totally obscured by dark background.
It was decided to attempt non-reducing western blotting on placental 
homogenates with the MMP-2 antibody to determine if the same difficulties would be 
encountered.
3.1.9 Detection of MMP-2 in term placental homogenates by non-reducing 
western blotting
A block of frozen term placenta was homogenised using various conditions. The 
conditions used were as described above (section 3.1.8) The cytosolic fraction (75pg) 
was loaded from each of these different experimental conditions and a western blot 
carried out with the MMP-2 Ab (figure 21).
Figure 21 Detection of MMP-2 in term placental homogenates by non­
reducing western blotting
a) 5 min exposure
72kDa
4 3 2 1 SOng
Term Placenta MMP-2
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b) 30 min exposure 1
72kDa
66kDa
4 3 2 1 50ng
Term Placenta MMP-2
Similar difficulties were encountered with western blotting of placental 
homogenates using MMP-2 antibody as had been found with MMP-9. While there 
appeared to be a band present at the correct molecular weight (72kDa) after a 5 min 
exposure, other bands were also present. Further inspection revealed that the bands 
detected by the MMP-2 antibody were very similar to the bands detected by the 
MMP-9 antibody, suggesting they may be non-specific. Moreover, a 30 min exposure 
was required to detect 50ng of control pro and active MMP-2. This resulted in 
extremely dark bands in the homogenates.
Thus it seemed that western blotting of homogenates would not be 
straightforward and it was decided to determine whether zymography would provide a 
more accurate method of detecting MMP-9 and MMP-2 in placental samples.
139
3.2 Zymography
Western blotting did detect both pro and active forms of purified MMP-9 however the 
presence of several other bands detected in placental homogenates raised doubt as to 
whether the bands at 92 and 84kDa were definitely MMP-9. Zymography offers an 
alternative method to detect MMP-9 (section 1.4.8). Not only does it detect both 
active and pro forms but it also reflects activity. Thus it was decided that zymography 
may provide an alternative to western blotting for detecting MMP-9 activity. It also 
has the advantage of detecting MMP-2 active and pro forms in the same gel as MMP- 
9 since both degrade the substrate gelatin (section 1.4.5).
3.2.1 Detection of pro and active MMP-9 by zymography
Previous published studies have all been performed using non-reducing conditions. 
Thus all zymography experiments herein were performed under non-reducing 
conditions. To first of all establish the technique was working adequately the 
zymography method (section 2.9) was tested using commercially available MMP-9 
protein (section 2.3).
MMP-9 protein was mixed with non-reducing loading buffer and separated on 
an SDS-PAGE gel impregnated with 0.05% gelatin. Pro-MMP-9 was loaded at 
concentrations of 12.5, 6.25 and 3.125ng. Activated MMP-9 (section 2.3) was loaded 
at concentrations of 12.5, 6.25, 3.125 and l.5ng (figure 22).
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Figure 22 Detection of purified pro and active MMP-9 protein by zymography
92kDa
84kDa
Pro Pro Pro 
12.5ng 6.25ng 3.1 ng
Active Active Active Active 
12.5ng 6.25ng 3.1 ng l.Sng
Pro MMP-9 was still clearly detectable at 3.1ng and active MMP-9 at 1.5ng. This was 
much more sensitive than western blotting and it was concluded that this would 
provide a more sensitive method for detecting MMP-9 in placental homogenates.
3.2.2 Detection of 0.5ng-3ng purified MMP-9 protein by zymography
Since 3.1 ng o f purified MMP-9 was easily detectable by zymography, a 0.05% gelatin 
impregnated gel was loaded with 3, 2.5, 2, 1.5, 1 and 0.5ng o f pro-MMP-9 to 
determine whether smaller amounts o f MMP activity were detectable and if so, was 
the method sensitive enough to detect small changes in activity (figure 23).
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Figure 23 Detection of 0.5ng-3ng purified pro-MMP-9 protein by 
zymography
92kDa
3ng 2.5ng 2ng l.Sng Ing O.Sng
0.5ng o f pro-MMP-9 was still clearly detectable as a single band at 92kDa and there 
was a definite change in band intensity as concentration decreased at least at double 
dilutions.
3.2.3 Detection of pro and active MMP-2 by zymography
Since the attempt at detecting MMP-9 by zymography had been successful, it was 
decided to attempt to detect purified MMP-2 protein by the same method. Since, 
unlike the MMP-9, the purified commercial MMP-2 contained both pro and active 
forms (section 3.1), there was no need to activate MMP-2 further. 12.5ng, 6.25ng and 
3 .Ing o f purified MMP-2 protein were mixed with non-reducing loading buffer and 
separated on an SDS-PAGE gel impregnated with 0.05% gelatin (figure 24).
Figure 24 Detection of purified pro and aetive MMP-2 protein by 
zymography
72kDa
68kl)a
12.5ng 6.25ng 3.1ng
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As with MMP-9, zymography was also much more sensitive in detecting 
MMP-2 than western blotting. The technique clearly differentiated between the 
activated and pro forms.
3.2.4 Effect of protease inhibitors used in placental homogenisation on 
detection of MMPs by zymography
Since purified MMP-2 and MMP-9 were clearly detected by zymography, the next 
stage was to determine whether MMP activity could be as easily detected in placental 
homogenates.
It is known that certain protease inhibitors used in homogenisation affect 
MMP activity, therefore it was decided to homogenise a term placenta with different 
combinations of protease inhibitors.
A block of frozen term placenta was homogenized under 4 different 
conditions:
1) Homogenisation buffer containing 5mM PMSF and 12.5 pl/ml Sigma protease
cocktail inhibitor.
2) Homogenisation buffer containing 12.5 jiil/ml Sigma protease cocktail
inhibitor.
3) Homogenisation buffer containing 5mM PMSF.
4) Homogenisation buffer containing neither inhibitor.
The homogenisation was carried out as described (section 2.7). EDTA was 
omitted from the homogenisation buffer due to its inhibitory effect on MMPs.
75pg total and cytosolic protein from conditions 1-4 were separated by SDS- 
PAGE on a gel impregnated with 0.05% gelatin. Both the cytosolic and total protein 
fractions were separated to determine if all the MMP activity was present in the 
cytosolic fraction as expected. 1.5ng of purified pro-MMP-9 protein was loaded as a 
control (figure 25).
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Figure 25 Effect of protease inhibitors used in placental homogenisation on 
detection of MMP-9 and MMP-2 by zymography
1.5ng
Pro-MMP-9
92kDa 
(pro-IM IMP-9)
72kDa 
(pro-IM IMP-2)
T = Total Protein (Membrane and Cytosolic)
C = Cytosolic Fraction
Both MMP-9 and MMP-2 were detectable in all of the homogenates. With 
both MMPs only the higher molecular weight pro forms were detectable. There did 
not appear to be much difference between the various combinations o f protease 
inhibitors added, although the homogenate that had no protease inhibitors added did 
seem to have less MMP activity and the homogenate with both inhibitors appeared to 
have slightly stronger bands. Thus homogenisation buffer containing 5mM PMSF and
12.5 pl/ml protease cocktail inhibitor was used in all homogenisations thereafter. As 
expected, since the protein is found in the cytosolic fraction, the amounts detected in 
the total and cytosolic fractions appeared to be the same.
3.2.5 Is detection of MMPs by zymography as sensitive on large SDS-PAGE 
gels as it is on mini-gels?
All experiments to date had been performed on mini gels. Due to the large number of 
samples to be analyzed zymography was next attempted on large gels. However 
several problems were encountered. Firstly the bands were not as clear, this is 
probably because o f the large well size. The concentration o f the sample in each well 
could be increased but as the samples were small there may not be enough o f each to
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allow this. Although the band separation is clearer and it would therefore be easier to 
differentiate between pro and active forms, the sharpness o f the bands on the mini-gel 
seemed more suitable for analysis by densitometry. The large gels were therefore not 
further investigated.
3.2.6 Does reducing the gelatin concentration increase detection of MMP-9 
and MMP-2 in placental homogenates?
While the zymography was clearly effective at detecting pro- MMP-9 and -2  in 
homogenates it was not clear whether there was little or no active forms in the 
homogenates, or whether the method was not sensitive enough to detect them. Since 
published studies do not show gels containing less than 0.05% gelatin, it was decided 
to determine if a 0.025% gelatin impregnated gel would be more sensitive for 
detection o f active MMP-9 and MMP-2 in placental homogenates. An 11 weeks o f 
gestation frozen placental block was homogenised, the cytosolic protein concentration 
was determined by Bradford’s assay (section 2.10) and increasing concentrations 
were run on a 0.025% gelatin zymography gel. Each was loaded with 2ng pro and 
active MMP-9, lOng MMP-2 and 12.5, 25, 50, 75, and 100 pg cytosolic protein o f the 
11 weeks o f gestation placental homogenate (figure 26).
Figure 26 A reduced gelatin concentration (0.025%) for detection of MMP-9 
and MMP-2 in placental homogenates is not as effective as 0.05%  
gelatin
2a.
I
92kI)(pro MMP-9) 
72kl)(pro MMP-2)
12.5 25 50 75 100
gg cytosolic protein
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3.2.7 Homogenate concentration optimisation
This experiment was designed to expand the range of concentrations of homogenates 
loaded onto both 0.025% and 0.05% gelatin gels. Two gels were prepared: a 0.05% 
gelatin gel loaded with 6.25, 12.5, 25, 50, 75, and 90pg cytosolic protein, and a 
0.025% gelatin gel loaded with 2.5, 7.5, 10, 15, and 20pg cytosolic protein.
The bands on the 0.025% gel still looked diffuse. It was difficult to distinguish 
a reduction in band intensity with reduced protein loading (figure 27a). However on 
the 0.05% gelatin gel, the lower bands were much sharper and were able to be 
quantified by densitometry (figure 27b). Quantification of bands by densitometry on 
the 0.05% gelatin gel revealed that the bands increased semi-linearly with increased 
protein concentration (figure 28).
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It was clear that an increase in protein loaded resulted in increased gelatinase 
activity until around 50 pg when it appeared to plateau. MMP-9 seemed to be present 
almost exclusively in the pro form. In contrast, while the pro form of MMP-2 
predominated, there appeared to be some evidence of active MMP-2, Densitometrical 
analysis of the bands showed that they were too diffuse to be quantified accurately by 
densitometry. To improve this there were two possible options. The concentration of 
gelatin could be increased or the amount of protein loaded could be decreased to give 
sharper bands. This was attempted in the next section.
;
Figure 27 Sample concentration optimisation for zymography
a) 0.025% Gelatin b) 0.05% Gelatin
20 15 10 7.5 5 2.5
cytosolic protein
100 75 50 25 12.5 6.25
pg cytosolic protein
Figure 28 Sample concentration optimisation - densitometry
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3.2.8 Trial zymography of placental homogenates
Before homogenising the whole collection of placentae to be investigated (> 40 
cases), a pilot study was carried out on one placenta from each week of gestation (7, 
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 weeks and term) to check that the gel would 
be suitable for placentae from all gestations to be investigated. A 0.05% gelatin gel 
was loaded with 6.5pg of protein from the cytosolic fraction of each placental 
homogenate.
In addition it was decided to test a concentration of gelatin higher than 0.05% 
to be absolutely sure that 0.05% was the optimum concentration.
1) 0.05% gelatin / 6.5pg protein loaded
7.8.9.10.11 weeks of gestation (Fig 29a)
12.13.14.15.16 weeks of gestation (Fig 29b)
112.17.18.19 weeks of gestation and term placenta (Fig 29c)
2) 0.1% gelatin / 6.5pg protein loaded
7.8.9.10.11 weeks of gestation (Fig 29d)
12.13.14.15.16 weeks of gestation (Fig 29e)
112.17.18.19 weeks of gestation and term placenta (Fig 29f)
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Figure 29 Trial zymography of placental homogenates: 0.05% vs 0.1% 
gelatin
0.05% gelatin
a)
0.1% gelatin
d)
7 8 9 10 11
h) e)
12 13 14 15 16
c)
92kDa
(pro MIVlP-9)
^  72kDa 
^  (pro MlVIP-2)
7 8 9 10 11
92kDa
72kDa
12 13 14 15 16
12 17 18 19 Term 12 17 18 19 Term
92kDa
72kDa
While both pro-MMP-9 and pro-M M P-2 were detectable at all gestations on both 
0.05% and 0.1% gelatin gel, the 0.1% gel gave much poorer results. It was concluded 
that using 6.5pg cytosolic protein on a 0.05% gelatin zymography gel would give 
good quantifiable results and this combination was subsequently used in analysing 
placental samples throughout gestation (chapter 4).
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3.3 Trial of a commercially available MMP-9 assay for detecting pro and
active MMP-9 in placental homogenates
Zymography was successful in detecting pro-MMP-2 and pro-MMP-9 in placental 
homogenates. However it was not sensitive enough to be used to detect and quantify 
active MMP-2 or MMP-9. While zymography is a very cost effective method it has 
the disadvantage of being only semi-quantitative for measuring MMP activity. Thus it 
was decided to investigate if the commercially available MMP-9 assay from 
Amersham would be a viable method for more accurately quantifying MMP-9 activity 
in placental homogenates, and for detecting both pro and active forms of MMP-9. The 
zymography and assays o f placental homogenates could be used in parallel to give a 
more comprehensive analysis of MMP-9 levels in placentae throughout gestation. An 
MMP-2 assay is also available but due to cost considerations, only the MMP-9 assay 
was investigated at this stage.
In the MMP-9 activity assay, both pro and active MMP-9 are captured by a 
specific antibody. Active MMP-9 is measured directly after addition of modified 
urokinase (UKCOL) and peptide substrate. Pro-MMP-9 is activated by APMA in an 
overnight incubation before activity can be measured. Each sample is assayed twice, 
activated and unactivated. Thus both total and active MMP-9 levels are obtained in 
the one assay. Specificity for pro-MMP-9 is reported to be 100% and specificity for 
active MMP-9 is reported to be around 65%. Complexes of pro and active MMP-9 
with both TIMP-1 and TIMP-2 are known to have a degree of cross-reactivity in the 
assay (between 20 and 38%). Figure 30 shows a flow diagram of the assay protocol.
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Figure 30 MMP-9 assay flow chart
APMA (if total MMP-9 is to be measured)
< MMP-9(Pro and Active) O/N4°C
Pro Detection Enzyme
All MMP-9 in activated form 90 minutes 
37°C
Substrate
Active Detection Enzyme
1 -6 hours
Measure OD at 405nm
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The assay had been commercially optimised for serum and plasma samples 
and in spiked samples gave recovery rates of above 80%. The assay had not, however 
been optimised for tissue homogenates, although it was stated these could be 
successfully assayed. No guidance on dilutions of homogenates or on expected 
accuracy was given so it was decided that it was necessary to investigate these 
aspects. Thus placental homogenates prepared prior to this stage (section 2.7) were 
used to test the efficiency of the assay at detecting MMP-9 in homogenates 
themselves.
3.3.1 Results for measuring MMP-9 in placental homogenates using the 
commercial MMP-9 assay
To determine if the assay would detect MMP-9 in placental homogenates from 
throughout gestation, a P \lO  weeks of gestation), 2"  ^ (19 weeks of gestation) and 3"^  ^
(38 weeks of gestation) trimester placental homogenates were assayed. The cytosolic 
fraction from each of the samples was diluted in assay buffer to give a final protein 
concentration of 2.5mg/ml. Each sample was assayed in the activated and non­
activated form to measure active and total MMP-9 and each of these was assayed in 
duplicate. In addition each activated homogenate was duplicated with the addition of 
a 5ng/ml active MMP-9 spike to determine how much of the spike would be detected. 
The standard curve was prepared using concentrations of 0.5, 1, 2, 4, 8 and 16ng/ml 
MMP-9 as described in the manufacturer’s instructions.
The assay was carried out as described in section 2.10.2. The manufacturers 
recommended reading the plate at 2 hours. The results shown in figure 31a show that 
the standard curve (0-16ng/ml) obtained at this time shows linearity for 0-8ng/ml. All 
the homogenate dilutions fell within this range. From the standard curve shown in 
figure 31a the concentration of MMP-9 in each of the homogenates was calculated. 
Standard curves after this 2-hour time-point did not show the same degree of linearity 
(figure 3Ib). The results for the homogenates are shown in table 6,
When active and total MMP-9 levels in the samples were compared, this 
initial experiment suggested that there was more total than active in all three 
gestations studied which is as would be expected. While these results were based on
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only one sample from each gestation, it seemed that at 10 weeks o f gestation total 
MMP-9 levels were 3x higher than active, at 19 weeks o f gestation total levels o f 
MMP-9 were only slightly higher than active and at 38 weeks o f gestation total MMP- 
9 levels were 12x higher than active. Active MMP-9 levels were fairly constant 
throughout. Only between 47% and 77% o f the spiked MMP-9 was detected in the 
wells. It was possible that MMP-9 was bound by proteins in the homogenate, possibly 
TIMPs, preventing some o f the MMP-9 from being captured in the assay, since 
TIMP/MMP-9 complexes only show partial cross-reactivity with the assay. When the 
homogenate values were corrected for the spike the active MMP-9 levels were lowest 
at ten weeks o f gestation, and the levels at 19 weeks o f gestation were almost double 
that found at ten weeks o f gestation. The levels o f  active MMP-9 at term were 
intermediate. Total MMP-9 levels at 10 and 19 weeks o f gestation were comparable to 
each other while total levels at term were around 1 Ox higher than during the first and 
second trimesters.
Figure 31 Standard curves for measuring MMP-9 in placental homogenates
a)
lMMP-9 standard  curve after 2 hours
10
M M P-9 ng/ml
15 20
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b)
MMP-9 standard  curve after various times
B 0.8
10
M M P-9 ng/ml
hrs
hrs
4hrs
-M-5hrs
-JK-6hrs
Table 6 MMP-9 assay of placental homogenates from 1**, 2"*^  and 3"^** 
trimester
Homogenate Active MMP-9 
in homogenate 
ng/ml
Total 
MMP-9 
in homogenate 
ng/ml
% Spike 
detected in 
duplicate well
Active MMP-9 
in homogenate 
ng/ml 
(corrected for 
spike)
Total 
MMP-9 
in homogenate 
ng/ml 
(corrected for 
spike)
lOwks 2.03 6.08 77 2.63 7.90
19wks 2.17 3.16 47 4.62 9.83
38wks 2.04 24.96 59 3.46 42.31
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Since the active MMP-9 levels lay at the lower end of the standard curve, it 
was necessary to perform the assay again, this time using the lower range standard 
curve protocol described in the manufacturer’s instructions to ensure the accuracy of 
the detected active MMP-9. No further dilutions of the homogenates were performed 
at this stage since the active MMP-9 levels were fairly low already.
3.3.2 MMP-9 assay of placental homogenates from Ÿ\  2"‘* and 3*^** trimester: 
lower range standard curve
The assay was repeated with 3 different homogenates from (9 weeks of gestation),
2”*^ (17 weeks of gestation) and 3*^  ^ (36 weeks of gestation) trimester placental 
homogenates. The procedure was carried out exactly as before with the exception that 
the wells used to construct the standard curve contained 0, 0.125, 0.25, 0.5, 1, 2 and 
4ng of MMP-9 as opposed to the higher amounts used in the previous assay. This was
to ensure that the range of the standard curve was appropriate to the amount of active 
MMP-9 likely to be present in the samples. Each of the samples was diluted in assay 
buffer to give a final protein concentration of 2.5mg/ml. The standard curve obtained 
after 5 hours was the best fitting curve (figure 32) so this was used in calculating 
values of MMP-9 from the unknown samples (table 7).
As in the assay carried out in 3.3.1, there wasn’t a large difference in the 
amount of active MMP-9 present in the samples of different trimesters, however there 
was a clear difference in the total MMP-9 detected in these homogenates. Much 
higher levels of pro-MMP-9 than active MMP-9 were detected, which agreed with the 
results from the preliminary zymographical analysis. Total MMP-9 levels in the 9 and 
36 weeks of gestation homogenate were above the standard curve. The 17 weeks of 
gestation homogenate had the lowest levels of total MMP-9 as in the previous assay 
before correction with the spike.
To rectify the difficulty of detecting both the low levels of active MMP-9 and 
the high levels of pro-MMP-9 it would be necessary to construct a larger standard 
curve than the ones recommended in the assay protocol.
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Figure 32 Standard curve: lower range assay for measuring MMP-9 in 
placental homogenates
E 0.08
<  0.04
0 2 3
MMP-9 (ng/ml)
Table 7 MMP-9 assay of placental homogenates from 1*‘, 2"^  and 3"^  ^
trimester: lower range standard curve
Sample Active (ng/ml) Total (ng/ml)
9wks 0.52 Above Std Curve
17wks 0.44 4.4
36wks 0.4 Above Std Curve
156
157
3.3.3 Recovery of a 5ng/ml MMP-9 Spike at various homogenate 
concentrations and at various BSA coneentrations
ISince the experiments in 3.3.1 suggested that detection of an MMP-9 spike was not 
satisfactory, the effect of increasing protein concentration on MMP-9 detection in the 
assay was investigated. Various concentrations (0 mg/ml, 1 mg/ml, 2mg/ml and 4 
mg/ml) of BSA were added to wells containing 5ng/ml MMP-9 in PBS to determine 
the effect of increasing non-specific protein concentration on MMP-9 detection. 
Various concentrations of a term placental homogenate (1.2mg/ml, 2.5mg/ml and 
5mg/ml) were also assayed with a 5ng/ml spike to determine if altering the dilution of 
the homogenate would affect the detection of the MMP-9 spike. A larger standard 
curve than had been used before was constructed over the range 0.1-16ng/ml from the 
standards provided in the kit as this would be necessary if both active and total MMP- 
9 levels are to be measured in the same assay. From the standard curve plotted after 2
hours of incubation (figure 33) the recovery of a 5ng/ml spike at various BSA 
concentrations (table 8) and at various homogenate concentrations (table 9) was 
calculated.
Increasing the concentration of BSA in the sample from 0-4mg/ml protein had 
virtually no effect on the recovery of the 5ng/ml spike (table 8) which was constantly 
over 100%.
Detection of the MMP-9 spike in placental homogenates (table 9) was greater 
at lower protein concentrations. However no more than 56% of the spike was 
recovered in any sample in this assay and detection varied between 31 and 56 %. The 
main concern therefore was that similar percentages of MMP-9 in the sample itself 
may be detected. The manufacturers of the assay (Amersham) were queried about this 
situation. Their reply was that this was probably as accurate as could be expected but 
that comparisons could still reliably be made between sample groups. It would not be 
desirable to dilute the homogenates much more than was done in this assay due to the 
small quantities of active MMP-9 which are present. .
Figure 33 Standard curve for determining recovery of a 5ng/ml MMP-9 
spike at various homogenate concentrations and at various BSA 
concentrations
MMP-9 ng/ml
Tables Recovery of a 5ng/ml Activated MMP-9 spike at various BSA 
concentrations
BSA mg/ml % Spike Recovery
0 116.1466
1 115.3092
2 115.5484
4 112.9163
Table 9 Recovery of a 5ng/ml MMP-9 spike at various homogenate 
concentrations
Homogenate
Concentration % Spike Recovery
5mg/ml 31.29786
2.5mg/ml 41.73047
1.2mg/ml 56.27871
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From these experiments it was concluded that while the assay does detect both active 
and pro- MMP-9 in placental homogenates from and 3'"^  trimester, detection of 
spiked MMP-9 protein was not entirely satisfactory, nor consistent. This may be due 
to binding of MMP-9 by TIMPs present at varying amounts in different homogenates. 
Due to time constraints it was therefore decided not to undertake further investigation 
of the assay at the current time.
3.4 Summary and discussion
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Evaluation of various methods for detecting and quantifying MMP-9 and MMP- 
2 in placental homogenates
The aim of this section of the study was to determine which methods would be most 
appropriate for determining MMP expression levels in placental homogenates. 
Western blotting was initially evaluated as it was a technique already in common use 
in the laboratory. In addition it was also hoped to establish the detection potential of 
the MMP-9 and MMP-2 antibodies that were later to be used in 
immunohistochemistry using western blotting. Several studies have attempted semi- 
quantitative analysis of MMP expression in medium from cultured trophoblast cells 
using zymography or activity assays. However no studies have examined MMP 
expression/activity in placental homogenates using these techniques and hence each 
of these were investigated to determine their suitablity. Important considerations in 
evaluating the methods were cost, time, ease of method, repeatability, and the 
potential for quantitative analysis.
-, "... .• ■•■■ '.
3.4.1 Western Blotting
Initially the experiments aimed to validate two commercially available antibodies for
detecting MMP-9 and one for detecting MMP-2. There are numerous other MMP-9
and MMP-2 antibodies on the market the majority of which detect both pro and active
MMP-2 and MMP-9. The datasheets from the particular antibodies evaluated gave no 
.indication which forms would be detected. Although western blotting is often carried 
out under reducing conditions the detection properties of some antibodies can be 
affected by whether or not the conditions are reducing. Initially the gels were run
under standard reducing conditions since no indication was given to the contrary on 
the antibody datasheets.
3.4.1.1 Detection of MMPs in placental homogenates under reducing 
conditions
The first attempt to detect either MMP in 50pg of total protein placental homogenates 
from a term and an early placenta using the Biogenesis MMP-9 and MMP-2 
antibodies or the Chemicon MMP-9 antibody was unsuccessful and only non-specific 
bands were present. An attempt was then made to detect pro-MMP-9 and pro-MMP-2 
purified proteins ‘spotted’ on nitrocellulose. This experiment showed that the 
Biogenesis MMP-9 antibody, which clearly detected 6.5ng of MMP-9 protein, was 
more sensitive than the Chemicon MMP-9 antibody. MMP-2 detection was not as 
sensitive and 50ng of purified protein was the smallest quantity that could readily be 
detected. It was decided to concentrate on the Biogenesis MMP-9 and MMP-2 
antibodies from this stage.
3.4.1.2 Detection of purified MMPs under reducing conditions
When the purified proteins were then run alongside homogenates on full western blots 
the MMP-9 antibody detected one clear band at 92kDa in the lanes where the purified 
protein had been loaded. There were some bands present in the homogenate lanes at 
around 92kDa although there were also numerous unspecific bands at other molecular 
weights. The MMP-2 antibody detected two bands in the purified protein lanes at 
72kDa and 68kDa, which was surprising as the protein was described as being pro- 
MMP-2 (72kDa). The manufacturers proposed that this extra band was probably the 
result of autocatalytic cleavage of the pro form of MMP-2. The protein was stored at 
-70C in accordance with the manufacturers instructions however it was possible that 
autocatalysis may still occur at a slow rate. It was clear from these experiments 
however that the MMP-2 antibody detected both pro and active MMP-2 under non­
reducing conditions.
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3.4.13 Activation of purified MMP-9 and determination of antibody 
specificity
Although the MMP-2 antibody detected both the pro and active forms of MMP-2, it 
was uncertain however whether the MMP-9 antibody detected both pro and active 
forms of MMP-9. Since both forms are likely to be present in placental tissue, it was 
important to determine which forms the antibody /detected. An initial attempt to 
activate MMP-9 was made using APMA as described on the manufacturers data sheet 
and western blotting was carried out under reducing conditions. No protein was 
detected in the lane where the activated MMP-9 was run, Since APMA activation is 
fairly harsh there was the possibility that all of the protein had been degraded. 
Alternatively it was possible that the antibody did not detect active MMP-9 under 
reducing conditions. Activated, non-activated and control MMP-9 were then spotted 
onto nitrocellulose and detected under non-reducing conditions. The pro-form spot 
was considerably more intense than either the control or activated spot. Although this 
would seem to suggest that the active form is not as readily detected as the pro-form 
even under non-reducing conditions, it could also have been the case that the spot 
remaining in the activated lane was some remaining pro-form.
Trypsin is an in vivo activator of MMP-9 and is without the biological hazards 
associated with APMA. Therefore it was decided to activate MMP-9 protein with 
trypsin to determine whether or not the antibody could detect MMP-9 activated in this 
way. With spotting almost exactly the same results were obtained as with activation 
by APMA.
A full western blot was then carried out to determine the molecular weight of 
each of the activated, non-activated and control MMP-9 to determine which forms of 
MMP-9 the antibody was actually detecting in each. A western blot was run under 
non-reducing conditions with APMA activated MMP-9 and control MMP-9 and 
trypsin activated MMP-9 and control MMP-9. The trypsin activation produced an
active form of MMP-9 at 84kDa and a 72kDa form whereas APMA activation!
released 72kDa and 30kDa forms, consistent with the concept that it is a harsh 
activator of MMPs. Neither of the controls were activated. Since the 84kDa form is 
the predominant active species in vivo trypsin activation was used from this stage 
onwards. The results clearly showed that the Biogenesis antibody detected both active 
and pro forms of MMP-9 under non-reducing conditions although it more readily
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detected the pro-form. This is important not only for Western Blotting but also for 
immunohistochemistry, the conditions in which are non-reducing.
3.4.1.4 Detection of MMPs in placental homogenates under non-reducing 
conditions
Ï
«
Cytosolic fraction (75pg) from placenta homogenised using various different protease
inhibitors were then run on a gel under non-reducing conditions and western blotting
was carried out using firstly the MMP-9 antibody and secondly the MMP-2 antibody.
The different protease inhibitors were tested to determine if either of the inhibitors
.regularly used in our laboratory had adverse effects on MMP detection. This is 
discussed further in the section on zymography. When the blot used to detect MMP-9
was exposed to film for 5 min, a band was present in the homogenates at 92kDa.
However there were also several other bands present. It was not possible to detect the
Ï
12.5ng control pro and activated MMP-9 until the blot had been exposed to the film 
for 30 min. This is longer exposure time than had been previously required for this 
amount of protein. By this stage the bands present in the homogenate were totally 
obscured by dark background. It is possible that the non-reducing conditions increase 
the non-specific protein detection. If western blotting was to be used in detecting 
MMP-9 in homogenate samples, it seems likely two exposure times would be 
necessary even if the amount of control was increased. Similar difficulties were 
encountered with western blotting of placental homogenates using MMP-2 antibody. 
While there appeared to be a band present at 72kDa after a 5 min exposure, other 
bands were also present. Further inspection revealed that the bands detected by the 
MMP-2 antibody were very similar to the bands detected by the MMP-9 antibody, 
suggesting they may be non-specific. Moreover, a 30 min exposure was required to 
detect 50ng of control pro and activated MMP-2. This resulted in extremely dark 
bands in the homogenates.
3.4.1.5 Conclusions of western blotting trial
Since the detection of any MMP-9 and MMP-2 in placental homogenates was difficult 
it is likely that any quantitative analysis of the bands would be almost impossible, 
although the technique is very cost and time effective. Thus western blotting of
I
I
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3.4.2.1 Detection of purified MMP-9 and MMP-2 protein by zymography
.placental homogenates may not be straightforward and it was decided to determine
whether zymography would provide a more accurate method of detecting MMP-9 and 
MMP-2 in placental samples. It is possible that other antibodies from other 
manufacturers may give better results. However, due to time considerations these 
were not evaluated. The validation of these antibodies for use in 
immunohistochemical studies was also satisfactorily achieved.
3.4.2 Gelatin Zymography
I
Gelatin zymography is an alternative method for detecting MMP-9 and MMP-2. Not 
only does it detect both active and non-active species hut it also reflects activity and is 
more sensitive than western blotting. It also has the advantage of detecting MMP-2 in 
the same gel as MMP-9 since both degrade the same substrate gelatin.
Previous published studies have all been performed using non-reducing conditions. 
Thus all zymography experiments herein were performed under non-reducing 
conditions. To establish the technique was working adequately the zymography 
method was tested using commercially available MMP-9 protein on a gel containing 
0.05% gelatin. This concentration of gelatin is lower than that used in many of the 
previously published studies which have used 0.3 or 0.1% gelatin and was chosen as a 
base point to determine sensitivity. Pro-MMP-9 was clearly detectable at 3.1ng and 
active MMP-9 at 1.5ng. A second gel showed that 0.5ng of MMP-9 was clearly 
detectable as a single band at 92kDa and there was a definite change in band intensity 
as concentration increased at least at double dilutions. The third experiment showed 
that zymography was also much more sensitive in detecting MMP-2 than western 
blotting. The technique detected 3.1ng of purified MMP-2 protein and clearly
differentiated between the pro and activated forms.
3.4.2.2 Detection of MMP-9 and MMP-2 in placental homogenates by 
zymography
Since purified active and pro-MMP-2 and MMP-9 were clearly detected by 
zymography, the next stage was to determine whether MMP activity could be as
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::ïeasily detected in plaeental homogenates. Plaeentas were homogenised using various -
combinations o f pro tease inhibitors and 75 pg o f both the total protein and cytosolic 
fractions were run. Both MMP-9 and MMP-2 were detectable in all of the :homogenates on a 0.05% gelatin gel. With both MMPs only the higher molecular 
weight pro-forms were detectable. There did not appear to be much difference
between the various combinations o f protease inhibitors added, although the
■homogenate that had no protease inhibitors added did seem to have less MMP activity
and the homogenate with two inhibitors appeared to have slightly stronger bands and
so both inhibitors were used in all the subsequent homogenisations. As expected,
since MMPs are cytosolic proteins, the amounts detected in the total and cytosolic
fractions were comparable. No EDTA was used in any homogenisation as it has an
inhibitory effect on MMPs, an important fact to take into consideration when :f
considering the results of some previously published studies.
Until this stage all experiments had been carried out on mini-gels. It was 
suggested that using large zymography gels as opposed to mini-gels would allow 
more protein to be added to each well and give clearer bands. However, the opposite 
occurred and while the bands obtained were larger they were also more diffuse and 
harder to quantify. This may have occurred for several reasons; e.g. diffusion o f the 
protein over the longer running time required or an over abundance o f MMP activity :§
for the amount o f gelatin present in the confined space hence mini gels were used in 
all experiments hereafter.
3.4.2.S Attempt to detect active MMP-9 and MMP-2 in placental 
homogenates
While the zymography was clearly effective at detecting pro-MMP-9 and -2  in
homogenates it was not clear whether there were little or no active forms in the
homogenates, or whether the method was not sensitive enough to detect them. Most
previous studies have used 0.1% or 0.3% gelatin (Fisher et al. 1989; Librach et al.
1991; Xu et al. 2000) and although lower than this concentration had been used for
the initial study, it was decided to determine if  a 0.025% gelatin impregnated gel
would be more sensitive for detection o f active MMP-9 and MMP-2 in placental
homogenates. On a 0.025% gelatin impregnated gel an increase in protein loaded Æn
.resulted in increased gelatinase activity until around 50pg. MMP-9 seemed to be
'
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present almost exclusively in the pro-form. In contrast, while the pro-form o f MMP-2 
predominated, there was some active MMP-2 at the con^ect molecular weight. 
Densitometrical analysis o f the bands showed that they were too diffuse to be 
quantified accurately by densitometry. When the amount o f protein loaded was 
decreased the active bands on the 0.025% gel still looked diffuse and it was difficult 
to distinguish between different concentrations o f protein. When the concentration of 
gelatin was increased to 0.05%, the lower concentration pro-bands were much sharper 
and were able to be quantified by densitometry. They also increased semi-linearly. 
However the active bands were undetectable. Hence it was decided to measure only 
the pro-form o f the enzymes in the study.
3.4.2.4 Pilot study and conclusions from zymography trial
A pilot study was carried out on one placenta from each week o f gestation to be 
investigated, to check that a 0.05% gelatin gel would be suitable. In addition, a 
concentration o f gelatin higher than 0.05% was tested to be absolutely sure that 0.05% 
was the optimum concentration for detection o f MMPs in placental homogenates. 
The gels were loaded with 6.5pg o f protein from the cytosolic fraction o f each 
placental homogenate. While both pro-MMP-9 and -2  were detectable at all 
gestations on both 0.05% and 0.1% gelatin gel, the 0.1% gel gave much poorer 
results. It was concluded that loading 6.5pg cytosolic protein on a 0.05% gelatin 
impregnated zymography gel would give quantifiable results using a time and cost 
effective method.
3.4.3 MMP-9 Activity Assay
An MMP-9 activity assay (Amersham) was also evaluated for detecting MMP-9 in 
placental homogenates. It had the advantage o f being able to measure both active and 
pro-MMP-9 in the same assay and was very time effective. An MMP-2 assay was also 
available but due to cost considerations, only the MMP-9 assay was investigated. In 
the instruction manual specificity for pro-MMP-9 was reported to be 100% and 
specificity for active MMP-9 around 65%. Complexes o f pro and active MMP-9 with 
both TIMP-1 and TIMP-2 were reported to have a degree o f cross-reactivity in the 
assay (between 20 and 38%).
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The assay had been commercially optimized for serum and plasma samples 
and in spiked samples gave recoveiy rates o f above 80%. It had not, however, been 
optimized for tissue homogenates, although it was stated in the manual that these 
could be successfully assayed. No guidance on dilutions o f homogenates or on 
expected accuracy was given.
3.4.3.1 Initial assay trial
To determine if  the assay would detect MMP-9 in placental homogenates throughout 
gestation, 1®‘(10 weeks o f gestation), 2"^ (19 weeks o f gestation) and 3*^  ^ (38 weeks of 
gestation) trimester placental homogenates were assayed. The homogenates were 
assayed at a coneentration o f 2.5mg/ml as this was the concentration o f the most 
dilute sample after homogenisation. Each activated homogenate was duplicated with 
the addition o f a 5ng/ml active MMP-9 spike to determine how much o f the spike 
would be detected. Only between 47% and 77% of the spiked MMP-9 was detected. It 
is possible that MMP-9 was bound by proteins in the homogenate, possibly TIMPs, 
preventing some o f the MMP-9 from being captured in the assay since TIMP/MMP-9 
complexes only show partial cross-reactivity with the assay. These results o f the 
initial experiment showed that there was more total than active MMP-9 at all three 
gestations studied. After each sample had been corrected for the spike, active MMP-9 
levels were fairly constant in comparison to total MMP-9. At both 10 and 19 weeks of 
gestation total MMP-9 levels were around 2x higher than active, and at 38 weeks o f 
gestation total MMP-9 levels were lOx higher than active. This was fairly surprising 
since while many studies have reported the importance of MMP-9 in the first 
trimester, few have implicated it at term (section 1.4.9).
3.4.3.2 Lower range standard curve I
A second assay was carried out using a lower range standard curve, as the active 
MMP-9 in the homogenates had been near the lower end o f the standard curve. 
Different homogenates (9 and 17 weeks o f gestation and term) were used from those 
in the first assay. Pro-MMP-9 levels were above the standard curve in two out o f three 
homogenates. As in the first assay there was not a large difference in the amount of 
active MMP-9 present in the samples o f different trimesters. The total MMP-9 levels
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in the 9 and 36 weeks o f gestation homogenate were above the standard curve. The 17 
weeks o f gestation homogenate had the lowest levels o f total MMP-9 as in the 
previous assay before (but not after) correction with the spike. No spike was included 
in this assay due to space constraints. To rectify the difficulty o f detecting both the 
low levels o f active MMP-9 and the high levels o f pro-MMP-9 it would be necessary 
to construct a larger standard curve than the ones recommended in the assay protocol.
3.4.3.3 Determination of effect of increasing protein concentration on assay 
detection of MMP-9
To determine the effect o f increasing protein concentration on MMP-9 detection in 
the assay, various concentrations (1 mg/ml, 2mg/ml and 4 mg/ml) o f BSA were added 
to wells containing a 5ng/ml MMP-9 in PBS. Various concentrations o f a term 
placental homogenate (1.2mg/ml, 2.4mg/ml and 5mg/ml) were also assayed to 
determine if  altering the dilution o f the homogenate would affect the detection o f the 
MMP-9 spike. Increasing the concentration o f BSA from 0-4mg/ml only slightly 
decreased the recovery o f the 5ng/ml spike implying that non-specific protein 
concentration at these dilutions does not affect MMP-9 detection in the assay.
Detection o f the MMP-9 spike in placental homogenates was better at lower protein 
concentrations. However no more than 56% o f the spike was recovered in any sample 
and detection varied between 31 and 56 %. The main concern was that this may imply 
that similar percentages o f MMP-9 in the sample itself are detected. The 
manufacturers were queried about this situation. Their reply was that this was 
probably as accurate as could be expected but that comparisons could still reliably be 
made between sample groups.
3.4.3.4 Conclusions from MMP-9 assay trial
The conclusion from these experiments were that while the assay did detect both 
active and pro-MMP-9 in placental homogenates from 1®^ 2"^ and trimester, 
detection o f  spiked MMP-9 protein was not entirely satisfactoiy, nor consistent. This 
may be due to binding o f MMP-9 by TIMPs present at varying amounts in different 
homogenates. It is possible that this could be controlled for by spiking the samples 
with purified MMP-9 protein, although this would be both time and resource 
consuming and not necessarily accurate. The assay is also very expensive compared lï
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to other methods of MMP detection. It was therefore decided not to undertake further 
investigation o f the assay at the current time.
3,4,4 Summary of conclusions on methodology for M M P detection and 
quantification
Zymography was the method that gave the most reliable semi-quantitative 
measurements o f MMP-9 and MMP-2 activity in placental homogenates. Since the 
MMP-9 and MMP-2 antibodies had been validated using western blotting and since 
immunohistochemistry was already a well-established technique in our laboratory it 
was hoped that immunohistochemistry in conjunction with zymography would 
provide the most viable means o f examining MMP-2 and MMP-9 distribution and 
activity in placentae throughout gestation.
I
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Chapter 4: Detection and quantification of 
MMP-9 and MMP-2 throughout pregnancy 
using zymography and 
immunohistochemistry
____ ______
Further to the trial o f various methods (chapter 3) it was concluded that zymography 
was the optimal method for semi-quantitative analysis of MMP activity in placental 
homogenates. Imniunohistochemistiy was chosen as the preferred method for 
determining cellular location o f MMP-2 and MMP-9 since the technique had been 
extensively used in the laboratory where the study was undertaken and to enable 
comparison with previous placental studies.
Hence zymography and imniunohistochemistiy were carried out to study the 
expression and activity o f MMP-2 and MMP-9 in placental homogenates and 
placental sections from 7-19 weeks o f gestation and from terni placentae. The aims o f 
this were several-fold:
• To perform semi-quantitative analysis o f MMP-2 and MMP-9 activity in 
placentae throughout gestation using zymogi*aphy
• To perform semi-quantitative analysis o f MMP-2 and MMP-9 expression in 
placentae throughout gestation using immunohistochemistry
• To determine in which cells MMP-2 and MMP-9 are expressed in the placenta
• To compare the results o f the semi-quantitative immunohistochemical analysis 
o f MMP-2 and MMP-9 with the zymography results
There is currently no consensus on precisely when and where MMP-2 and MMP-9 are 
expressed in the placenta during pregnancy. Thus a further aim was to compare the 
data obtained with those studies previously published.
4.1 Zymography of placental homogenates from 7-19 weeks of gestation
and from term placentae
Thirty-one placental blocks which had been collected immediately after delivery by 
ELCS in the trimester or TOP, and frozen at -70C , were homogenized as 
described in section 2.7. The gestations were as follows; 2x 7 weeks, 3x 8 weeks, 3x 9 
weeks, 2x 10 weeks, 2x 11 weeks, 2x 12 weeks, 2x 13, weeks 2x 14, weeks 2x 15 
weeks, 3x 16 weeks, 2x 17 weeks, Ix  18 weeks, Ix 19 weeks and 6x 40 weeks of 
gestation.
Cytosolic protein (6.5pg) from each homogenate was then separated on 0.05% 
gelatin zymography gels. Low range molecular weight markers were also run on each
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gel. The gels were washed in zymography wash buffer (section 2.1.2) to remove SDS 
and incubated in zymography reaction buffer (section 2.1.2) overnight, then stained in 
Coomassie blue and destained as described in section 2.9.2
Each band of digested gelatin representing pro-MMP-9 (92kDa) or pro-MMP- 
2 (72kDa) was quantified by negative densitometry and the background o f  the gel was 
subtracted from each reading. Thereafter each reading was divided by an internal 
control sample which was run on each gel to account for any day-to-day variations 
which may occur. No MMP-9 or MMP-2 activated bands were intense enough to be 
quantified. The final data was analysed to determine if  there were any variations in 
either pro-MMP-2 or pro-MMP-9 with gestation.
Figures 34 and 35 show the zymography gels for pro-MMP-2 (figure 34) and 
pro-MMP-9 (figure 35). For pro-MMP-2 a band at 72kDa was detectable in all the 
samples. For pro-MMP-9 a band at 92kDa was detectable in all the samples. Table 10 
shows the raw data and the values for these zymograms once they had been divided 
by the internal control sample value. The columns on the left show the values for pro- 
MMP-2 and the columns on the right show the values for pro-MMP-9.
Next the data was grouped into trimesters and represented as scattergrams. 
Figure 36 shows the scattergram for pro-MMP-2 and figure 37 shows the scattergram 
for pro-MMP-9. The bars show the median values. Following this, statistical analysis 
was carried out to determine if  there were any statistical differences in pro-MMP-2 or 
pro-MMP-9 activity between trimesters.
Table 1 la  shows the descriptive statistics for pro-MMP-2 and table 1 lb  shows 
the results o f the statistical analysis for pro-MMP-2. No assumptions were made as to 
the normality of the data and non-parametric testing was used throughout. A Kruskal- 
Wallis analysis showed a highly significant difference between the trimesters. There 
was significantly less pro-MMP-2 activity in the 2"^ trimester compared with the 
trimester (p<0.01). There was also significantly less pro-MMP-2 activity in the 3’*^ 
trimester compared with the trimester (p<0.01). There was no significant 
difference in pro-MMP-2 activity between the 2"^ and 3"^  ^trimesters.
Table 12a shows the descriptive statistics for pro-MMP-9 and table 12b shows 
the results o f the statistical analysis for pro-MMP-9. A Kruskal-Wallis analysis
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showed no significant differences between the three trimesters (p>0.05). Mann- 
Whitney analysis also showed no significant differences (p>0.05) between any o f the 
trimesters.
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Figure 34 Pro-MMP-2 activity in placental homogcnates - zymography
(weeks of gestation)
<-----  72kDa
(Pro-MMP-2)
<  72kDa
(ProMMP-2)
9 9 10 10 11 11
(weeks of gestation)
12
<-----  72kDa
(ProMMP-2)
12 13 13 14 14 15
(weeks of gestation)
15
M  72kDa
(Pro-MMP-2)
16 16 16 17 17 18 19
(weeks of gestation)
^ -----  72kDa
(Pro-MMP-2)
40 40 40 40 40 40
(weeks of gestation)
173
Figure 35 Pro-MMP-9 activity in placental homogcnates- zymography
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Table 10 Densitometrical analysis of zymography of placental homogcnates 
raw and corrected data
I
pro-MMP-2 pro-MMP-9
Gestation Pro-MMP-
2
OD
MMP-2
Control
OD
Final
Pro-MMP-2
(OD/con)
Pro-MMP-
9
OD
MMP-9
Control
OD
Final 
Pro-MMP- 
9 (OD/con)
7 0.23 0.14 1.64 0.05 0.02 2.5
7 0.31 0.14 2.21 0.15 0.02 7.5
8 0.41 0.14 2.92 0.15 0.02 7.5
8 0.21 0.14 1.50 0.19 0.02 9.5
8 0.17 0.14 1.21 0.14 0.02 7.0
9 0.19 0.14 1.36 0.08 0.02 4.0
9 0.23 0.19 1.21 0.08 0.03 2.6
9 0.23 0.19 1.21 0.09 0.03 3.0
10 0.12 0.19 0.63 0.09 0.03 3.0
10 0.19 0.19 1.00 0.03 0.03 1.0
11 0.22 0.19 1.15 0.12 0.03 4.0
11 0.23 0.19 1.21 0.15 0.03 5.0
12 0.19 0.19 1.00 0.06 0.03 2.0
12 0.08 0.15 0.53 0.08 0.04 2.0
13 0.17 0.15 1.13 0.13 0.04 T25
13 0.11 0.15 0.73 0.06 0.04 1.5
14 0.10 0.15 0.67 0.19 0.04 4.75
14 0.18 0.15 1.20 0.06 0.04 1.5
15 0.16 0.15 1.07 0.22 0.04 5.5
15 0.17 0.15 1.13 0.10 0.04 2.5
16 0.02 0.13 0.15 0.07 0.03 2,3
16 0.06 0.13 0.46 0.04 0.03 1.3
16 0.10 0.13 0.77 0.09 0.03 3.0
17 0.12 0.13 0.92 0.11 0.03 3.7
17 0.05 0.13 0.38 0.04 0.03 1.3
18 0.12 0.13 0.92 0.12 0.03 4.0
19 0.15 0.13 1.15 0.12 0.03 4.0
40 0.04 0.14 0.29 0.14 0.03 4.7
40 0.04 0.14 0.29 0.07 0.03 2.3
40 0.12 0.14 0.86 0.06 0.03 2.0
40 0.14 0.14 0.77 0.05 0.03 1.7
40 0.11 0.14 0.46 0.08 0.03 2.7
40 0.11 0.14 0.46 0.10 0.03 3.3
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Figure 36 Scattergraph of pro-MMP-2 activity in Ÿ , 2" and 3*^  trimesters
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Figure 37 Scattergraph of pro-MMP-9 activity in 1% 2"^ * and 3"* trimesters
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Table 11a Descriptive statistics for densitometrical analysis of pro-MMP-2
(after correction with control)
Mean Median Max Min Range 
between 
min and 
max 
values
SE SD
pro-MMP-2 
1 St Trimester
1.29 1 . 2 1 2.92 0.53 Z39 0.15 0.59
pro-MMP-2 
2‘“* Trimester
0.80 0.92 1 . 2 0.15 1.05 0 . 1 1 0.35
pro-MMP-2
Trimester
0.52 0.46 0 . 8 6 0.29 0.57 0 . 1 0 0.24
Table 11b Statistical analysis of the variation in pro-MMP-2 activity between 
the trimesters
Test pro-MMP-2
Trimesters compared p-value
Kruskal-Wallis p<0 . 0 1
Mann-W hitney ( l ’V2 "“) p< 0 . 0 1
Mann-W hitney (I'VS'") p< 0 . 0 1
Mann-Whitney (2'""3"') N/S
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Table 12a Descriptive statistics for densitometrical analysis of pro-MMP-9
(after correction with control)
Mean Median M ax Min Range 
between 
min and 
max 
values
SE SD
pro-MMP-9 
1®* Trimester
4.08 3.13 9.5 1.0 8.5 0.63 2.51
pro-MMP-9 
2"** Trimester
3.08 3.00 5.5 1.3 4.20 0.43 1.43
pro-MMP-9 
r^d Trimester
2.78 2.50 4.70 1.70 3.0 0.45 1.09
■.Î..ÜI
«
- i i
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Table 12b Statistical analysis of the variation in pro-MMP-9 activity between 
the trimesters
Test pro-MMP-9
Trimesters compared p-value
Kruskal-Wallis
(ist/jQd/jrd)
N/S
Mann-W hitney (I'Vz'") N/S
Mann-W hitney (1*73'^ '') N/S
Mann-W hitney (2"‘’'3'^ ‘‘) N/S
«
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The next stage in the analysis was to determine if  there were any coiTelations 
in pro-MMP-2 or pro-MMP-9 activity within each trimester. The corrected data was 
represented on histograms for pro-MMP-2 (figure 38) and pro-MMP-9 (figure 39). 
The data was then analysed using a Speam ian’s correlation. Analyses were carried out 
for both pro-MMP-2 and pro-MMP-9 to determine conelation of MMP activity 
within the trimester (7-13 weeks), 2"^ trimester (14-19 weeks), rV2"^ trimester (7- 
19 weeks), 2"^/3’^  ^ trimester (14-40 weeks) and l%"^/3'^^ trimesters (7-40 weeks).
The summary o f the statistics for the analysis is shown in table 13. In all 
significant correlations throughout this thesis the correlation coefficient (R) is stated. 
A highly significant negative conelation o f pro-MMP-2 activity with gestation was 
found from 7-13 weeks (p<0.01), 7-19 weeks (p<0.01) and from 7-40 weeks of 
gestation (p<0.01). No significant correlation was found when the and 3"^  
trimesters were analysed separately or together.
A significant negative correlation (ie band intensity decreased 
as gestation increased) o f pro-MMP-9 activity with gestation was found from 7-13 
weeks (p<0.05). No other significant correlations were found.
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Figure 38 Histogram of pro-MMP-2 activity throughout gestation
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Figure 39 Histogram of pro-MMP-9 activity throughout gestation
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Table 13 Pro-MMP-2 and pro-MMP-9 activity correlation with gestation
Test pro-MMP-2 pro-MMP-2 pro-MMP-9 pro-MMP-9
p-value R valu e p-value R-value
Spearman’s
Rank
trimester
p<0 . 0 1 -0.83 p<0.05 -0.54
Spearman’s 
Rank 
2"^  trimester
N/S N/S N/S N/S
Spearman’s
Rank
(rV 2”“
trimester)
p< 0 . 0 1 -0.71 N/S N/S
Spearman’s
Rank
(2 tid/3 rd
trimester)
N/S N/S N/S N/S
Spearman’s 
Rank (l®V2”“/3‘’‘* 
trimester)
p< 0 . 0 1 -0.76 N/S N/S
■ir
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In order to determine if  there was any correlation o f pro-MMP-9 with pro- 
MMP-2 activity, the ratio o f pro-MMP-9 to pro-MMP-2 was calculated for each 
sample and then the results were determined using a Spearman’s correlation. The 
uncon-ected values obtained by densitometiy o f the zymograms were used because 
pro-MMP-9 and pro-MMP-2 were always present on the same gel and indeed in the 
same lane. The descriptive statistics for this analysis are shown in table 14 for both 
pro-MMP-2 and pro-MMP-9. The results o f the Spearman’s correlation o f pro-MMP- 
9 with pro-MMP-2 are shown in table 15. No correlation was found between pro- 
MMP-9 and pro-MMP-2 activity in any o f the groups tested.
For the final analysis o f the zymography gels, a comparison was made o f band 
intensity o f pro-MMP-2 and pro-MMP-9 in the 1®^ and 2"^ trimesters and at term. 
Figure 40 shows a comparison o f pro-MMP-2 and pro-MMP-9 band intensity 
throughout gestation. The data was tested using a Wilcoxon signed ranks test. The 
results o f the statistical tests to compare band intensity are shown in table 16. A 
significantly higher band intensity o f pro-MMP-2 than pro-MMP-9 was found 
(p<0.01) in the first trimester. No significant differences were found in the second 
trimester or at term. When all three trimesters were included in the analysis a 
significantly higher band intensity o f pro-MMP-2 than MMP-9 was found (p<0.01).
a
.
■
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Table 14 Descriptive statistics for densitometrical analysis o f pro-MMP-2
and pro-MMP-9 (before correction with control)
Mean Median Max Min
Range 
between 
min and 
max values
SE SD
Pro-MMP-2 
jst xrim ester
0 . 2 1 0 . 2 0 0.41 0.08 0.33 0 . 0 2 0.08
Pro-MMP-2 
2nd Trimester
0 . 1 1 0 . 1 2 0.18 0 . 0 2 0.16 0 . 0 2 0.05
Pro-MMP-2 
3*^  ^Trimester
0.09 0 . 1 1 0.14 0.04 0 . 1 0 0 . 0 2 0.04
Pro-MMP-9
Trimester
0 . 1 0 0.09 0.19 0.03 0.16 0 . 0 1 0.04
Pro-MMP-9 
2nd Trimester
0 . 1 1 0 . 1 0 0 . 2 2 0.04 0.18 0 . 0 2 0.06
Pro-MMP-9 
3rd Trimester
0.08 0.08 0.14 0.05 0.09 0 . 0 1 0.03
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Table 15 Zymography statistical analysis: pro-MMP-2 with pro-MMP-9
correlation throughout gestation
Test p-value R va lu e
Spearman’s Rank  
1®* trimester N/S N/S
Spearman’s Rank 
2"^  trimester N/S N/S
Spearman’s Rank 
3'  ^trimester N/S N/S
Spearman’s Rank 
(jst/2nd ti-ijnester) N/S N/S
Spearman’s Rank 
(2'“*/3*^  trimester) N/S N/S
Spearman’s Rank
(ist/2iid/3rd trimester) N/S N/S
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Figure 40 Scattergraph comparison of pro-MMP-2 and pro-MMP-9 band
intensity throughout gestation
pro-MMP-2 and pro-MMP-9 band intensity during 
the 1st trimester
-
♦ pro-MMP-2
♦  pro-MMP-9
pro-MMP-2 and pro-MMP-9 band intensity during 
the 2nd trimester
1  0.23O0  0.15
1 -
c 0.053
•  pro-MMP-2
♦  pro-MMP-9
pro-MMP-2 and pro-MMP-9 band intensity at term
?
• pro-MMP-2
♦ pro-MMP-9
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Table 16 Comparison of pro-MMP-2 with pro-MMP-9 band Intensity
throughout gestation
a
Wilcoxon Signed Ranks 
test p-value
All trimesters p< 0 . 0 1
1®* trimester p< 0 . 0 1
2 ““* trimester N/S
3'  ^ trimester N/S
a-
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Summary of analysis of pro-MMP-2 and pro-MMP-9 activity in placental
homogenates by zymography
The analysis o f pro-MMP-9 activity showed a decrease in activity with increasing 
gestation during the first trimester using a Spearman's correlation. There were no 
other significant changes.
When pro-MMP-2 activity was analysed, a highly significant decrease was 
detected when a Spearman’s correlation was carried out on homogenates from 7-19 
weeks ( 1 % "^ trimester) and on homogenates from 7-40 weeks (rV2"^/3^^ trimester). 
No significant conelation was found on homogenates from 14-40 weeks alone 
trimester). W hen pro-MMP-2 levels were analysed by Kruskal-W allace and Mann- 
Whitney testing to determine variation throughout the different trimesters, a 
significant decrease was found between and 2 "^  trimesters and a highly significant 
decrease was found between and 3'^ trimesters.
No correlation was found between pro-MMP-2 and pro-MMP-9 levels at any 
stage in gestation when the data was analysed using Spearman’s correlation.
In comparing pro-MMP-2 and pro-MMP-9 band intensity using a Wilcoxon 
Signed Ranks test, a significantly higher band intensity o f pro-MMP-2 than MMP-9 
was found (p<0 .0 1 ) in the first trimester and when all three groups were included in 
the analysis. No significant differences were found in the second trimester or at term. 
When all three trimesters were included in the analysis a significantly higher band 
intensity o f pro-MMP-2 than MMP-9 was found (p<0.01).
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4.2 Determination of expression and location of MMP-9 and MMP-2 in
placenta throughout pregnancy using immunohistochemistry
4.2.1 MMP-9 immunohistochemistry
Zymography experiments had shown a decrease in pro-MMP-9 activity during the 
first trimester but no other changes with gestation. Next the expression and location of 
MMP-9 in placenta throughout gestation by immunohistochemistiy were investigated.
Frozen sections were cut from placental blocks from 7-19 weeks o f gestation 
and from the same term placentae which had been used for zymography. The ' ^
gestations were Ix  7, 2x 8 , 2x 9, 2x 10, 2x 11, 2x 12, 2x 13, 3x 14, 2x 15, 2x 16, Ix 
17, 2x 18, Ix  19, and 1 Ix 40 weeks o f gestation.
Immunohistochemistry was carried out using the Biogenesis MMP-9 antibody 
which detects both pro and active MMP-9 (section 3.1.7). The MMP-9 antibody was 
used at a dilution o f 1/500 as described previously (section 2.2). The staining was 
scored on a 0-4 scale as described in section 2.6. Control slides where sheep IgG or 
antibody diluent was substituted for prim aiy antibody showed no staining (section 
2.2). For all immunohistochemistry experiments described in this chapter and in 
chapter 5, staining was evenly distributed throughout the placental sections from the 
chorionic to the basal plate. Where EVT was evaluated it was present in the decidua 
or in cell columns. There was insufficient decidual tissue to perform a comprehensive 
analysis on decidua alone.
Across gestation MMP-9 was present to a greater or lesser extent in EVT, 
endothelium, muscle sun'ounding blood vessels and in the stroma. There was virtually 
no staining on vCTB or STB. Figure 41 shows photographs of representative MMP-9 
staining from selected gestations. Figure 41a shows a placenta at seven weeks of 
gestation with veiy little staining except in the intervillous blood space, which is 
likely to be endogenous peroxidase. Figure 41b shows limited staining in EVT at 8
weeks of gestation. Figure 41c shows a placenta at sixteen weeks o f gestation with 
moderately strong endothelial staining. Figure 41 d shows a placenta at teim  with even
stronger endothelial and stronger stromal staining.
'The raw data obtained from scoring the stained sections is shown in table 17.
The data was grouped into trimesters and statistical analysis was caiTied out to 
determine if  there were any statistical differences in MMP-9 expression between
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trimesters. A summary o f the descriptive statistics o f the data is given in table 18. No 
assumptions were made as to the normality o f the data and non-parametric testing was 
used throughout.
Table 19 shows the results o f the statistical analysis for MMP-9. Kruskal- 
Wallis analysis showed a significant difference between the trimesters in endothelial, 
muscle and stromal staining (p<0.01). When these groups were analysed individually 
by Mann-Whitney analysis, there were no significant changes between 1®^ and 2"  ^
trimesters in any cell types.
There was significantly more endothelial staining in the third trimester when 
compared with the second trimester (p<0 .0 1 ) and in the third trimester when 
compared with the first trimester (p<0.01). There was also significantly more stromal 
staining in the third trimester when compared with the second trimester (p<0 .0 1 ) and 
in the third trimester when compared with the first trimester (p<0.01). There was 
significantly more muscle staining in the third trimester when compared with the 
second trimester (p<0.05) and in the third trimester when compared with the first 
trimester (p<0.05). No significant differences in vCTB or EVT staining were found in 
any o f the tests. However the Kruskal-Wallace analysis for EVT almost reached 
significance as did the Mann-Whitney analysis between the first and second trimester 
(p=0.08) with staining tending to be lower in the second trimester than in the first.
I
•I
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Figure 41 Immunohistochemistry of MMP-9 throughout gestation
a) 7 weeks of gestation
50fj,m
b) 8 weeks of gestation
50|xm
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c) 16 weeks of gestation
50pm
d) Term
100pm
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Table 17 Semi-quantitative analysis of MMP-9 immunostaining
G estation
(weeks)
vCTB EV T E ndothélium M uscle S trom a
7 0 2 0 0 0
8 0 N/P* 0 0 0
8 0 2 0 0 2
9 0 2 0 0 0
9 0 N/P 0 0 0
1 0 0 1.5 0 0 0.5
1 0 1.5 1.5 0 0 0.5
1 1 0 3 0 0 0.5
1 1 0 N/P 0 0 0.5
1 2 0 0.5 0 0 0.5
1 2 0 N/P 0 0 0
13 1 1 0 0 0
13 1 N/P 1 0 0
14 0 0.5 0 0 0
14 0 0.5 0 0 0
14 0 0.5 1 0 0
15 0 1.5 0 0 0.5
15 0 1.5 0 0 0
16 0 1 2 0 0.5
16 1 N/P 2 0 0.5
17 0 1.5 0 0 0.5
18 1.5 1.5 0 0.5 0
18 0.5 N/P 1 0 0.5
19 0 N/P 0 0 1
40 0 N/P 2 . 0 1 2
40 0 0.5 1.5 0 1.5
40 0 N/P 2 0.5 1
40 0 N/P 1.5 0 2
40 0 N/P 2.5 0 1
40 0 N/P 2 0.5 0.5
40 0 N/P 2.5 0 2
40 0 N/P 2 1 1.5
40 0 N/P 2.5 1 1.5
40 1 N/P 3 1.5 2
*N/P = Not Present
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Table 18 MMP-9 immunohistochemistry descriptive statistics
Mean Median Max Min Range 
between 
min and 
max
SE SD
vCTB
l«t 0.27 0 . 0 1.5 0 . 0 1.5 0.15 0.53
2 iid 0.27 0 . 0 1.5 0 . 0 1.5 0.16 0.52
3 rd 0 . 1 0 0 . 0 1 . 0 0 . 0 1 . 0 0 . 1 0 0.32
trimester
EVT
1.69 1.75 3.0 0.5 2.5 0.27 0.75
1.06 1.25 1.5 0.5 1 . 0 0.18 0.5
3 rd 0.5 0.5 0.5 0.5 0 . 0 N/A* N/A*
trimester
Endothelium
ist 0.08 0 . 0 1 . 0 0 . 0 1 . 0 0.08 0.28
2 nd 0.55 0 . 0 2 . 0 0 . 0 2 . 0 0.25 0.82
3 rd 2.15 2 . 0 3.0 1.5 1.5 0.15 0.47
trimester
Muscle
jst 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0.0
a""* 0.05 0 . 0 0.50 0 . 0 0.50 0.05 0.15
3 rd 0,55 0.50 1.5 0 . 0 1.5 0.17 0.55
trimester
Stroma
0.35 0 . 0 2 . 0 0 . 0 2 . 0 0.15 0.55
2""* 0.32 0.50 1 . 0 0 . 0 1 . 0 0.10 0.34
3 rd 1.5 1.5 2 . 0 0.50 1.5 0.17 0.53
trimester
N /A ’®' =  Not Applicable
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Table 19 Analysis of variation in MMP-9 immunostaining between the three 
trimesters
Test vCTB EVT Endothelium Muscle Stroma
Kruskal-
Wallace p-value
3 st/2 nd/3 rd
trimester N/S* N/S p<0 . 0 1 p<0 . 0 1 p<0 . 0 1
Mann-W hitney
ist/2 iid trimester N/S N/S N/S N/S N/S
2 nd/3 rd trimester N/S N/S p<0 . 0 1 p<0.05 p< 0 . 0 1
ist/3 rd
trimester N/S N/S p< 0 . 0 1 p<0.05 p< 0 . 0 1
*N/S = Non-Significant
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The next stage in the analysis was to determine if  there were any correlations 
in MMP-9 expression within each trimester. The data was represented on histograms 
for each cell type (figure 42). Note that for some cell types many values were zero (no 
staining) and therefore do not appear as bars on the chart. The data was then analysed 
using a Spearman’s correlation. Analyses were carried out to determine correlation o f 
MMP-9 expression within the 1®‘ trimester (7-13 weeks), 2"^ trimester (14-19 weeks), 
1®V2"^  trimester (7-19 weeks), 2" /^3^  ^trimester (14-40 weeks) and l®V2”^ /3‘^  trimesters 
(7-40 weeks). The results o f the analysis are shown in table 20.
The data summarized in table 20 shows a significant positive correlation 
(staining increased as gestation increased) o f MMP-9 staining with gestation on EVT 
(figure 42a) between 14-19 weeks (p<0.02) but a negative correlation (staining 
decreased as gestation increased) between 7-40 weeks o f gestation (p<0.05).
A significant positive correlation (staining increased as gestation increased) o f 
MMP-9 staining with gestation on endothelium (figure 42b) was found between 7-19 
weeks (p<0.05), between 14-40 weeks (p<0.01) and between 7-40 weeks (p<0.01). 
No correlation was found between 7-13 weeks or between 14-19 weeks o f gestation.
A significant positive correlation (staining increased as gestation increased) o f 
MMP-9 staining with gestation on muscle (figure 42c) was found between 7-40 weeks
(p<0 .0 1 ).
A significant positive conelation (staining increased as gestation increased) o f 
MMP-9 stromal staining (figure 42d) with gestation was found between 14-19 weeks 
(p<0.05), between 14-40 weeks (p<0.01) and between 7-40 weeks (p<0.01). No 
coiTelation was found between 7-13 weeks or between 7-19 weeks o f gestation. No 
significant correlation o f vCTB staining (figure 42e) was found in any o f the tests.
s
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Figure 42 Histograms of MMP-9 immunostaining throughout gestation
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Table 20 Correlation of MMP-9 immunostaining with gestation
Î
?
Spearman’s Rank vCTB EVT Endothelium Muscle Stroma
p-value and 
R~value
trimester N/S* N/S N/S N/S N/S
2"^ * trimester N/S p< 0 . 0 2R=0.81 N/S N/S
p<0.05
R=0.66
1^ V2"^  trimester N/S N/S p<0.05R=0.43 N/S N/S
2 nd/3 rd N/S N/S p< 0 . 0 1
R=0.71 N/S
p<0 . 0 1
R=0.87
jst/2 nd/3 >-d trimester N/S p<0.05R=-0.51
p<0 . 0 1
R=0.80
p< 0 . 0 1
R=0.51
p< 0 . 0 1
R=0.62
I:|
*N/S = Non-Significant
201
:
4.2.2 MMP-2 iramunohistochemistry
Zymography experiments had shown a decrease in pro-MMP-2 activity with gestation 
throughout pregnancy. Next the expression and location o f MMP-2 in placenta 
throughout gestation by immunohistochemistry were investigated. The same placental 
sections were used as for MMP-9 immunohistochemistiy (section 4.2.1).
Immunohistochemistry was can'ied out using a Biogenesis antibody against 
MMP-2, which detects both pro and active MMP-2 (section 3.1.3). The MMP-2 
antibody was used at a dilution o f 1/250 (section 2.2) and the staining was scored on a 
0-4 scale as described previously (section 2.6). Control slides where sheep IgG or 
antibody diluent was substituted for primary antibody showed no staining (section
2 J0 '
Across gestation MMP-2 was present to a greater or lesser extent in vCTB and 
STB, EVT, endothelium, muscle surrounding blood vessels and in the stroma. Figure 
43 shows photographs o f representative MMP-2 staining from selected gestations. 
Figure 43 a shows a placenta at seven weeks o f gestation with moderate vCTB 
staining. Figure 43b shows EVT staining at 8  weeks o f gestation. Figure 43c shows a 
placenta at fifteen weeks o f gestation with moderately strong endothelial staining. 
Figure 43d shows a placenta at teim  with stronger endothelial staining.
The raw data obtained from scoring the stained sections is shown in table 21. 
Next the data was grouped into trimesters and statistical analysis was carried out to 
determine if  there were any statistical differences in MMP-2 expression between 
trimesters. A summary o f the descriptive statistics o f the data is given in table 22. No 
assumptions were made as to the normality o f the data and non-parametric testing was 
used throughout. Table 23 shows the results o f the statistical analysis for MMP-2. 
Kruskal-Wallis analysis showed a highly significant difference between the trimesters 
in vCTB, endothelial and muscle staining but not in EVT or stromal staining.
Mann-Whitney analysis detected that staining o f vCTB was lower in the third 
trimester compared with the first trimester and in the second trimester compared with 
the first trimester. There was significantly more endothelial staining in the third 
trimester compared with the second trimester (p<0 .0 1 ), in the second trimester 
compared with the first trimester and in the third trimester compared with the second 
trimester. No significant differences were found in EVT, muscle or stromal staining.
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Figure 43 Immunohistochemistry of MMP-2 throughout gestation
a) 7 weeks of gestation
50pm
b) 8 weeks of gestation
50pm
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c) 15 weeks of gestation
/ a T ^
50pm
d) Term
100pm
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Table 21 Semi-quantitative analysis of MMP-2 immunostaining
G estation
(W eeks)
vCTB EV T Endothelium M uscle S trom a
7 1.5 2 0 0 0.5
8 0.5 N/P* 0 0 0
8 2 2 0 0 1.5
9 0.5 1.5 0 0 0.5
9 0.5 N/P 0 0 0.5
1 0 1 1.5 0 0 0.5
1 0 2.5 2 2.5 2.5 2
1 1 1 2 0 0 1
1 1 0.5 N/P 0 0 0.5
1 2 1.5 2.5 0 0 1
13 1.5 2 2 0 0.5
13 2 1.5 2.5 0 1
14 0.5 2.5 1 0 0.5
14 1.5 2.5 2 0 1.5
14 0.5 0.5 2.5 0 0.5
15 1 0.5 1.5 1.5 1.5
15 0 N/P 1.5 0 0
16 0 0.5 2.5 0 0
16 0 N/P 2.5 0 0
17 0 N/P 2 0 0
18 1 0.5 1.5 0 0.5
18 0 N/P 2.5 0 0
19 0 1.5 2 0 1.5
40 0 N/P 2.5 0 1
40 0 N/P 2.5 1.5 1.5
40 1.5 0.5 2.5 0 0.5
40 0 N/P 2.5 0 2
40 2 N/P 3.5 2.5 2.5
40 0 N/P 2.5 1.5 1
40 0 N/P 2.5 0 1
40 0 N/P 2.5 0 0.5
40 0 N/P 2.5 1 0
40 0 N/P 2.5 1 0
40 0 N/P 2.5 0 0.5
*NP = Not present
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Table 22 MMP-2 immunohistochemistry descriptive statistics
M ean M edian M ax M in R ange 
between 
m in and 
m ax
SE SD
vCTB
l*t 1.19 1 . 0 2.5 0.50 2 . 0 0.19 0.69
2 iid 0.36 0 . 0 1.5 0 . 0 1.5 0.17 0.55
3 rd 0.35 0 . 0 2 . 0 0 . 0 2 . 0 0.24 0.75
trim ester
EVT
ist 1.89 2 . 0 2.5 1.5 1 . 0 0 . 1 1 0.33
2 ““ 1 . 2 1 0.5 2.5 0.5 2 . 0 0.36 0.95
3 rd 0.5 0.5 0.5 0,5 0 . 0 N/A* N/A*
trim ester
E ndothelium
jSt 0.62 0 . 0 2.5 0 . 0 2.5 0.28 1 . 0 2
2 »d 2.09 2 . 0 2.5 1.5 1 . 0 0.13 0.44
3 rd 2.60 2.5 3.5 2.5 1 . 0 0 . 1 0 0.32
trim ester
M uscle
ist 0.19 0 . 0 2.5 0 . 0 2,5 0,19 0.69
2 nd 0.14 0 . 0 1.5 0 . 0 1.5 0,14 0.45
3 rd 0.94 1 . 0 2.5 0 . 0 2.5 0.32 0.90
trim ester
S trom a
jSt 0.77 0.50 2 . 0 0 . 0 2 . 0 0.15 0.53
2 nd 0.59 0.50 1.5 0 . 0 1.5 0 . 2 0 0 . 6 6
3 rd 0.95 0.75 2.5 0 . 0 2.5 0.26 0.83
trim ester
a
#
I
' t
,
N/A* == Not Applicable
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Table 23 Analysis of variation in MMP-2 immunostaining between the three 
trimesters
Test vCTB EVT Endothelium Muscle Stroma
p-value
Kruskal-
W allace
(ist/2 nd/3 rd
trimester)
p<0 . 0 1 N/S* p< 0 . 0 1 p<0.05 N/S
M ann-W hitney
1®V2"^  trimester p< 0 . 0 1 N/S p< 0 . 0 2 N/S N/S
2 nd/3 rd N/S N/S p< 0 . 0 2 N/S N/S
jst/srd
trimester p< 0 . 0 1 N/S p<o.Oi N/S N/S
*N/S = Non-Significant
207
Following this the data was analysed to determine if  there were any 
correlations in MMP-2 expression within each trimester. The data was represented on 
histograms for each cell type (figure 44). Note that for some cell types many values 
were zero (no staining) and therefore do not appear as bars on the chart. The data was 
then analysed using a Spearman’s coiTelation. Analyses were carried out to detemiiiie 
correlation o f MMP-2 expression within the trimester (7-13 weeks), 2'^  ^ trimester 
(14-19 weeks), 1®V2"^  trimester (7-19 weeks), trimester (14-40 weeks) and
isy2 iid/3 rd (7_40 weeks). The results o f the analysis are shown in table 24.
The data summarized in table 24 shows vCTB staining (figure 44a) was 
negatively correlated (staining decreased as gestation increased) with gestation 
between 7-19 weeks and between 7-40 weeks o f gestation. EVT staining (figure 44b) 
was negatively correlated (staining decreased as gestation increased) with gestation 
between 7-40 weeks of gestation.
A significant positive con'elation (staining increased as gestation increased) of 
endothelial MMP-2 staining (figure 34c) with gestation was found between 7-13 
weeks, between 7-19 weeks, between 14-40 weeks and between 7-40 weeks of 
gestation. No significant correlations with gestation were found in muscle (figure 44d) 
or stromal staining (figure 44e),
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Figure 44 Histograms of MMP-2 immunostaining throughout gestation
a)
vCTB
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Table 24 Correlation o f MMP-2 immunostaining with gestation
Test vCTB EVT Endothelium Muscle Stroma
Spearman’s Rank p-value and R-value
ist
trimester N/S* N/S
p<0.05
R=0.58 N/S N/S
2 nd
trimester N/S N/S N/S N/S N/S
1®V2"^  trimester p< 0 . 0 1R=-0.59 N/S
p<0 . 0 1
R=0.67 N/S N/S
2 nd/3 rd N/S N/S p<0 . 0 1R=0.54 N/S N/S
jst/2 ..d/3 rd
trimester
p< 0 . 0 1
R—-0.56
p<0.05
R=-0.51
p<0 . 0 1
R=0.77 N/S N/S
*N/S = Non-Significant
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4,3 Discussion
4.3.1 MMP-9: Summary of results
4.3.1.1 Zymography
Analysis o f pro-MMP-9 zymography band intensity (and hence activity) showed no 
significant differences between the three trimesters. A significant negative correlation 
(i.e. band intensity decreased as gestation increased) o f pro-MMP-9 activity with 
gestation was found from 7-13 weeks. No other significant correlations were found.
The band intensity o f pro-MMP-9 was significantly lower than pro-MMP-2 in the first 
trimester. No significant differences were found in the second trimester or at term.
When all three trimesters were included in the analysis the band intensity o f pro-
MMP-9 was significantly lower than pro-MMP-2. No correlation was found between #
pro-MMP-9 and pro-MMP-2 band intensity at any stage in gestation.
4.3.1.2 Immunohistochemistry
, 0
;!■
Immunohistochemical analysis across gestation found that MMP-9 was present to a 
greater or lesser extent in EVT, endothelium, muscle suiTounding blood vessels and in 
the villous stroma. There was virtually no staining on vCTB or STB. There were no 
significant changes in MMP-9 expression between 1®^ and 2"^ trimesters in any cell i |
types. There was significantly more endothelial, stromal and muscle staining in the 
third trimester when compared with the second trimester and in the third trimester 
when compared with the first tiimester. MMP-9 staining on endothelium increased 
from 7-19 weeks, 14-40 weeks and 7-40 weeks and on the muscle surrounding blood 
vessels from 7-40 weeks. MMP-9 stromal staining also increased from 14-19 weeks,
14-40 weeks and 7-40 weeks.
No significant differences between the trimesters in vCTB or EVT staining 
were found. However the analysis for EVT almost reached significance between the 
first and second trimester (expression tended to be higher during the first trimester).
Staining for MMP-9 increased on EVT from 14-19 weeks bu t was negatively 
correlated on EVT between 7-40 weeks o f gestation.
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4.3.1.3 Comparison o f MMP-9 zymography and immunohistochemistry 
results
When the zymography data was split into three trimesters and analysed, no significant 
differences in pro-MMP-9 activity were found between any o f the trimesters. 
However, when zymography data was correlated with gestation a significant decrease 
in MMP-9 activity during the first trimester was detected. Analysis o f the 
immunohistochemical data showed a significant increase in endothelium, muscle and 
stromal MMP-9 staining in the second and third trimesters compared with the first 
trimester. The decrease in MMP-9 expression in EVT almost reached significance and 
when immunohistochemical data was correlated with gestation EVT expression of 
MMP-9 decreased overall from 7-40 weeks o f gestation. I f  more EVT had been 
present in the tissue it is possible a greater negative correlation would have been 
found. As such the increase in endothelial, muscle and stromal expression o f MMP-9 
and the decrease in EVT expression may in effect cancel each other and account for 
the inability o f zymography to detect any changes in MMP-9 activity between the 
trimesters. The fact that zymography did detect a decrease in MMP-9 activity during 
the first trimester suggests that any decrease in EVT expression may be fairly 
substantial.
4.3.2 MMP-2; Summary of results
4.3.2.1 Zymography
Wlien pro-MMP-2 expression was analysed by zymography there was significantly 
less pro-MMP-2 activity in the 2"^  ^ trimester compared with the 1®^ trimester. There 
was also significantly less pro-MMP-2 activity in the 3^  ^ trimester compared with the 
1®^ trimester. There were no significant differences in pro-MMP-2 activity between the 
2 "  ^and 3"^  trimesters.
A significant negative con'elation o f pro-MMP-2 activity with gestation was 
found from 7-13 weeks, 7-19 weeks and from 7-40 weeks o f gestation; No significant 
correlation was found when the 2 "^  and 3^  ^ trimesters were analysed separately or 
together without the first trimester samples.
214
4.3.2.2 Immunohistochemistry
Immunohistochemical analysis across gestation found that MMP-2 was present to a 
greater or lesser extent in vCTB and STB, EVT, endothelium, muscle surrounding ^
blood vessels and in the stroma.
MMP-2 staining on vCTB was lower in the third trimester compared with the first 
trimester and was also in lower in the second trimester compared with the first 
trimester. vCTB staining decreased from 7-19 weeks and from 7-40 weeks of 
gestation. There was significantly more endothelial staining in the third trimester 
compared with the second trimester, in the second trimester compared with the first 
trimester and in the third trimester compared with the second trimester. Endothelial 
MMP-2 staining increased from 7-13 weeks, 7-19 weeks, 14-40 weeks and from 7-40 
weeks o f gestation. No significant differences were found between individual 
trimesters in EVT, muscle or stromal staining although muscle staining did increase 
significantly overall. However EVT staining was negatively correlated with gestation 
between 7-40 weeks o f gestation.
4.3.3 Comparison of MMP-2 zymography and immunohistochemistry 
results
When the MMP-2 zymography data was split into three trimesters and analysed, pro- 
MMP-2 activity decreased significantly overall between the three trimesters, 
specifically declining from 1 ®‘ to the 2 "^  trimester and from 1 ®' to the 3'^ trimester.
W hen the MMP-2 zymography data was correlated with gestation a significant 
decrease in MMP-2 was found between 7-13 weeks, 7-19 weeks and 7-40 weeks o f 
gestation.
Immunohistochemical results showed a significant decrease in MMP-2 
expression in vCTB overall between the three trimesters, specifically declining from 
1®^ to 2"^ trimesters and from 1®^ to 3^  ^ trimesters. Both vCTB and EVT expression of 
MMP-2 decreased overall from 7-40 weeks o f gestation. An increase in MMP-2 
expression in the endothelium and in muscle through pregnancy was also detected 
with the staining on the endothelium increasing significantly from 1 ®*^ to 2 "^  trimesters,
1®^ to 3^ ^^  trimesters and from 2“*^ to 3*^  ^trimesters. It is likely that the decrease in vCTB
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expression o f MMP-2 is sufficiently large enough to be detected despite the increase 
in endothelial and muscle expression of MMP-2, which may be smaller. It is 
interesting to note in parallel with the MMP-2 results that MMP-9 expression in 
vCTB was very low throughout pregnancy and zymography did not detect any 
changes overall in MMP-9 expression.
4.3.3 Comparison of the current study with previously published studies
Before meaningful comparison o f the results o f the current study with others can 
occur it is necessary to understand that the study found that the pro forms of both 
MMP-9 and MMP-2 were predominant over the active forms and thus all discussion 
predominantly refers to the pro foims o f the enzymes. The MMP-9 assay, although 
only performed on a few samples would seem to support this argument. In other 
studies it is generally clear which form o f the enzyme is referred to if  zymography is 
the method used. However some published studies which use immunohistochemistiy 
are unclear as to what forms o f  the enzymes the antibodies used detect and thus care 
must be taken although many o f the antibodies on the market do detect both pro and 
active MMP-2 and MMP-9.
Clearly, in an environment where degradation o f the ECM must be tightly 
regulated it could be expected that an abundance o f the pro-form o f an enzyme would 
be available to be converted to the active form when required. Hence the mechanisms 
for regulating the conversion o f the pro to active forms o f MMPs may be as critical as 
the MMPs themselves. This will be discussed in chapter 5.
An early study o f MMPs and CTB invasion by Fisher et al. (1989) 
demonstrated, by zymography, the presence of several metalloproteinases in cellular 
extracts o f CTB which had been cultured on matrices. Several unique proteinases 
were present in the 1®‘ trimester extract (20-200kDa) compared with the second and 
third trimester extracts, in which a 92kDa proteinase was pre-dominant. This 
decreased from second to third trimester. Culture medium from the same cells 
predominantly showed 92kDa activity. Since then, many other studies have aimed to 
determine when and where MMPs are produced in the placenta. These will be 
discussed in the following section. MMP-9 and MMP-2 have become the focus for 
many o f these studies, which have generally taken one o f two forms -  non- 
quantitative immunohistochemistry of placental sections or semi-quantitative analysis
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of MMP activity in the culture medium from cultured trophoblasts or villous tissue 
from various stages in pregnancy. There is no general consensus on MMP expression 
throughout pregnancy and a prim aiy aim o f the current study was to attempt to 
undertake a semi-quantitative immunohistochemical analysis o f MMP-9 and MMP-2 
expression in conjunction with zymographical analysis of MMP-9 and MMP-2 
expression in placental honiogenates. Clearly zymographical analysis o f MMP 
secretion into culture medium from cultured trophoblasts and villous tissue from 
comparable gestations would also be desirable for comparison and indeed may 
perhaps show discrepancies between cell culture and in vivo studies, however this was 
deemed out-with the scope o f the current study. The study is most readily compared to 
others initially by direct comparison o f the immunohistochemical data and 
subsequently by comparing the zymography results with the published studies on 
CTB culture.
4.3.3.1 MMP-2 immunohistochemistry
A summaiy o f previously published studies which have used immunohistochemistry 
and other techniques to examine cellular distribution o f MMP-2 and MMP-9 in the 
placenta at various stages of pregnancy is shown in table 25. This table also shows the 
number o f samples from each gestation used in the studies. As can be seen, many 
studies have used only a few samples from limited gestations hence emphasizing the 
need for a more comprehensive analysis.
Two early immunohistochemical and in situ hybridisation studies showed 
expression o f MMP-2 in nonnal placentae from 8-11 weeks o f gestation. The first o f 
these reported that MMP-2 mRNA and protein were present in EVT. MMP-2 protein 
but not mRNA was present on vCTB and STB. Little MMP-2 mRNA or protein were 
present on the endothelium (Autio-Harmainen et al. 1992). In the same study it was 
also reported that type IV collagen was secreted by CTB and it was suggested that this 
may reflect a mechanism by which trophoblast cells modulate basement membrane 
deposition. An immunohistochemical study by Fernandez et al. (1992) also found 
MMP-2 protein expressed on vCTB and EVT and suggested that the vCTB may be 
involved in the initial degradation o f the superficial endometrium during the first 
trimester. MMP-2 expression was also found in the decidua and villous stroma in this 
study. Polette et al. (1994) found using in situ hybridisation and
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immunohistochemistry that during the first trimester EVT produced MMP-2 protein 
and mRNA but they also reported MMP-2 expression in the villous stromal 
compartment and underlying endothelium at tenn. The authors suggested this may 
implicate MMP-2 in other processes such as extracellular matrix remodelling or 
vascular network establishment, A further immunohistochemical study (Huppertz et 
al. 1998) found that MMP-2 expression was fairly weak during the first and second 
trimesters in EVT but fairly strong in EVT in the third trimester in frozen placental 
sections. Sawicki et al. (2000) localised pro-MMP-2 protein to the stromal vascular 
endothelium and vCTB at term. They also reported that vCTB expression o f pro- 
MMP-2 was not as pronounced as pro-MMP-9 expression at term.
None o f the previous studies have attempted any sort o f quantitative analysis 
and no study has analysed both MMP-2 and MMP-9 expression systematically 
throughout pregnancy in EVT, vCTB, endothelium and stroma. The current 
immunohistochemical study agrees with previous findings by Polette et al. that EVT 
expression o f MMP-2 tends to decrease with gestation, being strongest during the first 
trimester and declining towards term. Since not all o f the placental sections studied 
contained EVT it is possible that if  there had been more data, the analysis between the 
individual trimesters would have reached significance. The earlier studies by Autio- 
Harmainen et al. and Fernandez et al, also agree with the data presented herein on the 
EVT expression o f MMP-2 early in gestation. These studies did not examine placenta 
from later than 1 1  weeks o f gestation so no comparison with the cuinent study can be 
made.
The findings o f the current study are also in agreement with those which show 
vCTB MMP-2 expression early in pregnancy (Autio-Harmainen et al. 1992 and 
Fernandez et al. 1992) and further this by showing that this decreases towards term. 
The study by Sawicki et al. (2000) found low levels o f vCTB MMP-2 expression at 
term but did not study earlier placentae.
The data reported herein for endothelial MMP-2 expression supports the 
results reported by Autio-Haimainen et al. (1992) who found no endothelial 
expression o f MMP-2 protein or mRNA in early gestation placentae and Polette et al. 
(1994) who found endothelial expression o f MMP-2 protein in term placentae.
Thus taking all the studies into consideration it may be suggested that MMP-2 
is primarily expressed in the vCTB and EVT early in pregnancy around the time of 
invasion. Later in gestation it seems that expression o f both vCTB and EVT is down-
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regulated and endothelial and stormal expression increases. This would support a 
hypothesis that MMP-2 may be important in invasion in early pregnancy bu t may also 
have a role in vascular and matrix remodelling in the villi later in pregnancy.
4.3.3.2 MMP-9 immunohistochemistry
The most marked difference in the current study between MMP-9 and MMP-2 
expression was in the lack o f vCTB expression o f MMP-9 compared with MMP-2 
expression. Throughout gestation there was virtually no vCTB MMP-9 expression. 
These findings agree with the study by Vettraino et al. (1996) who reported no MMP- 
9 expression on vCTB although they found strong MMP-9 expression on neutrophils 
throughout the placenta. However, while Sawicki et al. (2000) reported that pro- 
MMP-9 protein was expressed strongly in the vascular endothelium at term as was 
found in the current study, they found that it was also expressed consistently in STB 
and weakly in CTB. Other previous studies on MMP-9 localisation using 
immunohistochemistry or in situ hybridization (Polette et al. 1994; Hurskainen et al. 
1996) have investigated EVT expression. Both o f these studies are in agreement that 
MMP-9 is expressed by EVT in early pregnancy but is downregulated towards term, 
which agrees with the results presented herein. Polette also reported MMP-9 
expression in vCTB and in the decidua during the first trimester and endothelial and 
stromal expression at term. Hurskainen et al. found both MMP-9 protein and mRNA 
on villous endothelium and stroma. Interestingly, while MMP-9 mRNA was present 
on vCTB the protein was not reliably present. Huppertz et al. (1998) also found 
MMP-9 immunoreactivity in EVT in the first trimester. In cryostat but not paraffin 
sections this was reduced in the second trimester. In term placenta the situation was 
unclear since strong EVT staining was found in cryostat but not in paraffin sections. 
This study illustrates one cause o f discrepancies between studies - the type o f section 
used (paraffin/cryostat). Other methodological problems may be caused by 
differences in tissue preparation and antigen retrieval techniques. In croystat sections 
missing reactivity may be caused by diffusion, although the antigenicity is better 
preserved than in paraffin sections. Furthermore, different antibodies may have 
different reaction patterns. Confounding data may also result from choice o f placental 
material - in the current study all cases were normal whereas some studies have 
allowed abnormal placentae (eg blighted ouvum) to be included. One other source of
219
difference may be the time taken between placental collection and specimen 
preparation which may result in partial degradation o f proteins within the tissue. It is 
interesting to note the increase in MMP-9 expression in EVT between 14-19 weeks of 
gestation which may correspond with the proposed second wave o f invasion.
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4.3,3.3 Studies of MMP secretion -  MMP-2 and MMP-9
Although the cun-ent study did not examine secretion o f MMPs by cultured CTB, it is 
informative to compare the results obtained from the zymography o f placental 
homogenates with published studies on CTB secretion o f MMPs.
Librach et al. (1991) reported that purified first trimester trophoblasts 
secreted MMP-9 and this was required for invasiveness in vitro. The same study 
supported previous data which showed that purified third trimester villous 
trophoblasts secreted MMP-2 but not MMP-9 (Fisher et al. 1989). However, a more 
recent study (Graham and McCrae, 1996) reported that cultured third trimester 
trophoblasts secrete primarily MMP-9 and Sawicki et al. (2000) reported that third 
trimester cultured CTB secreted MMP-9 and some MMP-2. Shimonovitz et al. (1994) 
also reported that cultured first trimester trophoblasts secreted both MMP-2 and 
MMP-9 in large amounts. By the third trimester only MMP-9 was secreted in large 
amounts although considerably less was secreted than during the first trimester.
Lim et al. (1997) studied MMP expression in culture medium from cultured 
CTB from normal and pre-eclamptic third trimester placentae. They found that pre­
eclamptic pregnancies were associated with both reduced invasion and decreased 
MMP-9 secretion. Hence this study supports the reports that MMP-9 is still expressed 
in the third trimester.
These four latter studies tend to agree with the current study in finding that 
MMP-9 is not exclusive to the first trimester but rather continues to be expressed until 
term. The study by Shimonovitz et al. (1994) also agrees with the findings presented 
here in the respect that MMP-2 secretion declined between the first to the third 
trimester. It is possible that different trophoblast isolation protocols may account for 
some o f the differences in in vitro data.
Using ELISA and zymography Niu et al. (2000) found that trimester 
cultured villous tissue secreted around lOx more pro-MMP-2 than pro-MMP-9, and 
that pro-MMP-2 levels decreased dmmatically in the 2"^ and 3^  ^ trimesters. MMP-9 
levels however did not decrease significantly. Active MMP-2 was also secreted from 
villous tissue in the first trimester in smaller quantities than pro-MMP-2. These results 
are comparable to those presented herein. In some o f the zymography gels in the 
cuiTent study it was possible to see faint bands o f active MMP-2 although these were 
not large enough to be quantified by zymography. On the other hand, Niu et al.
224
reported that trimester CTB cultured in the absence o f stromal cells had pro-MMP- 
9 levels lOx those o f pro-MMP-2. Many studies which have cultured CTB alone have 
emphasized the importance o f the role o f MMP-9 in invasion as opposed to MMP-2. 
This study, in conjunction with the previous one suggests that care should be taken in 
interpreting these results as the absence of stromal cells may influence production of 
MMPs dramatically. Moreover, Campbell et al. (2003) cultured CTB alone and with 
decidual endothelial cells (DEC) and found that coculture o f tenu CTB with DEC 
resulted in reduced pro-MMP-9 expression and reduced CTB invasion compared to 
CTB cultured alone. This further supports the concept that MMP secretion profiles o f 
CTB cultured alone may not accurately reflect the in vivo situation and that other cells 
may secrete critical regulators o f MMP expression and activity. Niu et al. also 
examined MMP-9 and MMP-2 levels in placental extracts and found no significant 
decrease in either MMP-2 or MMP-9 with gestation. We have found however that the 
presence o f EDTA in the homogenisation buffer causes inhibition o f MMP activity 
and in the study by Niu et al. EDTA was present. The homogenisations in this thesis 
were performed in the absence o f EDTA.
Xu et al. (2000) were the first to study the dynamics o f MMP secretion within 
the first trimester and reported a gradual increase in MMP-9 secretion from week 7 -  
11 cultured CTB and a corresponding decline in MMP-2 secretion. mRNA expression 
corresponded with the protein expression studies which used ELISA and 
zymographical methods. This finding is not in agreement with the zymography results 
herein, which showed that in placental homogenates MMP-9 activity decreased 
through the first trimester. The differences may again arise from the fact that the 
tissues used in this study were whole placenta and therefore contain many cell types. 
However the current study did not find vCTB expression o f MMP-9 in the first 
trimester and it is unlikely that all o f the isolated cells in the study by Xu et al. were 
EVT. Therefore it may be possible that the matrix on which CTB were cultured may 
affect MMP production (Bichof et al. 1991).
Sawicki et al. (2000) proposed that it was the differentiated STB as opposed to 
undifferentiated CTB which released MMP-9 and MMP-2, in particular the latter and 
also reported that >90% o f the secretion was in a basolateral direction. Basal release 
from STB, they suggested, would eject the gelatinases onto the trophoblast basal 
lamina in the third trimester when there are few underlying CTB and thus enable 
increased villous umbilical angiogenesis, growth o f villous STB and o f vascular
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endothelium. In this study the homogenates o f cultured term CTB had high levels o f 
MMP-9 but this was not reflected in the culture medium in the first 24 hours. No 
MMP-2 was secreted or was present in cell homogenates after 24 hours. On the 
contrary STB homogenates (7 day culture period) and culture medium had high 
MMP-9 levels and MMP-2 was present in the culture supernatant. The current study, 
in contrast, found veiy little vCTB or STB expression o f M MP-9 although MMP-2 
expression was present in small amounts at tenn.
Caniggia et al. have also studied the expression o f  MMP-9 and MMP-2 in 
early pregnancy (Caniggia et al. 1999; Caniggia et al. 2000b). Expiant studies by this 
group have led to the hypothesis that H IF -la  expression is high between 5-8 weeks of 
gestation, resulting in high TGF-P3 levels and consequent inhibition o f MMP-9 
expression. MMP-2 expression was reported to be high during early gestation during 
the low oxygen stage. The group reported that H IF -la  expression fell around 9 weeks 
o f gestation as did TGF-Ps and suggested that this led to increased MMP-9 expression 
and invasion. MMP-2 expression decreased at the same stage. The authors concluded 
that MMP-2 is involved in CTB proliferation and MMP-9 in EVT invasion.
Difficulties in comparing the current study or other studies to those perfonned 
by Caniggia and colleagues arise from the different classification systems for 
gestation used and furthermore there may be inherent problems with the explant 
culture model used by the group (chapter 8 ). The current study did find MMP-2 
expression in vCTB particularly in the first trimester but the expression did not seem 
to be particularly associated with proliferation nor was there a sudden reduction at the 
end of the first trimester although expression did decrease with increasing gestation. 
MMP-2 expression was also present on EVT which suggests it may also be involved 
in invasion. MMP-9 expression was present on EVT which supports the previous 
study in the role o f this molecule in invasion. The work o f  Caniggia et al. will be 
discussed further in chapter 5 in relation to hypoxia and H IF -la .
A very recent study (Isaka et al. 2003) studied expression of MMP-2 and 
MMP-9 protein and mRNA and also examined gelatinase activity on placental 
sections using film in situ zymography. In first trimester placental sections, MMP-2 
expression and activity was present in EVT and MMP-9 in vCTB. At term, although 
MMP-2 expression was seen in EVT, gelatinase activity was not. In purified CTB 
gelatinase activity was present in the first trimester but not at term. The invasive
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ability o f early CTB was inhibited by TIMP-2 or by MMP-2 antibody but not by 
TIM P-1 or by MMP-9 antibody to as great a degree, suggesting that MMP-2 may be 
important in invasion. The role o f TIMPs is considered in chapter 5.
In summary the current study supports several others previous studies in 
finding that MMP-9 continues to be expressed tlnough the 2"^ trimester and at tenn 
and hence may have other roles in addition to being involved in trophoblast invasion.
The decrease in MMP-2 throughout pregnancy presented in this thesis is also * Ij
supported by several other studies. The present study suggests MMP-2 may also be 
important during the first trimester in trophoblast invasion and that levels o f MMP-2 
may vary more with gestation than MMP-9 levels, in particular declining in the vCTB 
and EVT whilst increasing in the endothelium.
While the results presented herein on the location o f MMP-2 in the placenta 
tend to agree with published studies, discrepancies exist between studies as to where 
MMP-9 is expressed. The conclusion that vCTB expression o f MMP-9 is low 
throughout pregnancy is different from some other studies, although it is in agreement 
with the work o f Vettraino et al. (1996) and Hurskainen et al. (1996). However the 
results herein show decreasing EVT expression with progression o f pregnancy and 
increasing endothelial expression, which agiees with the findings o f several published 
studies. It thus seems likely that both MMP-2 and MMP-9 may be important in §
various processes during placentation in several different cell types.
;
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Chapter 5: Detection and quantification of 
TIMP-1, TIMP-2 and HIF-la in placenta 
throughout pregnancy using 
immunohistochemistry
I
I:
In the previous chapter the expression and activity o f MMP-2 and MMP-9 were 
studied in placenta throughout gestation. While MMPs are thought to be important in 
controlling aspects o f placental development, they themselves are subject to complex 
regulatory processes which may also have a role in placental development. Therefore 
the expression o f several regulators o f MMPs in sections o f the same placentae as had 
been used in MMP-2 and MMP-9 immunohistochemistry (chapter 4) was investigated 
next.
Thus the aims o f this section were three-fold:
•  Firstly to examine the cellular distribution o f TIMP-1, TIMP-2 and H IF -la  in
placentae fiom  7-19 weeks o f gestation and from term placentae
•  Secondly to perform a semi-quantitative analysis of the expression o f TIMP-1, 
TIMP-2 and H IF -la  in placentae from 7-19 weeks o f gestation and from term 
placentae
• Thirdly to compare the spatial and temporal distribution of these molecules to
the distribution o f MMP-2 and MMP-9 as reported in chapter 4
5.1 TIMP-1 immunohistochemistry
Immunohistochemistry was performed using a TIMP-1 antibody (Biogenesis) as 
described in section 2,2. The antibody was used at a dilution of 1/250 and controls 
where rabbit IgG or antibody diluent was substituted for the primary antibody were 
negative (section 2 .2 ).
Across gestation TIMP-1 was present to a greater or lesser extent on vCTB 
and STB, EVT, stroma and on muscle surrounding the endothelium bu t not on the 
endothelium itself.
Figure 45 shows photographs of representative TIMP-1 staining from selected 
gestations. Figure 45a shows a placenta at seven weeks o f gestation with very little 
staining except in the intervillous space, which is likely to be endogenous peroxidase. 
Figure 45b shows moderately stained EVT at 13 weeks o f gestation. Figure 45c shows 
a placenta at nineteen weeks of gestation with strong stromal and muscle staining.
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Figure 45d shows a placenta at terni again with strong stromal and muscle staining. 
The raw data obtained from scoring the stained sections is shown in table 26.
The data was grouped into trimesters and statistical analysis was carried out to 
determine if  there were any statistical differences in TIMP-1 expression between 
trimesters. A summary o f the descriptive statistics o f the data is given in table 27 and 
table 28 shows the results o f the statistical analysis for TIMP-1. No assumptions were 
made as to the normality of the distribution o f the data and non-parametric testing was 
used throughout.
Kruskal-Wallis analysis showed a highly significant change in muscle staining 
between the three trimesters (p<0.01). Mann-Whitney analysis subsequently showed 
significantly lower TIMP-1 expression in the first trimester compared with the third 
trimester (p<0.05) and significantly lower expression in the first trimester compared 
with the second trimester (p<0.05).
Kruskal-Wallis analysis also showed a significant change in stromal staining 
between the three trimesters (p<0.02). Mann-Whitney analysis subsequently showed 
significantly lower TIMP-1 expression in the second trimester compared with the 
third trimester (p<0 .0 2 ) and significantly lower expression in the first trimester 
compared with the third trimester (p<0 .0 1 ).
No significant changes in TIMP-1 expression were found in any o f the tests on 
vCTB, EVT or on the endothelium.
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Figure 45 Immunohistochemistry of TIMP-1 throughout gestation
a) 7 weeks of gestation
100pm
b) 13 weeks of gestation
50pm
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c) 19 weeks of gestation
m i
50pm
d) Term
100pm
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Table 26 Semi-quantitative analysis of TIMP-1 immunostaining
G estation (weeks) vCTB EVT Endothelium M uscle S trom a
7 0 0.5 0 0 0.5
7 2 2 0 0 2
8 0 2 0 0 0.5
9 1 1 0 0 2
1 1 0 N/P* 0 0 1
1 1 0.5 1.5 0 0 1.5
1 2 0.5 1.5 0 0 1.5
13 0 1.5 0 0 1.5
14 0.5 0.5 0 1.5 1.5
14 1 N/P 0 1.5 1.5
14 0 N/P 0 0 1.5
15 0 N/P 0 0 1
15 0 N/P 0 2 1.5
15 0 0.5 0 0 2
16 0 1 0 0 1
16 0 N/P 0 1 2.5
16 0 1 0 2 3
17 0 N/P 0 0 1
17 0 N/P 0 2 2
17 0 N/P 0 1.5 2
17 0 1 0 2 0.5
18 1.5 1.5 2 0 1.5
18 0 N/P 0 0 0.5
19 0 N/P 0 1.5 2
40 1 N/P 0 3 3
40 0.5 N/P 0 2.5 3.5
40 0 N/P 0 0 2
40 0 N/P 0 2.5 2.5
*NP = Not present
233
Table 27 TIMP-1 immunohistochemistry descriptive statistics
M ean M edian M ax M in R ange 
between 
m in and  
m ax
SE SD
vCTB
ist 0.5 0.25 2 . 0 0 . 0 2 . 0 0.25 0.71
2 nd 0.19 0 . 0 1.5 0 . 0 1.5 0 . 1 1 0.44
3 rd 0.38 0.25 1 . 0 0 . 0 1 . 0 0.24 0.48
trim ester
EV T
ist 1.43 1.5 2 . 0 0.5 1.5 0 . 2 0.53
2 nd 0.92 1 . 0 1.5 0.5 1 . 0 0.15 0.38
3 rd N/A* N/A N/A N/A N/A N/A N/A
trim ester
Endothelium
ist 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
2 nd 0.13 0 . 0 2 . 0 0 . 0 2 . 0 0.13 0.5
3 rd 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
trim ester
M uscle
1 ®‘ 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
2 "“ 0.94 1.25 2 . 0 0 . 0 2 . 0 0 . 2 2 0.89
3 rd 2 . 0 2.5 3.0 0 . 0 3.0 0 . 6 8 1.35
trim ester
S trom a
1 " 1.31 1.50 2 . 0 0.50 1.50 0 . 2 1 0.59
2 »d 1.56 1.50 3.0 0.50 2.5 0.17 0 . 6 8
3 rd 2.75 2.75 3.5 2 . 0 1.5 0.32 0.65
trim ester
*N/A = Not Applicable
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Table 28 Analysis of variation in TIMP-1 immunostaining between the three 
trimesters
Test vCTB EVT Endothelium Muscle Stroma
p-value
Kruskal-
Wallace
jst/2nd/3rd
trimester
N/S* N/S N/S p<0.01 p<0.02
Mann-Whitney
1*72"“
trimester N/S N/S N/S p<0.05 N/S
2nd/3rd
trimester N/S N/A*' N/S N/S p<0.02
ist/3rd
trimester N/S N/A N/S p<0.05 p<0.01
*N/S = Non Significant
** N/A = test not applicable (too few samples)
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Correlation analysis was then performed to determine if  there were any 
correlations in TIMP-1 expression within each trimester. The data was represented on 
histograms for each cell type (figure 46). Note that for some cell types many values 
were zero (no staining) and therefore do not appear as bars on the graph. The data was 
then analyzed using a Spearman’s congelation. Analyses were carried out to detennine 
conelation o f TIMP-1 expression within the trimester (7-13 weeks), 2"*^  trimester 
(14-19 weeks), CV2”  ^ trimester (7-19 weeks), 2" /^3'^  ^ trimester (14-40 weeks) and 
isty2 nd/3 rd (7-40 wceks). The results of the analysis are shown in table 29.
No significant coiTclations in TIMP-1 expression were found in any of the 
tests on vCTB (figure 46a) or on the endothelium (not shown as virtually all values 
were = 0). TIMP-1 staining on EVT (figure 46b) was positively correlated with 
gestation (staining increased as gestation increased) between 14-19 weeks (p<0 .0 1 ). 
TIMP-1 staining on muscle (figure 46c) was positively correlated with gestation 
(staining increased as gestation increased) between 7-19 weeks (p<0.05) and between 
7-40 weeks (p<0.01) o f gestation. TIMP-1 staining on the stroma (figure 46d) was 
positively con-elated with gestation (staining increased as gestation increased) 
between 7-40 weeks o f gestation (p<0.05).
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Figure 46 Histograms of TIMP-1 immunostaining throughout gestation
a)
vCTB
2.5
O)
0.5
7 7 8 9 11 11 12 13 14 14 14 15 15 15 16 16 16 17 17 17 17 18 18 19 40 40 40 40
Weeks of Gestation
b)
EVT
2.5
2
o) 1.5 
'E
CO 1
0.5
0
7 7 8 9 11 11 12 13 14 14 14 15 15 15 16 16 16 17 17 17 17 18 18 19 40 40 40 40
Weeks of Gestation
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c)
Muscle
3.5
2.5
O)
0.5
Weeks of Gestation
d)
Stroma
3.5
0.5
Weeks of Gestation
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Table 29 Correlation o f TIMP-1 immunostaining with gestation
'f !:5;;|
Test vCTB EVT Endothelium Muscle Stroma
Spearman’s
Rank
p-value and 
R-value
trimester N/S* N/S N/S N/S N/S
2.id
trimester N/S
p<0.01
R=0.93 N/S N/S N/S
1®V2”‘’ trimester N/S N/S N/S p<0.05R=0.44 N/S
2nd/3id |^j.||ug5ter N/S N/S N/S N/S N/S
trimester N/S N/S N/S
p<0.01
R=0.54
p<0.05
R=0.41
* N/S = Non-Significant
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5.2 TIMP-2 immunohistochemistry
Immunohistochemistry was subsequently performed using a TIMP-2 antibody 
(Biogenesis) as described in section 2.2. The antibody was used at a dilution o f 1/300. 
The staining was scored on a 0-4 scale (section 2.6). Control slides where sheep IgG 
or antibody diluent was substituted for primary antibody showed no staining (section 
2 .2).
Across gestation TIMP-2 staining was present to a greater or lesser extent on 
vCTB and STB, EVT, stroma, endothelium, and on the muscle surrounding the 
endothelium.
Figure 47 shows photographs o f representative TIMP-2 staining from 
selected gestations. Figure 47a shows a placenta at seven weeks o f gestation with 
strong vCTB staining but little other staining. Figure 47b shows a placenta at nine 
weeks o f gestation with stronger endothelial staining. Figure 47c shows moderately 
stained EVT at 16 weeks o f gestation. Figure 47d shows a placenta at term with 
strong endothelial staining, some muscle staining but little vCTB staining.
The raw data obtained from scoring the stained sections is shown in table 30. 
The data was grouped into trimesters and statistical analysis was carried out to 
determine if  there were any statistical differences in TIMP-2 expression between 
trimesters. A summary o f the descriptive statistics o f the data is given in table 31 and 
table 32 shows the results o f the statistical analysis for TIMP-2. No assumptions were 
made as to the normality o f the distribution o f the data and non-parametric testing was 
used throughout.
Kruskal-Wallis analysis showed a significant change in vCTB and EVT 
staining between the three trimesters (p<0.05) and a highly significant change in 
endothelial staining between the three trimesters (p<0 .0 1 ) but no differences in 
muscle or stromal staining.
Mann-Whitney analysis showed significantly lower TIMP-2 expression in 
the first trimester compared with the third trimester on the vCTB (p<0.01), muscle 
(p<0.05) and stroma (p<0.05).
Mann-Whitney analysis also showed significantly lower TIMP-2 expression 
in the endothelium in the first trimester compared with the third trimester (p<0 .0 2 ) 
and in the first trimester compared with the second trimester (p<0 .0 2 ).
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There were no significant differences in EVT scoring although the 1®V2"^  
trimester comparison almost reached significance.
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Figure 47 Immunohistochemistry of TIMP 2 throughout gestation
a) 7 weeks of gestation
100pm
b) 9 weeks of gestation
100pm
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c) 16 weeks of gestation
50pm
d) Term
100pm
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Table 30 Semi-quantitative analysis of TIMP-2 immunostaining
Gestation
(weeks) vCTB EVT Endothelium Muscle Stroma
7 2 2 0 0 0
7 1.5 N/P* 0 0 0
8 2 2 0 0 0
9 2 2 0 0 0.5
9 2.5 N/P 2.5 1 2
9 1.5 2 2 1 1
1 0 1.5 1.5 0 0 0.5
1 0 2.5 2.5 0 0 0.5
1 1 1.5 2 1.5 0.5 0.5
1 1 1 N/P 1 0 0.5
1 2 0 N/P 1 0 0.5
13 0.5 0.5 1.5 0.5 0.5
13 1.5 1.5 1.5 0.5 0.5
14 2 N/P 1.5 0 0.5
15 0.5 0.5 2 0 0
16 1.5 1.5 2 1.5 1
16 0 N/P 1.5 0 0.5
17 1 0.5 2.5 1.5 1.5
17 0 N/P 2 0.5 0.5
40 0 N/P 2.5 1 1.5
40 0.5 N/P 2 1 1
40 0.5 N/P 2.5 1 1
NP -N o t present
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Table 31 TIMP-2 immunohistochemistry descriptive statistics
Mean Median Max Min Range 
between 
min and 
max
SE SD
vCTB
l t^ 1.54 1.5 2.5 0,0 2.5 0.20 0.72
0.83 0,75 2.0 0.0 2.0 0.33 0.82
3 rd 0.33 0.50 0.50 0.0 0.50 0.17 0.29
trimester
EVT
ist 1.78 2.0 2.5 0.5 2.0 0.19 0.57
2 nd 0.83 0.5 1.5 0.5 1.0 0.33 0.58
3 rd N/A* N/A N/A N/A N/A N/A N/A
trimester
Endothelium
1'* 0.85 1.0 2.5 0.0 2.5 0.25 0.90
2 nd 1.92 2.0 2.5 1.5 1.0 0.15 0.38
3 rd 2.33 2.5 2.5 2.0 0.5 0.17 0.29
trimester
Muscle
1 " 0.27 0.0 1.0 0.0 1.0 0.11 0.39
2 nd 0.58 0.25 1.5 0.0 1.5 0.30 0.74
3 rd 1.0 1.0 1.0 1.0 0.0 0.0 0.0
trimester
Stroma
0.54 0.50 2.0 0.0 2.0 0.14 0.52
2 «d 0.67 0.50 1.5 0.0 1.5 0.21 0.52
3 rd 1.17 1.0 1.5 1.0 0.5 0.17 0.29
trimester
*N/A = Not Applicable
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Table 32 Analysis of variation in TIMP-2 immunostaining between the three
trimesters
Test vCTB EVT Endothelium M uscle Stroma
Kruskal-
Wallace p-value
jst/2"<l/3ni
trimester p<0.05 p<0.05 p<0 . 0 1 N/S* N/S
Mann-W hitney
1®V2"^  trimester N/S N/S p< 0 . 0 2 N/S N/S
2 ad|3 rd trimester N/S N/A*' N/S N/S N/S
fSt/3 rd
trimester p<0 . 0 1 N/A p< 0 . 0 2 p<0.05 p<0.05
*N/S = Non Significant 
* 1 N/A = test not applicable (too few samples)
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The data was then analysed to determine if  there were any correlations in 
TIMP-2 expression within each trimester. The data was represented on histograms for 
each cell type (figure 48). Note that for some cell types many values were zero (no 
staining) and therefore do not appear as bars on the chart. The data was then analyzed 
using a Spearman’s correlation. Analyses were carried out to determine correlation of 
TIMP-2 expression within the 1®^ trimester (7-13 weeks), 2"^ trimester (14-19 weeks), 
1^V2"  ^trimester (7-19 weeks), 2" /^3^  ^ trimester (14-40 weeks) and PV2" /^3'^  ^trimesters 
(7-40 weeks). The results o f the analysis are shown in table 33.
TIMP-2 staining on vCTB (figure 48a) was negatively correlated with 
gestation (staining decreased as gestation increased) between 7-13 weeks (p<0.05), 
between 7-19 weeks (p<0.01) and between 7-40 weeks (p<0.01) o f gestation. TIMP-2 
staining on EVT (figure 48b) was negatively coiTelated with gestation (staining 
decreased as gestation increased) between 7-19 weeks (p<0.01) and between 7-40 
weeks (p<0.01) o f gestation. TIMP-2 staining on endothelium (figure 48c) was 
positively correlated with gestation (staining increased as gestation increased) 
between 7-19 weeks (p<0.01), between 14-40 weeks (p<0.05) and between 7-40 
weeks (p<0.01) o f gestation. TIMP-2 staining on the stroma (figure 48d) was 
positively correlated with gestation (staining increased as gestation increased) 
between 14-40 weeks (p<0.05) and between 7-40 weeks (p<0.02) o f gestation. No 
significant correlations in TIMP-2 expression were found in any o f the tests on muscle 
(figure 48e) staining.
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Figure 48 Histograms of TIMP-2 immunostaining throughout gestation
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Table 33 Correlation of TIMP-2 immunostaining with gestation
Test vCTB EVT Endothelium Muscle Stroma
Spearman’s Rank p“value and R-value
jSt
trimester
p<0.05
R=-0.61 N/S* N/S N/S N/S
2 »d
trimester N/S N/S N/S N/S N/S
trimester p<0 . 0 1R=-0.64
p<0 . 0 1
R=-0.76
p< 0 . 0 1
R-0.63 N/S N/S
211(1 / 3  Id N/S N/S p<0.05R-0.72 N/S
p<0.05
R=0.69
ist/jnd/grd p< 0 . 0 1 p<0 . 0 1 p< 0 . 0 1 N/S p< 0 . 0 2trimester R=-0.71 R=-0.76 R-0.71 R=0.51
*N/S = Non-Significant
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5.3 Discussion
5.3.1 Detection and quantification of TIMP-1 and TIMP-2 in placental
sections using immunohistochemistry
TIMPs are well-documented regulators o f MMP activity throughout mammalian 
systems (section 1.4). TIMPs inhibit the activity o f MMPs by binding to activated 
MMPs in a 1:1 ratio to form a high affinity, essentially iixeversible complex. Wliile 
TIMPs bind most MMPs at the highly conserved active zinc-binding site, they can 
also bind other domains o f both MMP-9 and MMP-2 (Birkedal-Hansen, 1995). 
TIMP-1 can bind to and inhibit both active and pro-MMP-9 (Goldberg et al. 1992) 
although it can also inhibit the active forms o f most other MMPs. TIMP-2 binds 
preferentially to active and pro-MMP-2. It is the balance between activated MMP and 
free TIMP that determines overall MMP activity. TIMP-1 is responsive to a variety o f 
factors such as cytokines, growth factors and phorbol esters, whereas TIMP-2 is 
largely constitutively expressed in mammalian tissue (reviewed in W oessner and 
Nagase, 2000).
It is unknown whether the MMP-9 and MMP-2 antibodies which were used in 
the immunohistochemistry experiments in chapter 4 detect only free MMPs or if  they 
also detect MMPs bound to TIMPs. It may be that bound MMP-TIMP complexes 
show partial cross-reactivity with the antibodies. Zymography does not detect bound 
MMP-TIMP complexes as these are unable to degrade the gelatin and thus the 
experiments in section 4.1 should provide an accurate summary o f MMP activity 
across gestation. It is also possible to perform reverse zymography to quantify levels 
o f TIMPs in a sample or to perform film in-situ zymography, a technique which 
detects gelatinase activity in a placental section. Additionally TIMP expression could 
possibly be assessed semi-quantitatively by western blotting. Due to time constraints 
none o f these experiments was undertaken but would be interest for further study. 
This current study undertook to examine the distribution o f TIMP-1 and TIMP-2 
within the placenta to determine whether either o f the TIMPs were co-distributed with 
MMP-9 or MMP-2 in the hope that this would provide further insight into the 
mechanisms which govern placental development. For such potentially important 
regulators o f MMP activity and thus o f placental development there are surprisingly 
few studies which have previously examined TIMP distribution by
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immunohistochemistry in the placenta and these will be discussed in relation to the 
results presented in this thesis.
5.3.2 TIMP-1 : Summary of immunohistochemical analysis
Across gestation TIMP-1 was present to a greater or lesser extent on vCTB and STB, 
EVT, stroma and on muscle surrounding the endothelium but not on the endothelium 
itself. Statistical analysis showed no significant changes in TIMP-1 expression 
between the three trimesters on vCTB, EVT or on the endothelium. However, TIMP-1 
staining on EVT was positively correlated with gestation between 14-19 weeks. 
Analysis showed significantly lower TIMP-1 expression in muscle in the first 
trimester compared with the third trimester and significantly lower expression in the 
first trimester compared with the second trimester. TIMP-1 staining on muscle was 
positively correlated with gestation between 7-19 weeks and between 7-40 weeks of 
gestation. It was also found that stromal TIMP-1 expression was significantly lower in 
the second trimester compared with the third trimester and significantly lower 
expression in the first trimester compared with the third trimester. TIMP-1 staining on 
the stroma was positively correlated with gestation between 7-40 weeks o f gestation.
5.3.3 Comparison with MMP-9 immunohistochemical analysis
Since TIMP-1 is known to specifically inhibit both pro and active MMP-9 the 
distributions o f TIMP-1 with MMP-9 were compared. While MMP-9 was localised to 
EVT, endothelium, muscle and stroma, TIMP-1 was localised to vCTB, EVT, muscle 
and stroma. The main change in MMP-9 staining with increasing gestation was an 
increase in endothelial staining. A significant positive correlation o f MMP-9 staining 
with gestation on EVT between 14-19 weeks but a negative correlation overall 
between 7-40 weeks o f gestation was also found. Interestingly TIMP-1 expression on 
EVT was also positively correlated with gestation between 14-19 weeks although no 
condation  in EVT expression was found at any other stage in gestation. This may 
correspond with the proposed second wave o f trophoblast invasion. TIMP-1 
expression decreased in the muscle and stroma with increasing gestation while MMP- 
9 expression did not change. Thus the only cell type where MMP-9 and TIMP-1 
seemed to have a degree o f co-distribution spatially and temporally was on the EVT.
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Since tight control of trophoblast is veiy important this may reflect a protective 
mechanism. TIMP-1 may also have roles in regulating other MMPs in vCTB, while it 
may be that endothelial expression o f MMP-9 during the third trimester is not subject 
to control by TIMP-1 and is perhaps regulated by other mechanisms.
5.3.4 TIMP-2: Summary of immunohistochemical analysis
Across gestation TIMP-2 staining was present to a greater or lesser extent on vCTB 
and STB, EVT, stroma, endothelium, and on the muscle surrounding the endothelium. 
There was significantly lower TIMP-2 expression in the first trimester compared with 
the third trimester on the endothelium, muscle and stroma. TIMP-2 staining on the 
stroma was positively correlated with gestation between 14-40 weeks and between 7- 
40 weeks o f gestation. There was also lower TIMP-2 expression in the endothelium in 
the first trimester compared with the second trimester. TIMP-2 staining on 
endothelium was positively correlated with gestation between 7-19 weeks, between 
14-40 weeks and between 7-40 weeks o f gestation. vCTB staining was significantly 
higher in the first trimester compared with the second and third trimesters. TIMP-2 
staining on vCTB was negatively correlated with gestation between 7-13 weeks, 
between 7-19 weeks and between 7-40 weeks o f gestation. An overall analysis of 
TIMP-2 expression in EVT across gestation was significant although there were no 
differences between the individual trimesters. TIMP-2 staining on EVT was 
negatively correlated with gestation between 7-19 weeks and between 7-40 weeks of 
gestation.
5.3.5 Comparison with MMP-2 immunohistochemical analysis
Since TIMP-2 is known to specifically inhibit both pro and active MMP-2 the 
distributions of TIMP-2 and MMP-2 as detennined by immunohistochemistry were 
compared. MMP-2 was localised to vCTB, EVT, muscle and stroma and endothelium. 
TIMP-2 staining was present on the same cells. The main changes in MMP-2 
expression with gestation were an increase in endothelial staining with gestation and a 
decrease in vCTB staining. EVT staining was negatively correlated with gestation. 
TIMP-2 staining in vCTB also decreased with gestation while staining on 
endothelium, muscle and stroma increased. EVT expression o f TIMP-2 was
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negatively coiTelated with gestation. From the results o f this analysis it appears that 
TIMP-2 and MMP-2 are co-distributed within the placenta and their temporal 
expression patterns are very similar. With regard to the pattern o f MMP-2 and TIMP- 
2 expression, it was found that staining was highest in vCTB and EVT in the early 
stages o f gestation. This expression decreased and endothelial, muscle and stromal 
expression o f TIMP-2 rose, while only MMP-2 expression rose only in endothelial 
cells. This may indicate the involvement o f TIMP-2 in regulating MMP-2 
participation in vascular remodelling later in pregnancy. It is interesting that while 
many studies have suggested that MMP-9 may be regulated by oxygen tension, the 
same has not been reported for MMP-2. Thus TIMP-2 may be o f vital significance in 
regulating MMP-2 activity and as such be an important factor in various aspects of 
placental development.
5.3.6 Comparison to previous studies
Several immunohistochemical studies o f TIMP expression in placenta have focused 
on whether trophoblast invasion is regulated in an autocrine or a paracrine manner. 
Nomura et al. (1989) and Werb et al. (1992) observed that murine decidua expressed 
high levels o f TIMP-1 and TIMP-2 in vivo. Polette et al. (1994) made similar 
observations in human decidua using in situ and immunohistochemical techniques to 
investigate protein and mRNA distribution. They found that MMP-2 and TIMP-2 
were expressed at comparable levels throughout pregnancy in the placental bed. 
TIMP-1 expression was highest in the placental bed at term whilst MMP-9 expression 
in the placental bed was highest in the first trimester. The same study further reported 
that the mRNAs o f MMP-2 and TIMP-1 were co-distributed in the villous stroma and 
endothelial cells throughout pregnancy whilst MMP-9 and TIMP-2 were co­
distributed in the vCTB. This study only involved two placental bed biopsies from 
first and third trimester however, although it included seven placentae from each 
trimester, hence the placental bed results need to be interpreted with care. The current 
study found conflicting results in that no co-distribution o f MMP-9 with TIMP-2 in 
the vCTB was present, while MMP-2 and TIMP-2 were co-distributed in these cells. 
Moreover, no TIMP-1 was present on the endothelium. These differences may arise 
from various factors discussed in section 4.3.3.2 with regard to the MMP 
immunohistochemical studies. Interestingly Ruck et al. (1996) also found TIMP-2
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expression in vCTB particularly in the first trimester and suggested it may be co­
distributed with MMP-2.
Several other studies have examined TIMP distribution in the placenta and 
placental bed. Damsky et al. (1993) and Nawrocki et al. (1997) both reported TIMP 
expression in decidual cells. Further in situ and immunohistochemical data showed 
TIMP 1-3 expression in cell columns, endothelium, fibroblast stroma and decidua in 
early pregnancy (Hurskainen et al. 1996). O f particular note in relation to the current 
study was strong TIMP-2 bu t not TIMP-1 mRNA expression on the STB and CTB of 
the villi. An immunohistochemical study by Huppertz et al. (1998) supported the 
concept that trophoblast expression o f TIMP-1 and TIMP-2 may be important in 
autocrine regulation o f trophoblast invasion and reported TIMP-1 expression in EVT 
throughout pregnancy. In the first and second trimester TIMP-2 was strongly 
expressed on EVT that had invaded deeply, while in the third trimester TIMP-2 was 
present in the basement membrane dividing CTB from the villous stroma. Ruck et al.
(1996) also reported EVT expression of TIMP-2. Interestingly, an 
immunohistochemical study performed by Vegh et al. (1999) showed decreased levels 
of TIMP-1 expression in the STB in choriocarcinoma compared with normal 
pregnancies at term, suggesting that a decrease in TIMP expression may lead to 
conditions whereby trophoblast invasion proceeds in an uncontrolled manner.
5.3.7 In vitro studies o f TIMP expression
Various in vitro studies o f cultured CTB have reported conflicting results as to the 
role o f TIMPs in the placenta. The presence o f TIMP-1 (Lala and Graham, 1990;
Graham and Lala, 1991; Librach et al. 1991 and Behrendtsen et al. 1992) and TIMP-2 
(Librach et al. 1991; Isaka et al. 2003) have been found to completely inhibit invasion 
in vitro in several studies.
Niu et al. (2000) found constant levels o f both TIMPs throughout gestation in 
tissue extracts and cell culture medium and a concurrent immunohistochemical study 
showed particularly strong immunoreactivity for TIMP-2 in vCTB at term. In contrast 
the current study found that vCTB expression o f TIMP-2 had decreased to a low level 
by term. Xu et al. (2000) found no TIMP-2 expression in culture medium from ■'trimester CTB using ELISA but reported that TIMP-1 expression increased from 
weeks 6-11. The immunohistochemical data herein, however, shows no change in
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TIMP-1 and a decrease in TIMP-2 expression in vCTB staining during the first 
trimester. Differences are likely to arise from the fact that cultured cells may behave 
differently from those in vivo. B ischof et al. (1998a; 1998b) reported that culture 
medium conditioned by decidualised stromal cells stimulated trophoblastic secretion 
o f TIMP-1 further supporting the paracrine role o f the decidua in regulating 
trophoblast invasion.
5.3.8 Summary of TIMP analysis
In summary this current study found evidence to support the theory that some 
autocrine regulation o f MMPs by TIMPs in EVT may occur in addition to paracrine 
regulation by the decidua. A larger amount o f EVT present in the samples used in the 
study would have allowed a more comprehensive analysis to be undertaken. 
Furthermore, this study also presents evidence that TIMPs may have a role in 
regulation o f MMP activity in a variety o f other cell types within the placenta, in 
particular in the endothelium and vCTB. The co-distribution o f  TIMP-2 with MMP-2 
was particularly interesting with regard to the results discussed in the previous chapter 
where MMP-2 expression varied considerably throughout pregnancy in vCTB and 
EVT. The potential role o f MMPs in vascular and villous remodelling later in 
pregnancy may thus be connected with the expression and activity o f TIMPs.
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5.4 Determination of expression and location of H IF -la  in placenta
throughout pregnancy using immunohistochemistry
Immunohistochemistiy was performed using a H IF -la  antibody (Serotec) as 
described in section 2.2. The antibody was used at a dilution of 1/250 and control 
slides where goat IgG or antibody diluent was substituted for primary antibody 
showed no staining (section 2.2). The staining was scored on a 0-4 scale (section 2.6).
Across gestation H IF -la  staining was present to a greater or lesser extent on 
vCTB and STB, EVT and on the endothelium o f blood vessels and very lightly and 
variably on the stroma. There was no staining on the muscle surrounding the blood 
vessels. Figure 49 shows H IF -la  expression at various stages o f gestation. Figure 49a 
shows a placenta at seven weeks o f gestation with strong vCTB staining. Figure 49b 
shows moderately stained EVT at 15 weeks o f gestation. Figure 49c shows a placenta 
at sixteen weeks o f gestation with stronger endothelial staining. Figure 49d shows a 
placenta at term with even stronger endothelial staining but less vCTB staining.
The raw data obtained from scoring the stained sections is shown in table 34. 
The data was grouped into trimesters and statistical analysis was carried out to 
determine if  there were any statistical differences in H IF -la  expression between 
trimesters. A summary o f the descriptive statistics o f the data is given in table 35 and 
table 36 shows the results o f the statistical analysis for H IF -la . No assumptions were 
made as to the normality o f the distribution o f the data and non-parametric testing was 
used throughout.
Kruskal-Wallis analysis showed a significant change in vCTB staining between 
the three trimesters (p<0.01). Mann-Whitney analysis showed significantly higher 
H IF - la  expression in vCTB in the first trimester compared with the third trimester 
(p<0 .0 2 ) and in the first trimester compared with the second trimester (p<0 .0 2 ). 
Kruskal-Wallis analysis showed a highly significant change in EVT staining between 
the three trimesters (p<0.01). M ann-Whitney analysis showed significantly higher 
H IF -la  expression in EVT in the first trimester compared with the second trimester 
(p<0.02). No differences in staining were found in muscle, endothelium or stroma.
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Figure 49 Immunohistochemistry of H IF-la throughout gestation
a) 7 weeks of gestation
100pm
b) 15 weeks of gestation
100pm
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c) 16 weeks of gestation
100pm
d) Term
50pm
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Table 34 Semi-quantitative analysis of H IF -la  immunostaining
*NP = Not present
G estation
(weeks) vCTB EV T Endothelium M uscle s tro m a
7 2.5 2.5 0 0 0
8 2 2 1 0 0
9 2 2 1.5 0 0.5
1 0 2 N/P* 1 0 0
1 0 2 2 1 0 0
1 1 2 N/P 1.5 0 0
1 1 1.5 2 1 0 0.5
14 1.5 1.5 0 0 0
15 2 N/P 1.5 0 0.5
15 1.5 1.5 0.5 0 0
16 1.5 N/P 1.5 0 0
17 1 1.5 2.5 0 0.5
17 1 0.5 1.5 0 0.5
18 1.5 N/P 1.5 0 0
40 1.5 N/P 2 0 1
40 0.5 N/P 1 0 0
40 1.5 N/P 2.5 0 0.5
40 1 N/P 2 0 0.5
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Table 35 H IF -la  immunohistochemistry descriptive statistics
M ean M edian M ax M in R ange 
betw een 
m in and  
m ax
SE SD
vCTB
jst 2 . 0 2 . 0 2.5 1.5 1 . 0 0 . 1 1 0.29
^nd 1.43 1.5 2 . 0 1 . 0 1 . 0 0.13 0.35
3 rd 1.13 1.25 1.50 0.5 1 . 0 0.24 0.48
trim ester
EV T
l*t 2 . 1 2 . 0 2.5 2 . 0 2 . 0 0 . 1 0 . 2 2
2 nd 1.25 1.5 1.5 1.5 0.5 0.25 0.5
3 rd N/A* N/A N/A N/A N/A N/A N/A
trim ester
Endothelium
jSt 1 . 0 1 . 0 1.5 0 . 0 1.5 0.19 0.50
2nd 1.29 1.5 2.5 0 . 0 2.5 0.31 0.81
3rd 1 . 8 8 2 . 0 2,5 1 . 0 1.5 0.31 0.16
trim ester
M uscle
1 '* 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
2nd 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
3'" 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
trim este r
S trom a
0.14 0 . 0 0.5 0 . 0 0.5 0.09 0.24
2nd 0 . 2 1 0 . 0 0.5 0 . 0 0.5 0 , 1 0.27
3rd 0.5 0.5 1 . 0 0 . 0 1 . 0 0 . 2 0 0.41
trim este r
'’'N/A = Not Applicable
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Table 36 Analysis of variation in H IF -la  immunostaining between the three
trimesters
Test vCTB 1 EVT Endothelium Muscle Stroma
Kruskal-
W allace p-value
rV2*“’/3‘’^
trimester p< 0 . 0 1 p< 0 . 0 1 N/S* N/S
N/S
M ann-W hitney
jst/2nd trimester p< 0 . 0 2 p< 0 . 0 2 N/S N/S N/S
2  nd/ 3  Id trimester N/S N/A*' N/S N/S N/S
jst/jrd
trimester p< 0 . 0 2 N/A N/S
N/S N/S
*N/S =  Non Significant 
* * N/A = test not applicable (too few samples)
Î
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The data was then analysed to detemiine if  there were any coiTelations in HIF- 
1 a  expression within each trimester. The data was represented on histograms for each 
cell type (figure 50). Note that for some cell types many values were zero (no 
staining) and therefore do not appear as bars on the chart. The data was then analyzed 
using a Spearman’s correlation. Analyses were carried out to determine correlation of 
H IF - la  expression within the trimester (7-13 weeks), 2"'  ^ trimester (14-19 weeks), 
FV2"^ trimester (7-19 weeks), 2"^ /3*^  ^ trimester (14-40 weeks) and FV2” /^3*^  ^trimesters 
(7-40 weeks). The results o f the analysis are shown in table 37.
H IF - la  staining on vCTB (figure 50a) was negatively correlated with 
gestation (staining decreased as gestation increased) between 7-13 weeks (p<0.05), 
between 7-19 weeks (p<0.01) and between 7-40 weeks (p<0.01) o f  gestation. H IF -la  
staining on EVT (figure 50b) was negatively correlated with gestation (staining 
decreased as gestation increased) between 7-19 weeks (p<0.01) and between 7-40 
weeks (p<0.01) o f gestation. H IF -la  staining on endothelium (figure 50c) was 
positively correlated (staining increased as gestation increased) with gestation 
between 7-19 weeks (p<0.05), between 14-40 weeks (p<0.05) and between 7-40 
weeks (p<0.01) o f gestation. No significant correlations in H IF - la  expression were 
found in any o f the tests on muscle or stromal (figure 50d) staining. No histogram of 
muscle staining is shown as all o f  the values were zero.
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Figure 50 Histograms of H IF-la immunostaining throughout gestation
a)
b)
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Table 37 Correlation of H IF -la  immunostaining with gestation
Test vCTB EVT I Endothelium Muscle Stroma
Spearman’s
Rank
p-value 
and R-value
p=0.05
R --0.75 N/S* N/S N/S N/S
2 nd N/S N/S N/S N/S N/S
1*72'“* trimester p< 0 . 0 1
R=-0.83
p<0 . 0 1
R=-0.93
p<0.05
R=0.55 N/S N/S
2"d/3*‘‘* trimester N/S N/S p-0.05
R=0.60 N/S N/S
jst/2 Hd/3 rd
trimester
p< 0 . 0 1
R=-0.82
p< 0 . 0 1
R=-0.93
p< 0 . 0 1
R~0.62 N/S N/S
*N/S = Non-Significant
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5.5 H IF -la  immunohistochemistry: discussion
5.5.1 Summary of immunohistochemical analysis
Unlike TIMPs, which are specific regulators o f MMPs, HIF is a transcription factor 
that is thought to control the expression o f many factors in response to hypoxia 
(section 1.5). As discussed in section 1.5.4, HIF-1 is a heteromeric complex that is 
composed o f  two subunits, H IF-1(3 which is constitutively expressed and H IF -la  
which is inducible. Previous published studies have examined 
immunohistochemically the distribution o f HIF in placental sections throughout 
gestation and in placental explants cultured in varying oxygen tensions. The aim o f 
the cun*ent study was to carry out semi-quantitative immunohistochemical analysis on 
H IF - la  distribution in the placenta from 7-19 weeks o f gestation and at term and to 
compare this to the previous data.
Across gestation H IF - la  staining was present to a greater or lesser extent on vCTB 
and STB, EVT, on the endothelium o f blood vessels and very lightly and variably on 
the stroma. There was no staining on the muscle surrounding the blood vessels.
,Analysis showed significantly higher H IF -la  expression in vCTB in the first trimester
compared with the third trimester and in the first trimester compared with the second 
.trimester. H IF -la  staining on vCTB was negatively correlated with gestation between 
7-13 weeks, 7-19 weeks and between 7-40 weeks o f gestation. There was also a 
significantly higher level o f H IF - la  expression on EVT in the first trimester 
compared with the second trimester. H IF - la  staining on EVT was negatively 
correlated with gestation between 7-19 weeks and between 7-40 weeks o f gestation.
No differences in staining were found in muscle, endothelium or stroma. However 
H IF - la  staining on endothelium was positively correlated with gestation between 7-
-19 weeks, between 14-40 weeks and between 7-40 weeks o f gestation.
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5.5.2 Comparison to previous studies
In a survey of various human tissues, Weiner et al. (1996) demonsti'ated the presence 
o f H IF -la  and HIF Ip  in mRNA in the human placenta by northern blotting. The 
presence o f HIF-1 DNA binding activity in CTB isolated from term placenta has also 
been reported (Seligman et al. 1997). A further study reported H IF -la , H IF -ip  and 
the related subunit H IF-2a mRNA expression in isolated CTB from first trimester 
placentae (Jantapour et al. 1999).
However, only two groups have studied the expression o f  HIF-1 within the 
placenta in further detail. Rajakumar and Conrad, (2000) examined HIF expression in 
placentae from first trimester to term using a variety o f techniques and reported that 
overall H IF - la  mRNA was expressed at constant levels throughout pregnancy while 
protein levels varied. H IF -la  expression declined with gestation and was expressed in 
vCTB and STB, and in the villous endothelium. These findings were comparable to 
the current study. Interestingly the same group also reported that H IF - la  and H IF-2a 
protein bu t not H IF-ip  were over-expressed in placentae from women with pre- 
eclampsia (Rajakumar et al. 2001) and showed that explants from placentae from pre­
eclamptic pregnancies failed to adequately down regulate HIF protein upon 
oxygenation.
However, studies by Cannigia and co-workers have reported different 
conclusions from the results presented herein and from those studies outlined above. 
Initial studies by this group showed high H IF - la  mRNA expression in vCTB between 
5-8 weeks o f gestation in both placental sections and in explants. This expression 
decreased dramatically between 1 0 - 1 2  weeks around the time that placental 
oxygenation is reported to occur and staining was virtually non-existent by the second 
trimester (Caniggia et al. 1996b). In contrast the current study found that H IF -la  was 
still expressed in the second trimester albeit at reduced levels. Antisense inhibition of 
H IF -la  resulted in an increase in EVT invasion in explants cultured in 3% oxygen 
(Caniggia et al. 1996b). Difficulties in interpreting studies by this group arise from the 
dating system used for estimating the gestational age o f placentae collected which is 
not consistent with that used by many other groups. Moreover, there may be a number 
o f difficulties with regard to the explant model favoured by Caniggia and co-workers. 
This is discussed in chapter 8 . A further study connected the role o f HIF with the
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regulation o f TGFps and subsequently with MMP-9 and MMP-2 and other markers of 
trophoblast invasion and postulated that if  the increase in oxygen does not occur, or is 
not detected, then H IF - la  and TGFps remain high and MMP-9 expression will not 
increase. The involvement o f TGFp in defective invasion is not consistent with 
studies by Lyall et al. (2001a) who showed no change in this protein in pre-eclampsia. 
The current study however did find expression o f H IF -la  on EVT and this expression 
decreased with gestation. This supports the hypothesis that H IF -la  may have a role in 
preventing invasion in the very early stages of pregnancy.
It is interesting to note the strong expression o f H IF -la  on vCTB early in 
pregnancy at the same time that high expression o f MMP-2 and TIMP-2 was found. In 
contrast MMP-9 was not observed on the vCTB in early pregnancy, suggesting its 
expression may be tightly controlled and that H IF -la  may have a role in this 
regulation. The reason for the increase in the expression o f H IF - la  on the 
endothelium through gestation is unknown but it may be involved in the regulation of 
vascular development.
Thus while H IF -la  may have a role in regulating the response o f the placenta 
to oxygen, the pathways by which it does so are likely to be complex. Control of 
trophoblast invasion in the first trimester may only be part o f a wider role in 
regulation o f vascular remodeling and villous development.
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Chapter 6: MMP-9 and MMP-2 expression 
in placenta from high, moderate and low
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It has been reported that women living at high altitude are more likely to develop pre­
eclampsia and that even women residing at high altitude who have normal pregnancy 
outcomes may have many physiological changes similar to those seen in pre­
eclampsia (section 1.6). MMP-9 expression has been reported to be decreased in 
placentae obtained from women with pregnancies complicated by pre-eclampsia 
(section 1 .7 ) and it has also been reported that its expression is regulated by oxygen 
(section 1.5). Hence the hypothesis that MMP-9 expression may be altered in 
placentae from women residing at high altitude, even in pregnancies with normal 
outcomes, was tested. MMP-2 expression at high altitude was also studied. Placentae 
were collected and processed as described in section 2.4.2. MMP-9 and MMP-2 
expression in full thickness placental sections was analysed by immunohistochemistry 
using the antibodies described in section 2.2. Immunohistochemistry, rather than 
zymography, was used to enable M MP expression in specific cell types to be 
examined.
6.1 MMP-9 expression in placental sections from varying altitudes
Immunohistochemistry was carried out to detect MMP-9 expression and location in 
the terai placental sections from low (Glasgow), moderate (Denver) and high 
(Leadville) altitudes. The procedure was as described previously (section 2.6). 
Staining was scored with the identity o f the tissues concealed to avoid bias, on a 0-4 
scale where 0 = no staining and 4 = very strong staining. Since some o f the sections 
were very large 1 0  fields o f view were scored on each section and an average taken. 
Control slides where sheep IgG or antibody diluent was substituted for primary 
antibody showed no staining (section 2 .2 ).
The raw data for scoring the sections is shown in table 38 and the descriptive 
statistics are shown in table 39. Staining was present in endothelium, muscle and 
stroma at all altitudes (the amount o f EVT and decidua present were not large enough 
for analysis). The vCTB was only very lightly stained similar to the staining observed 
in section 4.2. Figure 51 shows a representative section from each altitude. Figure 51a 
and 51b show placentae from high and moderate altitudes respectively with stromal, 
endothelial and muscle staining. Figure 51c shows a placenta from low altitude with
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stromal staining and with stronger endothelial staining. Figure 52 shows the data in 
scattergram form for a) vCTB, b) endothelium, c) muscle and d) stroma. The mean 
value for each cell type is illustrated by a bar.
273
Table 38 Semi-quantitative analysis of MMP-9 immunostaining at various
altitudes
P atien t
N um ber vCTB E ndothelium M uscle S trom a
H igh
A ltitude
1 0 1 . 8 1.7 2.5
2 0.7 0 0 . 2 0 . 8
3 1 0 0 . 8 2.5
4 0 1.3 2.5 3
5 1.4 1.7 1.5 2 . 2
6 0 0 0 . 2 1 . 8
7 0 . 2 0 . 6 1 2
8 1 . 2 1 1.9 2
9 0 2.3 1.45 1.7
1 0 0 0 . 8 1.9 2 . 1
M oderate
A ltitude
1 0 1 . 1 1 2.3
2 0.4 1.4 1 2 . 1
3 0.4 1.9 1.7 2.3
4 0.05 1 . 1 1 . 2 2.5
5 0 . 2 1 . 8 0.9 1 . 8
6 1.3 1.7 0.5 2.5
Low
A ltitude
1 0 1.9 1 . 1 1.4
2 0 1.65 0.54 1 . 2
3 0.4 1.35 0.85 1 . 2
4 0.15 2 1.4 1 . 6
5 0 . 8 1 , 6 8 0 . 6 1
6 0.45 0.3 0.65 1.85
7 0.25 2.55 2.35 2 . 1
8 0.05 1.9 1 . 1 1 . 8
9 0 1.4 1 . 2 2
1 0 0 1.7 1 . 2 1.85
Note that the scores shown denote the average score from 10 fields o f view
274
Table 39 Descriptive statistics for MMP-9 immunostaining at various
altitudes
Altitude Cell Type Max Min Range 
between 
min and 
max
Mean Median SE SD
High vCTB 1.4 0 1.4 0.45 0 . 1 0.17 0.57
Moderate vCTB 1.3 0 1.3 0.39 0.3 0.26 0.48
Low vCTB 0 . 8 0 0 . 8 0 . 2 1 0 . 1 0.24 0.27
High Endothelium 2.3 0 2.3 0.95 0.9 0.19 0.82
Moderate Endothelium 1.9 1 . 1 0 . 8 1.5 1 . 6 0.19 0.35
Low Endothelium 2.55 0.3 2.25 1.64 1.7 0.14 0.58
High Muscle 2.5 0 . 2 2.3 1.3 1.47 0.16 0.76
Moderate Muscle 1.7 0.5 1 . 2 1 . 1 1 . 0 0 . 1 1 0.39
Low Muscle 2.35 0.54 1.81 1 . 1 1 . 1 0.08 0.53
High Stroma 3.0 0 . 8 2 . 2 2 . 1 2 . 1 0.18 0.59
Moderate Stroma 2.5 1 . 8 0.7 2.25 2.3 0.17 0.27
Low Stroma 2 . 1 1 . 0 1 . 1 1 . 6 1.7 0 . 1 2 0.38
«
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Figure 51 MMP-9 expression in placentae from various altitudes
a) MMP-9 expression at high altitude (Leadville = 3100m)
100pm
b) MMP-9 expression at moderate altitude (Denver = 1600m)
100pm
c) MMP-9 expression at low altitude (Glasgow = sea level)
100pm
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Figure 52 Scattergrams of MMP-9 expression at various altitudes
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The data was tested for normality using Shapiro-Wilk analysis and was found 
to have a normal distribution. Hence parametric testing was used for the statistical ; |
analysis. The statistical analysis is summarized in table 40.
A one-way ANOVA showed no differences in vCTB staining between the two 
altitudes. A  one-way ANOVA for endothelial MMP-9 staining almost reached 
significance (p=0.066). Post-hoc analysis using Fisher’s PLSD showed significantly 
lower staining at high altitude than at low altitude (p<0.05). No other differences were 
found in endothelial staining. ANOVA showed a significant change in stromal MMP- 
9 staining with increasing altitude (p<0.05). Post-hoc analysis using Fisher’s PLSD 
showed significantly higher staining at high altitude than at low altitude (p<0.05). 
Post-hoc analysis using Fisher’s PLSD also showed significantly higher staining at 
moderate altitude than at low altitude (p<0.05). There was no signifieant difference 
between high and moderate altitudes. No differences were observed in muscle 
staining between the two altitudes.
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Table 40 Analysis of variation in MMP-9 immunostaining between various
altitudes
Test Altitudescompared vCTB Endothelium M uscle Stroma
ANOVA All three N/S* N/S N/S p<0.05
Fisher’s
PLSD
Low/
moderate N/S N/S N/S p<0.05
Fisher’s
PLSD
Low/
high N/S p<0.05 N/S p<0.05
Fisher’s
PLSD
Moderate/
high N/S N/S N/S N/S
*N/S = Non-significant (p>0.05)
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6.2 MMP-2 expression in placental sections from varying altitudes
Fewer studies implicate MMP-2 than MMP-9 in pre-eclampsia and MMP-2 has not 
been shown to be sensitive to oxygen tension. It was therefore decided to repeat the 
experiment canied out in section 6.1 with an MMP-2 antibody (section 2.2). Due to 
availability o f samples only high (Leadville) and low (Glasgow) altitudes were 
compared. There were 6  placental sections in each group. Immunohistochemistry was 
carried out to detect MMP-2 levels and locations in full thickness placental sections. 
The procedure was as described previously. Staining was scored with the identity of 
the tissues concealed to avoid bias, on a 0-4 scale where 0 = no staining and 4 = veiy 
strong staining. Control slides where sheep IgG or antibody diluent was substituted 
for primary antibody showed no staining (section 2 .2 ).
The raw data is shown in table 41 and the descriptive statistics are given in 
table 42. Staining was present in vCTB, endothelium muscle and stroma at all 
altitudes. Figure 53 shows a representative section from each altitude (Figures 53a 
high altitude, 53b low altitude). In each picture staining is present on the vCTB, 
stroma, endothelium and on the muscle surrounding the endothelium. Figure 54 
shows the data in scattergram form for a) vCTB, b) endothelium, c) muscle and d) 
stroma. The median value for each cell type is illustrated by a bar.
The data was tested using Shapiro-Wilk analysis and was found to have a non­
normal distribution. Hence non-parametric tests were used in the statistical analysis. 
The data was analysed using Mann-Wliitney analysis (table 43). No significant 
differences were found in MMP-2 staining between low and high altitude in any of 
the cell types.
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Table 41 Semi-quantitative analysis of MMP-2 immunostaining at various
altitudes
P a tien t
N um ber vCTB E ndothelium M uscle S trom a
Low
A ltitude
1 0.5 2.5 1 1
2 0.5 1.5 0.5 0.5
3 0.5 2.5 0.5 0.5
4 0.5 1 0.5 0.5
5 0.5 1.5 0.5 0.5
6 1 1.5 0.5 0.5
H igh
A ltitude
1 1 1 0.5 0.5
2 1 1 0.5 0.5
3 0.5 0 0.5 0.5
4 0.5 0 0.5 0.5
5 0.5 1.5 1 1
6 0.5 2 0.5 0.5
i
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Table 42 Descriptive statistics for MMP-2 immunostaining at various
altitudes
Altitude Cell Type Max Min Range Mean Median SE SD
High vCTB 1 0.5 0.5 0.67 0.5 0 . 1 1 0.26
Low vCTB 1 0.5 0.5 0.58 0.5 0.08 0 . 2
High Endothelium 2 0 2 0.92 1 0.33 0,80
Low Endothelium 2.5 1 1.5 1.75 1.5 0.25 0.61
High Muscle 1 0.5 0.5 0.58 0.5 0.08 0 . 2 0
Low Muscle 1 0.5 0.5 0 . 6 0.5 0 . 1 0 0 . 2 2
High Stroma 1 0.5 0.5 0.58 0.5 0.08 0 . 2
Low Stroma 1 0.5 0.5 0 . 6 0.5 0 . 1 0 . 2 2
I
i
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Figure 53 MMP-2 expression in placentae from various altitudes
a) MMP-2 expression at high altitude (Leadville = 3100m)
100pm
b) MMP-2 expression at low altitude (Glasgow = sea level)
lOOpm
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a)
Figure 54 Scattergrams of MMP-2 expression at various altitudes
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Table 43 Analysis o f variation in MMP-2 immunostaining between various
altitudes
vCTB Endothelium M uscle Stroma
M ann-W hitney 
comparison of 
low/high 
Altitude
N/S* N/S* N/S* N/S*
'‘'N/S -  Non-significant (p>0.05)
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6.3 Discussion
There are no known published studies on MMP expression in placentae from high 
altitude pregnancies. It has previously been reported that MMP-9 is reduced in term 
placental extracts from women with pre-eclampsia (Kolben et al. 1996). A  further 
study reported that term trophoblast cell cultures from normal pregnancies secreted 
high levels o f active MMP-9 while term trophoblast cultures from pregnancies 
complicated by pre-eclampsia secreted higher levels o f inactive pro-MMP-9 (Graham 
and McCrae, 1996; Lim et al. 1997). Hence it was hypothesised that MMP expression 
may also be reduced in high altitude placentae. The results o f this study showed that ‘§
MMP-9, but not MMP-2, expression is increased in the villous stroma and reduced in 
the endothelium in placentae from high altitude pregnancies compared to those at low 
altitude. None o f the studies on pre-eelampsia have reported any differences in MMP 
expression in the endothelium or stroma.
Gallery et al reported significantly reduced levels o f M M P-1 but not MMP-9 
secreted by cultured decidual microvascular endothelial cells from pre-eclamptic 
patients (Gallery et al. 1999). The authors suggested that this may be associated with 
the relative failure o f  trophoblasts to invade maternal decidual blood vessels in pre­
eclamptic pregnancy. If  MMP expression in the endothelium is associated with 
vascular remodeling during the later stages o f gestation, redueed MMP expression at 
high altitude may represent a failure o f physiological adaptation to reduced oxygen 
levels found in such environments. Since maternal blood has lower oxygen saturation 
it follows that the endothelial lining o f blood vessels would also be exposed to lower 
O2 levels. Reduced MMP-9 expression in CTB has been linked to low oxygen in 
several studies (Caniggia et al. 1999; Caniggia et al. 2000a). It is thought that the low 
oxygen environment present in the intervillous space during the early weeks of 
gestation may in fact prevent MMP expression and therefore trophoblast invasion.
Hence it is not inconceivable that a similar mechanism may operate in the 
endothelium although there are no published studies on H IF - la  expression in the 
placenta. In the current study the levels o f endothelial MMP-9 expression at moderate 
altitude were not significantly different from high altitude or low altitude and 
therefore moderate altitude may be a partial intermediate between the two extremes.
The increase in stromal staining with increasing altitude was even more 
marked than the difference in endothelial staining in the current study. Staining
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increased between low and moderate and between low and high bu t not between 
moderate and high altitudes. Staining tended to be fairly general throughout the 
stroma. The role o f MMP-9 in the stromal villi during pregnaney is unclear but it is 
possible that in the third trimester it may have a role in structural remodelling. As 
described in section 1 .6 , pregnancy at high altitude is associated with increased 
markers o f placental hypoxia such as formation o f syncytial knots, persistence of 
vCTB at term and hypercapillarisation (AH, 1997). To adjust to the hypoxia it has 
been suggested that diffusion distances across the intravascular barrier might 
decrease, particularly across the trophoblast layer which may be sparser (Jackson et 
al. 1988). A decrease in perivascular cells around many o f the villous capillaries has 
also been noted (Zhang et al. 2002) perhaps adding to the thinning o f the maternal 
fetal interface. Alterations in villous capillary diameter have also been found at high 
altitude (reviewed in Mayhew, 2003). Above 3600m villous surface area is reduced 
and to compensate, there is an enlargement o f the intervillous space. Under hypoxic 
conditions, increased branching o f fetal capillaries is thought to occur (Kaufmann et 
al. 1985; Kaufmann, Luckhardt and Leiser, 1988). It is possible that changes in MMP- 
9 expression may contribute to some o f these changes in villous configuration.
It would have been informative to study placentae from earlier in pregnancy in 
order to establish whether EVT expression o f MMP-9 was reduced at high altitude as 
this would further establish the suitability o f high altitude as a model for pre­
eclampsia. Logistically this was not possible in the current study bu t would be o f 
interest for future work.
Fewer studies have associated MMP-2 expression in cultured CTB with 
oxygen tension, trophoblast invasion and in the development o f pre-eclampsia. It was 
found in this study that MMP-2 expression did not differ significantly between high 
and low altitude in any o f the cell types examined. Again it would be interesting to 
study expression in EVT in early pregnancy to determine if  there were any differences 
between the two altitudes. While MMP-2 is constitutively expressed in many human 
tissues, the regulation o f its gene expression is likely to be sensitive to numerous 
agents through the upstream binding site for various transcription factors. While high 
altitude pregnancy may be a suitable model for some aspects o f pre-eclampsia, care 
must be taken when evaluating it as a potential model. This is discussed further in 
chapter 7.
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Chapter 7: Serum markers of pre-eclampsia in 
serum from high and moderate altitude
pregnancies
G:
7.1 M aternal concentrations of circulating VCAM-1 at high and moderate
altitude
Maternal circulating concenti'ations o f the cell adhesion molecule VCAM-1, a marker 
o f endothelial activation, are increased in pre-eclampsia (section 1.7,5). The 
hypothesis was tested that pregnant women living at high altitude, although the 
pregnancy outcomes are normal, may show similarities to women with pre-eclampsia 
regarding endothelial cell activation.
Semm samples were obtained from pregnant women living at high (HA) and 
moderate altitudes (MA) as described in section 2.4.2.3. The demographic details of 
the overall sample group are shown in table 44a. For each assay (VCAM-1, E- 
Selectin and ICAM-1) the majority o f the samples were used. The samples were 
initially assayed blind and hence in a few cases two samples were obtained from the 
same patient in a particular trimester were included in the assay and analysis.
However the data was reanalyzed without these samples and the means did not differ 
substantially and there were no differences in statistical test results. Hence the initial 
results are presented herein. The precise numbers for each are shown in table 44b.
Concentrations o f VCAM-1 were assayed by ELISA (R&D Systems, UK) in 
early (8-14 weeks), mid (15-28 weeks) and late (29 w eeks-term ) pregnancy and post 
partum (FF) (n = 5, 21, 15 and 13 at MA and 10, 17, 19 and 11 at HA respectively) as 
described in section 2.10.3.
The gestations o f the samples were analyzed using Shapiro-W ilk analysis and 
the data was found to have a non-normal distribution. Thus the median gestation for 
each trimester was calculated and is shown in table 45. W hen the gestations of the 
samples were compared using a Mann-W hitney U test there were no significant 
differences between the gestations o f  high and moderate samples in first, second or 
third trimesters. All post-partum samples were collected at three months post-partum.
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Table 44a Demographic details o f sample populations in altitude study
M aternal Characteristics, means ± SD
■i|i
1600 m n=15 3100 m n~16
Age (years) 28 ± 4 27 ± 7
Height (cm) 167 ± 6 165 ± 8
Pre-pregnant weight (kg) 62 ± 6 61 ± 6
BMI (kg/m^) 2 2  ± 2 2 2  ± 2
Weight gain with pregnancy (kg) 14 ± 4 1 6 ± 5
Maternal Education (years) 1 7 ± 3 1 4 ±  3**
Paternal Education (years) 16 ± 3 1 6 ± 3
Birth weight (grams) 3332±346 3076±390*
Gestational Age (weeks) 39.2 ± 1.2 39.8 ± 1.7
Baby Length (cm) 50.2 ±2 . 6 50.3 ±3.1
Placental weight (grams) 517 ±109 596 ±85**
*p<0.05, one tailed test (p=0.06 two tailed test)
** P<0.05 two tailed test
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Table 44b Number of samples used in each assay
Assay VCAM-1 VCAM-1 E-Selectin E-Selectin ICAM-1 ICAM-1
Trimester M oderate
Altitude
High
Altitude
Moderate
Altitude
High
Altitude
M oderate
Altitude
High
Altitude
1 5 1 0 5 1 0 5 1 0
2 2 1 17 15 17 2 1 16
3 15 19 11 16 15 18
Post-Partum 13 11 7 11 13 11
:
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Table 45 Statistical comparison of the gestations o f serum samples from  
high and moderate altitude used in VCAM-1 assay
Moderate Altitude 
Median (Range)
High Altitude 
Median (Range)
p-value
1 ®* trimester 12 (12-14) 12(11-14) N/S*
2 “** trimester 25 (15-27) 25 (15-28) N/S
3‘  ^ trimester 37 (32-39) 37(31-40) N/S
* N/S = Non-Significant (p>0.05)
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After the assay was performed, a standard curve was drawn using the standard 
samples provided in the assay kit. The standard curve is shown in figure 55. The 
calculated values for the samples in the assay using the standard curve are shown in 
table 46 and the descriptive statistics o f the data are shown in table 47. The data was 
then plotted on a scattergram (figure 56). The mean + SE values (ng/ml) were as 
follows: 1®* trimester 563.82+108.18 at M A and 468,3 ±27.87 at HA, trimester 
529.3+40.1 at M A and 456.3+24.4 at HA, 3*^  ^ trimester 639.39+62,0 at MA and 
545.21+38.5 at HA and PP 585.77±61.05 at M A and 450.5±30.35 at HA.
The data was initially analyzed at the two altitudes separately to determine if 
there were any variations in VCAM-1 concentrations between the individual 
trimesters. The data was first tested to determine if  it approached a normal distribution 
using Shapiro-W ilk analysis. Since it did, an ANOVA/ Fisher’s PLSD test was used 
and the results are shown in table 48 (moderate altitude) and table 49 (high altitude). 
No variation in VCAM-1 concentration with trimester was found at moderate altitude 
bu t at high altitude VCAM-1 was significantly higher in the third trimester than in the 
second trimester (p<0.05).
The data was subsequently analyzed using a t-test to determine if  there were 
any significant differences in circulating VCAM-1 concentrations at high compared 
with moderate altitude firstly in the groups as a whole and then in each o f the three 
trimesters or post-partum. The results o f the statistical analysis are shown in table 50. 
Although the initial t-test reached significance (p<0.01), frirther analysis showed no 
significant differences between the two altitudes in the 1 ®\ 2 ”  ^ or 3*^*^ trimesters or 
post-partum samples.
Finally, to test i f  there was any correlation between gestation and VCAM-1 
concentration a Pearson’s correlation analysis was carried out. The results are shown 
in table 51. There was no correlation between VCAM-1 and gestation in either the 
HA or MA groups individually bu t when the groups were combined there was a 
positive correlation o f  VCAM-1 with gestation.
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Figure 55 Standard curve for VCAM-1 assay
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Table 46 VCAM-1 concentrations in maternal serum throughout
pregnancy -  raw data
Patient Number Sample Gestation 
(weeks)
VCAM-1
ng/ml
M oderate Altitude 
1 Denver (D) 22
27
39
PP
560.5
678.5 
572
400.34
2D 27
37
PP
497.4
580
321.1
3D 12
27
32
PP
479.45
404
417.15
520.37
4D 14
26
34
256.29
400.9
394.3
5D 12
24
34
PP
497.4
464.3
458.15
613
6 D 12
24
34
PP
900
518
1128
766
7D 14
27
38
PP
686
1096
689
891.5
8 D 27
36
PP
626
852
453.15
9D 17
26
37
681
756.5
943.5
297
pp 1053.5
lOD
IID
12D
13D
14D
15D
High Altitude 
1 Leadville (L)
15
26
39
PP
15
25
37 
PP
17
26 
39 
PP
24
36
PP
16 
26 
36 
PP
16
38
25
38
451.95
621
880
458.15
645.5
347.15
854.5 
562.38
405.14 
618.8 
834.86
758
289.9
389.53 
391.93
363.12
303.11
390.73
425.54
485.56
507.14
349.9
482.5
PP 317.51
2L 394.3 
397.6
394.3 
523.5PP
3L 442.6
404.15
962.1
592.39
298
5L 11
25
36
339.3
339.3
360.4
6 L
8 L
lOL
I I L
12L
13L
14L
14 
26 
37 
PP
12
25 
35 
PP
12
27
37
PP
15
26 
37 
PP
24
37
PP
12
24 
37 
PP
25
433.15
374.15
479.45 
448.85
563.5 
538
485.5 
591
574.5
746.5 
251
566.5
549.5
470.4 
535
563.5
500.5 
610
417.14
461.2
526.5
479.45 
410.7
439.45
580
454.35PP
15L 480.76
481.96
355.92PP
16L 417.15
736.5
711.5 
306.71PP
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A
i
17L 13 607.5
28 342.85
38 585.5
18L 13 476.45
24 410.7
35 778
25L 1 2 390.5
25 470
36 506
38 347.52
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Table 47 VC AM-1 concentrations in maternal serum throughout
pregnancy -  descriptive statistics 1
(ng/ml) Mean Median SD SE Min M ax Range
between
min
and
max
HA .
1 st
trimester
468 .3 451.9 8 8 . 1 2 27.87 339.3 607.5 268.2
HA
2 nd
trimester
456.3 439.5 100.7 24.4 339.3 746.5 407.2
HA
3rd
trimester
545.21 506 167.6 38.5 251 962.1 711.1
HA
Post
Partum
450.5 448.85 1 0 0 . 6 6 30.35 306.7 591.0 284.29
MA
1 st
trimester
563.82 497.4 241.89 108.18 256.29 900 643.71
MA
2 nd
trimester
529.3 497.4 183.74 40.1 289.9 1096 806.1
MA
3rd
trimester
659.39 580.0 240.15 62.0 389.53 1128.0 738.47
MA Post 
Partum
585.77 520.37 220.13 61.05 321.1 1053.5 732.4
'. i
:
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:
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Figure 56 Scattergraph of maternal concentrations of circulating VCAM-1 at 
high and moderate altitude
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Table 48 Statistical analysis o f VCAM-1 concentration variation at
moderate altitude
Test T rim estersanalysed p-value
ANOVA All three trimesters + PP N/S*
Fisher’s PLSD N/S
Fisher’s PLSD ist/jrf N/S
Fisher’s PLSD N/S
Fisher’s PLSD ist/pp N/S
Fisher’s PLSD 2"‘‘/PP N/S
Fisher’s PLSD grd/pp N/S
* N/S = Non-Significant (p>0.05)
f
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Table 49 Statistical analysis o f VCAM-1 concentration variation at high
altitude
Test T rim estersanalysed p-value
ANOVA All three trimesters + PP N/S*
Fisher’s PLSD jst/2 nd N/S
Fisher’s PLSD N/S
Fisher’s PLSD jnd/jrd p<0.05
Fisher’s PLSD r'/pp N/S
Fisher’s PLSD 2"‘‘/PP N/S
Fisher’s PLSD jrd/pp N/S
N/S = Non-Significant (p>0.05)
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Table 50 Statistical comparison of VCAM-1 concentrations at moderate and 
high altitude
Test Trimestersanalysed p-value
t-test All three trimesters + PP p< 0 . 0 1
t-test 1 st N/S*
t-test 2 nd N/S
t-test 3 rd N/S
t-test Post-Partum N/S
* N/S = Non-Significant (p>0.05)
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Table 51 Correlation analysis of VCAM-1 concentration with gestation at
moderate and high altitude
Altitudes p-value
Moderate N/S*
High N/S
M oderate and High 0.04R=0.22
N/S = Non-Significant (p>0.05)
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7.2 M aternal concentrations o f circulating E-Selectin at high and
moderate altitude
trimesters.
i
Maternal circulating concentrations o f  the cell adhesion molecule E-Selectin, another 
marker o f endothelial activation, are also increased in pre-eclampsia (section 1.7.5). 
Therefore in the next experiment concentrations o f E-Selectin were assayed in the 
maternal circulation from women living at high and moderate altitude. E-Selectin was 
assayed by ELISA (R&D systems) in early (8-14 weeks), mid (15-28 weeks) and late 
(29 weeks-term ) pregnancy and post partum (n = 5, 15, 11 and 7 at M A and 10, 17, 
16 and 11 at HA respectively). The gestations o f the samples were analyzed using 
Shapiro-Wilk analysis and the data was found to have a non-normal distribution. Thus 
the median gestation for each trimester was calculated and is shown in table 52. When
the gestations o f  the samples were compared using a Mann-W hitney U test there were 
no significant differences between high and moderate samples in first, second or third
I
1':
■Si
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Table 52 Statistical comparison of the gestations of serum samples from  
high and moderate altitude used in E-Selectin assay
M oderate Altitude 
Median (Range)
High Altitude 
Median (Range)
p-value
1 ®* trimester 12 (12-14) 12(11-14) N/S*
2 "^  trimester 26 (15-27) 25 (15-28) N/S
3^^^ trimester 37 (32-39) 37 (32-39) N/S
N/S = Non-Significant (p>0.05)
%
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After the assay was performed a standard curve was drawn using the standard 
samples provided in the assay kit. The standard curve is shown in figure 57. The raw 
data for the samples in the assay is shown in table 53 and the descriptive statistics o f 
the data are shown in table 54. The data was then plotted on a scattergram (figure 58). 
The mean + SE (ng/ml) values were as follows; 1®^ trimester 32.49+5.32 at MA and 
38.87+4.77 at HA, 2"^ trimester 39.8+2.95 at MA and 37.05+2.92 at HA, 3^  ^trimester 
36.6±4.63 at MA and 37.09±4.27 at HA and PP 37.1+4.03 at M A and 43.3±5.88 at 
HA.
Initially the data was analyzed at the two altitudes separately to determine if  
there were any variations in E-Selectin concentrations between the individual 
trimesters at either altitude using an ANOVA/ Fisher’s PLSD test. No variation in E- 
Selectin concentration with trimester was found at either of the altitudes (p>0.05).
The data was subsequently analyzed using t-tests to determine if  there were 
any significant differences in circulating E-Selectin concentrations at high compared 
with moderate altitude initially between the two groups as a whole and subsequently 
in any o f the three trimesters or post-partum. There were no significant differences in 
E-Selectin concentration between moderate and high altitudes in 1®‘, 2"^ or 3“^^  
trimester or post-partum.
Finally, to test if  there was any correlation between gestation and E-Selectin 
concentration a Pearson’s coiTelation analysis was carried out. There was no 
correlation between E-Selectin and gestation in either the HA or MA groups or in 
both groups combined.
' I
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Figure 57 Standard curve for E-Selectin assay i:
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Table 53 E-Selectin concentrations in maternal serum throughout
pregnancy -  raw data
Patient Number Sample Gestation 
(weeks)
E-Selectin
ng/ml
M oderate Altitude
1 Denver (D) 2 2 47.28
27 57.48
39 39.98
PP 52.06
2D 27 47.78
37 48.28
3D 1 2 31.16
- 27 36.2
32 31.41
PP 33.55
4D 14 28.51
26 29.77
34 29.9
5D 1 2 52.69
24 62.64
34 73.59
6 D 1 2 29.02
24 37.33
34 45.26
PP 32.29
7D 14 21.09
27 30.78
38 24.74
PP 27.26
8 D 27 28.9
36 19.83
PP 52.44
9D 17 35.94
26 28.89
37 22A7
PP 33.68
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lOD
IID
15
26
39
PP
15
25
37
28.14 
29.52
28.14
28.14
52.44
44.51
38.97
High Altitude 
1 Leadville (L)
2L
25
38
PP
11
24
37
PP
53.95
32.92
40.98
32.42
30.03
21.97
36.32
3L
5L
6 L
8 L
lOL
IIL
12
27
PP
11
25
36
14
26
37 
PP
12
25 
35 
PP
12
27
37
PP
15
26
42.49
49.17
74.48
33.3
22.97
20.58
51.31
56.6
52.82
57.1
27.76
28.64
29.52
29.14
15.8
14.92
4.59
18.19
28.26
34.81
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12L
13L
37
PP
24
37
PP
12
24
37
PP
22.72
22.97
23.35
43.63
49.29
30.78
34.94
28.89
21.59
- I
■
14L 25
37
PP
45.89
33.93
57.98
15L 26
39
38.08
37.58
16L 24
32
38
PP
49.17
70.32
60.37
68.31
17L 13
28
38
71.58
44.76
53.07
ISL 13
24
35
41.36
2&77
29.27
25L 12
25
36
41.86
45.51
51.18
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Table 54 E-Selectîn concentrations in maternai serum throughout
pregnancy -  descriptive statistics
II
(ng/ml) M ean M edian SD SE M in M ax Range 
between 
m in and 
m ax
HA
1 st
tr im este r
38.87 37.3 15.1 4.77 15.8 71.58 55.78
H A
2 ud
trim este r
37.05 34.94 12.05 2.92 14.92 56.6 41.68
H A
3rd
trim este r
37.09 33.43 17.06 4.27 4.59 70.32 65.73
HA
Post
P a rtu m
43.3 40.98 19.52 5 j # 18.19 74.48 56.29
M A
1 st
trim este r
32.49 29.02 11.91 5.32 21.09 52.69 31.6
M A
2 nd
trim este r
39.8 36.2 11.4 2.95 28.14 62.64 34.5
M A
3rd
trim ester
36.6 31.4 15.37 4.63 19.83 73.59 53.76
M A
Post
P a rtu m
37.1 33.6 10.7 4.03 2T26 52.44 25.18
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Figure 58 Scattergraph of maternal concentrations of circulating E-Selectin 
at high and moderate altitude
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7.3 M aternal concentrations o f circulating ICAM-1 at high and moderate
altitude
Maternal circulating concentrations o f the cell adhesion molecule ICAM-1, another 
marker o f endothelial activation, are not increased in pre-eclampsia (section 1.7.5). 
Therefore in the next experiment concentrations of ICAM-1 were assayed in the 
maternal circulation from women living at high and moderate altitude. ICAM-1 
concentrations were assayed by ELISA (R&D systems) in early (8-14 weeks), mid 
(15-28 weeks) and late (29 weeks -  term) pregnancy and post partum (n = 5, 21, 15 
and 13 at M A and 10, 16, 18 and 11 at HA respectively). The gestations o f the 
samples were analyzed using Shapiro-Wilk analysis and the data was found to have a 
non-normal distribution. Thus the median gestation for each trimester was calculated 
and is shown in table 55. W hen the gestations o f the samples were compared using a 
Mann-W hitney U test there were no significant differences between high and 
moderate samples in first, second or third trimesters.
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Table 55 Statistical comparison of the gestations of serum samples from  
high and moderate altitude used in ICAM-1 assay
M oderate Altitude 
Median (Range)
High Altitude 
Median (Range)
p-value
1 ®* trimester 12(12-14) 12(11-14) N/S*
2 "^trimester 25 (15-27) 25 (15-28) N/S
3*^ *^ trimester 37 (32-39) 37(31-40) N/S
* N/S = Non-Significant (p>0.05)
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After the assay was carried out a standard curve was drawn using the standard 
samples provided in the assay kit. The standard curve is shown in figure 59. The raw 
data for the samples in the assay is shown in table 56 and the descriptive statistics o f 
the data are shown in table 57. The data was then plotted on a scattergram (figure 
60). As seen in table 57, the mean ICAM-1 concentrations (ng/ml) were as follows: 
trimester: 270.65+31.8 at M A vs 255.29+20.09 at HA, 2"^ trimester: 279.16+13.79 at 
M A vs 246.7+14.29 at HA, 3'"^  trimester: 279.89±28.15 at MA vs 272.87+24.0 at HA 
and for PP 33 1.7±39.3 at MA vs 316.02+24.88 at HA.
Initially the data was analyzed at the two altitudes separately to determine if  
there were any variations in ICAM-1 concentrations between the individual trimesters 
at either altitude using an ANOVA/ Fisher’s PLSD test. At high altitude ICAM-1 was 
significantly lower (p<0,05) in the second trimester than post partum. No other 
significant differences were found.
The data was subsequently analyzed using t-tests to determine if  there were 
any significant differences in circulating ICAM-1 concentrations at high compared 
with moderate altitude firstly in the groups as a whole and then in each o f the three 
trimesters or post-partum. There were no significant differences between high and 
moderate ICAM-1 concentrations in any trimester or post partum.
To test i f  there was any correlation between gestation and ICAM-1 
concentration a Pearson’s correlation was carried out. There was no correlation 
between ICAM-1 and gestation at moderate or high altitude or in both groups 
combined.
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Figure 59 Standard curve for ICAM-1 assay
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Table 56 ICAM-1 concentrations in maternal serum throughout
pregnancy -  raw data
Patient Number Sample gestation ICAM
(weeks)___________ ng/ml
M oderate Altitude 
1 Denver (D) 22
27
39
PP
263.65
209.11
233.59
14Z87
2D 27
37
PP
255.67
247.03
401.11
3D 12
27
32
PP
378.56
288.79
296.47
211.51
4D 14
26
34
277.27
298.39
85.26
5D 12
24
34
PP
191.35
192.79
252.31
310.39
6 D 12
24
34
PP
282.07 
183.19 
266.71
222.07
7D 14
27
38
PP
223.99
231.67
175.03
284.47
8 D 27
36
260.47
233.59
PP 253.27
9D 292.63
256.15
283.51
320
pp 179.83
lOD 15 223.51
26 239.35
39 190.87
PP 282.07
I ID  15 287.83
25 284.47
37 296.95
PP 444.8
12D 17 369.43
26 422.71
39 571.04
PP 464
13D 24 387.2
36 367.51
PP 499.5
14D 16 239.83
26 331.99
36 331.99
PP 616.17
15D 16 343.51
38 366.55
H igh A ltitude
1 Leadville (L) 25 248.95
38 213.43
PP 282.55
2L 11 233.11
24 128.94
37 189.91
PP 370.39
3L 12 397.76
27 331.03
31 449.6
40 507.2
PP 445.76
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5L 1 1 213.9
25 223.51
36 228.79
6L 14 319.51
26 313.27
37 285.43
PP 305.11
8L 1 2 230.23
25 230.71
35 224.47
PP 278.71
lOL 1 2 243.67
27 175.99
37 106.39
PP 243.67
IIL 15 304.63
12L 24 343.03
37 419.36
PP 470.71
13L 1 2 233.59
24 275.83
37 255.67
PP 256.63
14L 25 267.67
37 220.63
PP 334.39
15L 26 221.59
39 228.79
PP 210.07
16L 24 235.99
32 329.59
38 320.47
PP 278.23
17L 13 283.99
28 205.27
38 201.91
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18L 13 223.03
24 217.75
35 316.15
25L 1 2 174.07
25 222.55
36 205.27
38 208.63
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Table 57 ICA M -1 concentrations in m aterna i serum  th ro u g h o u t p regnancy 
-  descriptive statistics
(ng/m l) M ean M edian SD SE M in M ax R ange 
between 
m in and 
m ax
HA
1 st
trim ester
255.29 233.35 63.53 20.09 174.07 397.76 223.69
HA
2 iid
trim ester
246.7 233.35 57.16 14.29 339.3 746.5 214.09
HA
3 rd
trim ester
272.87 228.79 101.82 24.0 106.39 507.2 400.81
HA
Post
P artu m
316.02 282.55 82.52 24.88 210.07 470.71 260.64
M A
1 st
tr im este r
270.65 277.27 71.2 31.8 191.35 378.56 643.71
M A
2 nd
trim ester
279.16 263.65 63.18 13.79 183.19 422.71 239.52
M A
3 rd
trim ester
279.89 266.71 109.0 28.15 85.26 571.04 485.78
M A
Post
P a rtu m
331.7 284.5 141.6 39.3 142.87 616.17 473.3
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Figure 60 Scattergraph of maternal concentrations of circulating ICAM-1 at 
high and moderate altitude
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7.4 Correlation of VCAM-1, ICAM-1 and E-Selectin throughout
p regnancy
VCAM-1, ICAM-1 and E-Selectin concentrations were analysed to determine if  there 
was any coiTelation between the concentrations o f each at either or both altitudes. 
When high altitude was analysed alone there was a positive correlation between 
ICAM-1 and VCAM-1 concentrations (p<0.01 R=0.4) i.e. when a woman had high 
concentrations o f ICAM-1 she also tended to have high concentrations o f VCAM-1. 
There were no correlations when moderate altitude samples were analysed alone. 
When both altitudes were included in the analysis there was a positive con'elation 
between ICAM-1 and E-Selectin concentrations (p<0.01 R=0.33) i.e. when a woman 
had high concentrations o f  ICAM-1 she also tended to have high concentrations o f E- 
Selectin.
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7.5 Discussion
A central pathological characteristic o f pre-eclampsia is endothelial dysfunction. 
W omen with the disease show increases in markers o f endothelial dysfunction and 
blood vessels o f these women also show altered endothelial function ex-vivo. Markers 
o f  endothelial activation include increased cytokines such as interleukin (IL ) - 6  (Greer, 
1995) and cell adhesion molecules such as E-Selectin and VCAM-1 (Lyall et al. 1994, 
Lyall et al. 1995).
Women residing at high altitude with normal pregnancy outcomes have 
physiological changes and placental vascular remodelling intermediate between that 
observed in normal pregnancy and pre-eclampsia (Palmer et al. 1999, Zamudio et al. 
1993). The model o f chronic hypoxia in pregnancy offered by high altitude residence 
is unique in allowing the opportunity to distinguish between specific circulating and 
molecular markers o f  pre-eclampsia fi'om those which may be due to hypoxia alone, 
without pathological consequences.
The aim of this study was to measure maternal circulating concentrations o f  
the cell adhesion molecules VCAM-1, E-Selectin and ICAM-1 throughout pregnancy 
and post-partum in pregnant women residing at high altitude who had normal 
pregnancy outcomes. The hypothesis tested was that circulating cell adhesion 
molecule concentrations would be increased as a result o f chronic hypoxia even in the 
absence o f any symptoms o f pre-eclampsia. No variation in VCAM-1 concentration 
between the trimesters was found at moderate altitude but at high altitude VCAM-1 
was significantly higher in the third trimester than in the second trimester (p<0.05). It 
is possible that this increase is related to chronic exposure to hypoxia. VCAM-1 
concenti'ations were lower overall in the high altitude group than in the moderate 
altitude group. However no differences in VCAM-1 were found between the moderate 
altitude and high altitude group between any o f the individual trimesters. No other 
major changes were observed with either E-Selectin or ICAM-1. These data suggest 
that chronic hypoxia per se is not responsible for increased cell adhesion molecules in 
pre-eclampsia and is likely to be a secondary response to other events.
Acute high altitude exposure leads to an increase in IL - 6  and other indicators 
o f an immune system inflammatory response (Mazzeo et al. 2001, Bailey et al. 2004,
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Kubo et al. 1998). Maternal circulating concentrations o f the pro-inflammatory 
cytokines IL-6 , TNF-alpha, and IL - 8  are all elevated late in pregnancy in women 
residing at high altitude, but did not differ even marginally in the non-pregnant state. 
The same subjects failed to increase their levels o f anti-inflammatory (Th-2) IL-10 
during pregnancy, causing a marked reduction in circulating concentrations relative to 
low altitude control subjects that was, again, most pronounced in the third trimester 
when pregnancy complications develop (Coussons-Read et al. 2002). It may be that 
pregnant women at high altitude do not make a complete switch from T h l to Th2-type 
immune responsiveness as women residing at lower altitude (Coussons-Read et al.
2 0 0 2 ) or that the overall profile o f  cytokine production during pregnancy at high 
altitude is altered by sympathoadrenal activation secondary to the interaction of 
hypoxia and pregnancy and therefore favours the development o f complications at the 
extremes o f the normal range o f variation. Alternatively, altered cytokine production 
or degradation may be a reflection o f underlying mechanisms that contribute both to 
the observed alterations in circulating concentrations and the development o f 
complications without one necessarily causing the other.
Vascular endothelial growth factor (VEGF) is an important survival factor for 
endothelium so systemic inhibition would be expected to cause generalised 
endothelial dysfunction. Circulating concentrations o f free VEGF are reduced in the 
maternal circulation in pre-eclampsia and it was predicted that this may be related to 
alterations in receptors for VEGF (Lyall et al. 1997) e.g. the soluble receptor for 
vascular endothelial growth factor known as sFlt-1, sFlt-1 was first detected in 1993 
(Kendall and Thomas, 1993) who confirmed (Kendall et al. 1996) that it could inhibit 
the actions o f VEGF. Clinical trials o f a neutralising monoclonal antibody to VEGF 
for the treatment o f metastatic colorectal or renal cancer have shown that hypertension 
and proteinuria are the commonest side effects (Kabbinavar et al. 2003, Yang et al.
2003). Serum soluble flt-1 is increased in pre-eclampsia (Maynard et al. 2003). 
Because it is complexed to VEGF, its high levels in pre-eclampsia can explain the 
variable reports o f changes o f  plasma VEGF in this condition. The findings may 
explain the results o f some studies which have reported that total VEGF, rather than 
unbound free VEGF is increased in pre-eclampsia (Baker et al. 1995). The origin of 
the circulating sflt- 1  is presumed to be the placenta although this has not yet been 
directly demonstrated. The most compelling evidence is its rapid decline in
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concentration after delivery (Maynard et al. 2003). In agreement the highest 
concentrations o f free VEGF are found in non-pregnant women (Lyall et al. 1997). 
VEGF is increased by hypoxia and in a similar population to the present study total 
(bound and free) VEGF was increased in pregnant women at 3100m throughout 
pregnancy compared with pregnant women living at 1600m (W heeler et al. 2002). 
That the VEGF may o f placental origin was supported by the obseiwation that no 
differences were found post-partum. VEGF was inversely associated with birth- 
weight at 3100m bu t not at 1600m. Measurements o f  free VEGF were not performed. 
The observation that not all o f the endothelial factors such as cell adhesion molecules 
are elevated in maternal plasma at high altitude suggest that chronic hypoxia is only 
responsible for some aspects o f  maternal activation in pre-eclampsia.
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Chapter 8: Villous explant culture as a 
model for trophoblast invasion
330
■8.1 Explant Culture: Determination of oxygen tension in culture medium
incubated in a low oxygen incubator
CTB proliferation and differentiation has been reported to be regulated by oxygen 
tension (section 1.5). The development o f  in vitro models to determine the effects o f 
different oxygen concentrations has been important in beginning to understand this 
process (Genbacev et al. 1996; Genbacev et al. 1997; Watson et al. 1998; Caniggia et 
al. 2000a; Huppertz et al. 2003). A key issue in the studies o f this type is the actual 
oxygen levels which cultured cells are exposed to during incubation in different 
oxygen conditions. In some studies, specific methods to determine the oxygen 
concentration in the culture medium is reported (Genbacev et al. 1996; Fitzpatrick and 
Graham, 1998; W atson et al, 1998; Huppertz et al. 2003) while in others only the 
measurement o f oxygen in the incubator is mentioned (Caniggia et al. 2000a; Kudo et 
al. 2003; Nelson et al. 2003). The aim o f this study was to determine the oxygen 
environments encountered in the cell culture system which would subsequently be 
used to culture placental villous explants.
As described in section 2.5, studies were carried out using two Forma 
Scientific water-jacketed incubators, one set at 5% CO2  (18% O2) in air for standard 
culture conditions and one set at 5% CO2 / 93% Ng (2 % O 2) for low oxygen 
conditions. Oxygen levels in each incubator were measured using a Fyrite gas 
analyser and were 18% and 2 % in the standard and low oxygen incubators 
respectively.
There are many commercially available oxygen probes and meters for 
measuring dissolved oxygen in a liquid environment but various difficulties exist in 
measuring oxygen in eell culture systems such as those used in trophoblast and 
explant cultures. A Jenway portable dissolved Oxygen/°C meter and electrode was 
chosen because o f its suitability, in particular the integral temperature compensation. 
The oxygen meter was calibrated as described in the manufacturers instructions in 
21% oxygen in water saturated air and to 0% using the zero salts supplied. All 
experiments were performed in 125ml o f M l 99 supplemented with 10% FBS and 1% 
antibiotic/antimycotic solution) in a T75 vented-lid culture flask to allow stirring and 
so that the depth o f culture medium was sufficient to cover the electrode. The flask 
was placed flat in the incubators to allow maximum surface area for gaseous 
exchange.
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The surface area/ volume was 75 cm / 125ml compared to 8  cm / 4 ml in 35 mm 
culture dishes, 1,9 cm^/ 0.4 -  1 ml in 24 well plates and 0.6 cm^/ 200 pi in the 
Millicell inserts used in many trophoblast and explant culture experiments. Three 
experiments were performed.
a) Culture medium was warmed to 37°C in standard culture conditions. Dissolved 
oxygen levels were measured and the flask was then transferred to low oxygen 
conditions at 37°C for up to 24hr. Dissolved oxygen levels in the culture medium 
were measured at intervals during the incubation period.
The dissolved oxygen concentration in culture medium in standard culture 
conditions measured approximately 18%. When culture medium was transferred to 
the low oxygen incubator, oxygen levels decreased gradually to 6 - 8 % after 4hr and 2- 
3% after 24hr o f incubation (figure 61).
b) Nitrogen gas was bubbled through the culture medium (2-3 psi) for 30min to 
eliminate dissolved oxygen in the culture medium. The opening to the flask was 
sealed with parafîlm in which there was an inlet for the pipette delivering the nitrogen 
gas and an outlet to allow gas to escape. The flask was immediately transferred to a 
2% oxygen environment at 37°C. Dissolved oxygen levels in the culture medium 
were measured after Ihr and following an overnight (16hr) incubation.
W hen nitrogen gas was bubbled through the culture medium, dissolved 
oxygen levels fell from 18-20% to approximately 1.5% after 15min and to 0% after 
30min. W hen pre-gassed culture medium (0%) was placed directly into the incubator 
with the 2 % oxygen environment, oxygen levels in the culture medium equilibrated to 
approximately 2% after Ihr and remained at 2-3% following overnight incubation.
c) Nitrogen gas was bubbled through culture medium for 30min to eliminate dissolved 
oxygen in the culture medium, as described above. The culture medium was then 
dispensed into smaller volumes (5 x 25ml) to mimic culture medium ehanges (total 
dispensing time 4min) and then returned to the flask. Dissolved oxygen in the culture 
medium was measured immediately and the flask placed in the low oxygen incubator 
at 37°C. Dissolved oxygen levels were measured at time-points up to 16hr.
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W hen culture medium pre-gassed with nitrogen to eliminate oxygen (0%) had 
been dispensed in air, dissolved oxygen levels increased to 8.5%. Further incubation 
o f the cell culture medium in a hypoxic environment o f 2 % oxygen for approximately 
16hr was required for dissolved oxygen levels in the culture medium to decrease to 
2%.
8.1.2 Discussion
There are many factors that must be given consideration when measuring dissolved 
oxygen levels in a cell culture system. Many oxygen electrodes and meters are not 
suitable for use with cell cultures. M any are too large for the direct measurement o f 
oxygen in cell cultures maintained in, for example, 35 mm dishes, 24-well plates or 
Millicell inserts. Smaller probes are available but often at much greater expense. 
Temperature is o f vital importance as it affects the concentration o f dissolved oxygen 
in a liquid e.g. the MI-730 electrode (Microelectrodes, Inc, USA) is quoted by the 
manufacturers as having a change in probe response o f 2 .2 % per degree change in 
temperature. Thus, unless an electrode has an integral temperature compensation 
function care must be taken to ensure that calibration and all measurements are 
carried out at the same temperature, which may be difficult. Many manufacturers 
recommend calibration in ambient air, while pre-gassing liquids results in changes in 
liquid temperature that are difficult to control. Dissolved oxygen measurements 
cannot accurately be carried out in a static system such as that used in explant culture 
due to oxygen starvation at the membrane o f the electrode. This would result in false 
low oxygen readings, while agitation o f  cultures could dislodge cells or explants. 
Some authors have reported using a hlood gas analyser to measure dissolved oxygen 
in culture medium sampled from cell cultures (Huppertz et ah, 2003). Initially a Bayer 
288 blood gas analyser was used in these experiments. However, this was not suitable 
as the analyser could only accurately measure oxygen levels in whole blood and gave 
false readings with culture medium.
In order to characterise oxygen levels within the oxygen controlled cell culture 
environment in a way that best compensated for the factors discussed above, an 
oxygen electrode with automatic temperature compensation was chosen. Dissolved 
oxygen levels were measured in test culture medium maintained within the same 
environments as are our cultured cells.
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Dissolved oxygen levels in culture medium incubated in a hypoxic 
environment o f 2 % oxygen following prior exposure to atmospheric oxygen or 
standard culture conditions decreased gradually to 2 % over an incubation period o f 
24hr. During this time eultured cells would be exposed to varying oxygen 
concentrations and degrees o f hypoxia depending on the length o f time in culture 
before the desired oxygen concentration was reached. These experiments were carried 
out using a large volume o f culture medium due to the requirements o f the oxygen 
electrode in use. With the much smaller volumes o f culture medium used in the actual 
cell culture experiments, the rate o f gaseous exchange between the culture medium 
and the environment would presumably he greater and hypoxic conditions would be 
established more quickly. However, problems associated with culturing cells in a 
static environment, which may limit the rate o f  gaseous exchange, still remain.
Pre-gassing the culture medium, either with nitrogen to eliminate oxygen from 
the medium or with a gas o f the desired mix and oxygen level has been suggested as a 
means o f  avoiding the situation described above. Experiment b) showed that after pre­
gassing with nitrogen to 0 % oxygen, dissolved oxygen levels equilibriated to 2 % and 
remain at that level when maintained within a 2% oxygen environment. However, 
manipulation and microscopic monitoring o f cultured cells is often earned out in air, 
thus exposing the culture medium and cells to atmospheric oxygen.
As shown in experiment c) culture medium that has been pre-gassed with 
nitrogen quickly absorbs atmospheric oxygen on exposure to air. Further incubation in 
a 2 % oxygen environment for 16hr was required for dissolved oxygen levels in the 
culture medium to equilibrate back to 2%. Gassing cultures directly to avoid uptake of 
atmospheric oxygen also has difficulties particularly when millicell dishes are used 
e.g. dislodging the cells or explants during gassing, the cooling effect o f the gas on the 
culture medium and the time involved in gassing individual cultures in an experiment.
Cultures maintained in a low oxygen environment would be exposed to 
increased oxygen levels during handling and during the associated time delay before 
the cell culture environment equilibrated to appropriate levels on return to the 
incubator, thus disrupting the exposure o f the cells to the required oxygen 
concentration. The only way to avoid uptake o f atmospheric oxygen would be to use a 
chamber flushed with the appropriate gas mix to allow manipulation o f cultures in the 
same oxygen environment as the incubator atmosphere (Genbacev et al. 1996) and
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then to be able to transfer the dishes to the incubator without exposure to atmospheric 
air.
The experiments described in this section highlight the importance of, and 
difficulties associated with, the validation o f  oxygen levels in vitro cell culture studies 
investigating the effects o f oxygen on placental development and function. The issues 
highlighted are particularly important with regard to reproducibility and the 
comparison o f data between different research laboratories.
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Figure 61 Oxygen concentration in culture medium incubated in a 2% O2 
incubator after various time-points
#  f  10
Time (h)
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8.2 Proliferation/invasion at high and low oxygen tension
The initial aim o f this experiment was to set up an explant culture system similar to 
the one described in section 1.3. Villous explant cultures were prepared using a 
method based on that o f Genbacev et al. (1992) as described in section 2.5.2. The 
collection o f all tissue is described in section 2.4.
Briefly, villous tissue was isolated from TOPs, washed several times in sterile 
PBS and dissected to isolate small fragments o f placental villi. Villous tissue (5-15mg 
wet weight) was arranged on the surface o f matrigel-coated inserts and cultures placed 
in a 37°C incubator (5% CO 2  in air) for 2hr after which culture medium was added to 
the lower chamber o f the culture dishes. Cultures were maintained at 37°C in standard 
culture conditions for a further 24hr and then 200pl o f supplemented culture medium 
was carefully added to the upper chamber o f the culture dish containing the explant 
(Ohr). A set o f  6  explants were maintained at 37°C in standard culture conditions 
(18% O 2) for 144hr. Six separate placentae were studied and from each placenta six 
explants (i.e. 36 explants) were cultured under standard conditions.
To compare explants cultured in low oxygen with those cultured in standard 
conditions, a subset o f explants from each placenta were transferred to a low oxygen 
incubator at Ohr (following incubation o f explants in standard conditions and addition 
o f culture medium to the upper chamber o f the insert). As for those cultured in normal 
conditions, six explants from each o f six separate placentae were cultured for 144 h.
Attachment of villous explants was observed following incubation at 37°C in 
standard culture conditions (5% CO 2  in air) overnight. There was little change in the 
overall morphology o f explants from plating down o f the tissue to the addition o f 
culture medium to the upper culture chamber and the start o f the culture period (Ohr) 
(figure 62a). Areas o f outgrowth o f cells were observed extending from the tips o f 
some but not all villi after 72 and 144hr in culture (figure 62b and 62c). Outgrowth 
was observed during the first 24hr of culture in some o f the explants studied but most 
outgrowth occurred between 24hr and 72hr. In some cases, the number o f villous tips 
exhibiting outgrowth increased from 72hr to 144hr and in many cases the area o f 
existing regions o f outgrowth increased between 72hr and 144hr. 
Immunohistochemistry showed that cells at regions o f outgrowth were cytokeratin- 
positive CTB cells (figure 62d).
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Migration of individual cells and groups of cells out into the matrigel and 
down through the matrigel was observed in most explants at 72 (figure 62b) and 
144hr (figure 62c), Migration of cells into the matrigel became apparent mainly 
between 24hr and 72hr o f culture. Cells were also visible emerging from the tips o f 
villi where regions o f  cell proliferation and outgrowth were observed (figure 62b and 
62c). Migrating cells in the matrigel were easier to visualise and quantify when 
viewed directly under the microscope than following photography and image 
reproduction.
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Figure 62 Expiant of first trimester villous tissue ( 8  weeks of gestation) 
cultured at 37"C in standard conditions
a - 0 h b - 7 2 h
c - 144 h
owth
outgrowth 
d -  144h
Cytokeratin staining
r
migration
€
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8.3 M orphology and semi-quantitative analysis o f explant outgrowth and
migration
8.3.1 Standard culture conditions
Explant morphology was examined at 0, 72 and 144hr by two independent observers 
using an Olympus CK2 inverted pbase contrast microscope to assess cell outgrowth 
and migration. Cultures were photographed at 0, 72 and 144hr using an Olympus 5ZH 
microscope and Olympus camera attachment and detailed sketches o f  each explant 
were drawn to record any changes over the cultui'e time period. The number o f sites o f 
outgrowth o f cytotrophoblast cells in each explant were recorded and migration o f 
cells into or through the matrigel was scored on a scale o f 0 -  5 (0 -  no migration, 1 -  
one or two sites o f localised migration, 2 -  several sites o f  localised migration, 3 -  
moderate migration, 4 - moderate to extensive migration, 5 - extensive migration from 
several sites around the explant).
The number o f villous tips exhibiting outgrowth and the area o f outgrowth 
varied between explants from the same placenta as well as from explants from 
different placentae. The number o f villous tips exhibiting outgrowth at 0, 72 and 
144hr in six explants from the same placenta cultured under standard conditions are 
shown graphically in Figure 63 a. Figure 64a illustrates the mean number of villous 
tips giving rise to outgrowth in explants cultured under standard conditions, derived 
from analysis o f the complete data set, which included six explants for each condition 
from six different placentae (36 explants).
Migration scores at 0, 72 and 144hr o f six explants from one placenta cultured 
under standard conditions are shown in figure 63b. Mean (±SE) migration scores 
derived from the complete set o f explants cultured under standard conditions are 
presented in figure 64b. Migration scores representing the number o f sites where 
migration originated from and the extent o f the migration into the matrigel tended to 
increase from 0 -  72hr (p<0.05) and from 72 -  144hr (p<0.05) as detennined by a 
Spearman’s correlation.
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8.3.2 Low oxygen conditions
I
-'s..
Outgrowth and migration o f cells in explants cultured under low oxygen conditions 
following an overnight pre-incubation in standard culture conditions was also 
examined. The morphological changes were found to be similar to those described 
above for explants cultured in standard conditions. Villous outgrowth and migration E
o f cells into the matrigel was present in some bu t not all cultures and where present 
tended to increase during the culture period. The number o f sites o f  outgrowth (figure 
63 c) and the migration scores (figure 63d) of six explants from one placenta cultured
in low oxygen conditions is shown in figure 63. The number o f  villous tips exhibiting 
outgrowth, the area o f villous outgrowth, the extent o f migration into the matrigel and 
the number o f sites from which migrating cells originated varied considerably J
between explants from the same placenta and between different placentae in low 
oxygen as with explants cultured under standard conditions. The mean number o f 
villous tips that produced outgrowth and the mean migration scores o f explants 
cultured under both standard and hypoxic culture conditions from the six placentae ;
studied are presented in figure 64.
'Mi
I
■S
Figure 63 Time course of outgrowth and migration of cells in first trimester
villous explant cultured in either standard or hypoxic conditions
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Figure 63: Time course o f outgrowth and migration o f cells in explants from one first 
trimester placenta ( 8  weeks o f  gestation) cultured at 37°C in either standard (18% O2) 
or low oxygen conditions (2 % O2, with 24hr pre-incubation in standard conditions) 
for up to 144hr. These graphs illustrate the variation in the number o f  sites o f  
outgrowth and migration scores between explants from one placenta cultured 
simultaneously in either standard or low oxygen conditions.
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Figure 64 Cytotrophoblast outgrowth and migration in villous expiants
cultured in either standard or hypoxic conditions
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Figure 64: Cytotrophoblast outgrowth (A) and migration (B) in first trimester ( 8 - 9  
weeks o f  gestation) villous explants cultured at 37°C in standard (18% O2) or low 
oxygen (2% O2) conditions for up to 144hr. Data is expressed as the mean ± SE o f  
observations from explants cultured from six different placentae (six explants per 
treatment from each placenta).
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8.3.3 Comparison of expiants cultured under standard and low oxygen 
conditions
In comparing the morphology o f the explants cultured under standard and hypoxic 
conditions, it would be possible to identify subsets o f explants that appeared to show 
greater outgrowth and migration under standard conditions than in low oxygen 
conditions and vice versa. For example, figure 65a shows an explant cultured in 
standard conditions for 144hr. There are four clear sites o f  outgrowth extending from 
villous tips and eells can be seen migrating into the matrigel. On the other hand, in 
Figure 65b, an explant cultured for the same time in a low oxygen environment shows 
no evidence o f  outgrowth or migration. This may lead to the interpretation that 
explants cultured in standard conditions produce more outgrowth and migration than 
those cultured in a low oxygen environment. In contrast figure 65b shows an explant 
cultured in standard conditions that shows little evidence o f outgrowth or migration, 
while in figure 65d both outgrowth and migration are clearly visible in an explant 
cultured in low oxygen conditions. Thus the opposing conclusion, that greater 
outgrowth and migration occurs in a low oxygen environment compared to standard 
conditions, could be assumed.
Analysis o f the complete data set o f 36 explants eultured in standard 
conditions and 36 explants cultured in low oxygen conditions showed no significant 
differences in the number o f sites o f outgrowth or in the migration scores from 
explants cultured in a low oxygen environment compared to those maintained in 
standard culture conditions (p>0.05) as determined by Wilcoxon analysis.
344
Figure 65 Villous expiants from first trimester placentae cultured at 37°C in 
either standard or hypoxic conditions for 144 hr
a -  18% b -2%
c - 18% d -2%
O utgrow th
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8.4 Analysis o f expiants exposed directly to low oxygen without
preincubation in standard culture conditions
To address the possibility that the trigger that determines whether or not explants 
form outgrowths or migrate into the matrigel may occur during the 24hr pre­
incubation in standard conditions prior to exposure to a reduced oxygen environment, 
additional explant cultures (six explants per culture condition from two placentae) 
were set up and were placed directly into the low oxygen incubator without prior 
incubation (used to facilitate attachment) under standard conditions. Explants from 
the same placentae cultured as described previously with pre-incubation in standard 
conditions before culture under either standard or low oxygen conditions were also set 
up as controls.
Analysis o f explant behaviour with regard to the establishment o f sites o f 
outgrowth and migration o f cells into the matrigel revealed similar morphological 
changes in explants placed directly into a low oxygen environment compared to those 
that were exposed to standard culture conditions prior to incubation in the 2 % oxygen 
environment (figure 6 6 ).
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Figure 66 Time course of outgrowth and migration of cells in first trimester 
villous explants cultured in either standard or hypoxic conditions 
without preincuhation in standard culture conditions
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Figure 66: Time course o f  outgrowth and migration o f  cells in explants from one
first trimester placenta ( 6  weeks o f  gestation) cultured at 37°C in either standard (18% 
O2) or low oxygen conditions (2% O2, without preincubation in standard conditions) 
for up to 144hr. Migration o f  cells into the matrigel tended to increase throughout the 
culture period both standard (A) and low oxygen (B) conditions. The number o f sites 
o f outgrowth originating from the tips o f villi, visible mainly after 72hr in culture, 
ranged from none to 4 in explants cultured in standard (C) and low oxygen (D) 
conditions. Changes in explant morphology observed in explants placed directly into a 
low oxygen environment were similar to those observed in explants exposed to 
standard conditions prior to incubation in 2 % oxygen.
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8,5 Attempt to culture chorionic villous sample (CVS) explants
Since placental villous tissue from 6-10 weeks o f gestation was successfully cultured 
on matrigel, it was decided to attempt to culture CVS on the same matrix. It was 
hoped that it would be possible to correlate invasive potential o f the CVS explant with 
pregnancy outcome in terms o f  the development o f  pre-eclampsia or lUGR.
CVS from 10-14 weeks gestation are routinely processed in the department in 
which the study was undertaken for pre-natal diagnosis o f chromosome abnormalities. 
Hence small pieces of leftover tissue were readily available. No tissue from earlier 
than 10 weeks o f  gestation was available since CVS is not generally performed before 
this gestation. When pieces o f villous tissue from 10 CVS were cultured on matrigel, 
no proliferation or migration o f cells was seen in any o f the explants in either 2 % or 
18% oxygen. Around three explants were obtained from each sample and the tissue 
pieces were considerably smaller (2 mg) than those obtained from termination samples 
(5mg-15mg). Frozen explants were sectioned and subsequent slides were stained with 
LP34 and Ki67 antibodies as trophoblast and proliferation markers respectively. No 
signs o f proliferation or cell migration were observed in any o f the explants. 
Photographs are shown below o f a representative CVS (figure 67) cultured in normal 
(a) and low (b) oxygen tension for 144hr.
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Figure 67 Villous expiants from CVS cultured at 37®C in either standard or 
hypoxic conditions
a)
b)
10 weeks of gestation CVS 144hr culture period (standard O2)
10 weeks of gestation CVS 144hr culture period (low O2)
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8.6 Discussion
8.6.1 M orphology o f villous expiants cultured in standard culture
conditions
Culture of villous explants from first trimester placentae on matrigel resulted in 
outgrowth o f  CTB at the tips o f  placental villi and migration o f individual cells and 
groups o f cells into the matrigel. Outgrowth o f CTB cells at villous tips was visible in 
92% o f  cultures maintained in standard culture conditions and migration in 94% of 
cultures. Villous outgrowth and migration tended to increase during the culture 
period. These changes described are comparable with other studies that have
demonstrated that culture o f first trimester villous explants on an ECM  resulted in 
CTB proliferation and differentiation and migration o f cells into the suiTOunding 
matrix (Genbacev et al. 1993a; Genbacev et al. 1993b; Genbacev et al. 1993c; 
Caniggia et al. 1997; Aplin et al. 1999).
8 .6 . 2  Comparison of villous explants cultured in normal and low oxygen
conditions
One objective o f this study was to evaluate and characterise explant cultures by semi- 
quantitative analysis o f these morphological changes to allow statistical comparisons 
between explants cultured under different conditions to be made. Explants cultured in 
a low oxygen environment (2 % O2 ) showed similar changes to explants cultured in 
standard conditions. Villous outgrowth and migration was observed in 8 6 % and 8 8 % 
respectively o f  explants o f explants cultured in 2 % oxygen. Statistical analysis 
showed no differences in the number o f sites o f outgrowth or in the migration scores 
in explants cultured in low oxygen condition compared to those cultured in standard 
conditions.
These results contrast with some previous studies that have demonstrated a 
more defined role for oxygen tension in the regulation o f  trophoblast differentiation 
and proliferation in vitro. Genbacev et al. (1997) reported that explants cultured from 
first trimester placentae in an environment o f 2 % oxygen showed more prominent 
outgrowth than in explants cultured in 2 0 % oxygen due to increased proliferation o f 
EVT. Invasion o f CTB into the matrigel was inhibited by exposure to hypoxia.
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Caniggia et al. (2000a) reported that expiants cultured in standard conditions showed 
little outgrowth and migration while those cultured in 3% oxygen showed extensive 
outgrowth but no evidence o f migration o f cells into the matrigel. The increased 
outgrowth in low oxygen conditions was reported to be due to increased proliferation 
rather than migration o f cells. Increased proliferation in first trimester explants in a 
2% oxygen environment was also reported by Huppertz et al. (2003). Genbacev et al. 
(1996) reported that a low oxygen environment induced proliferation and inhibited 
differentiation o f  CTB. These in vitro studies suggest that low oxygen tension 
maintains CTB cells in a highly proliferative, non-invasive state.
The reasons for the lack o f effect o f low oxygen tension on explant outgrowth 
and migration in this current study are not clear. However a number o f  issues may 
have an impact in the comparison o f data between laboratories. M ost notably, there 
was considerable variation with regard to the extent o f outgrowth and migration 
observed in explants cultured in similar environments. Variability in the size of 
villous outgrowth in explants cultured in standard conditions was also described by 
Aplin et al, (1999). Consistent with the present study, they showed that the area of 
outgrowth from an explant varied greatly, mainly depending on the size and number 
o f sites o f origin. The size o f  outgrowth also varied widely between cultures and was 
apparent in different cultures from the same or different placentae. This variability 
may be due to a number o f factors that are difficult to control e.g. size and quality of 
the tissue used for individual explants, the region o f the placenta from which the villi 
are sampled and whether or not the selected tissue contains or has begun to form 
anchoring villi. Aplin also pointed out that CTB proliferation, migration, and 
colonization o f decidua occur in vivo both before and after the oxygen transition 
(Aplin et al. 2000; Pijnenborg et al. 1980; Kaufmann et al. 1997). The findings raise 
the questions o f how morphological changes should be assessed, the appropriate 
number o f explants required per condition and how many placentae should be studied 
for accurate and reproducible data on explant behaviour. Another key issue in in vitro 
culture studies is the validation o f the oxygen levels to which the cultures are exposed 
as discussed in section 8 . 1 .
Processing o f  villous tissue for explant culture, culture medium changes and 
daily microscopic monitoring o f  cultures tissues is usually carried ou t in air, so from 
the time o f delivery o f the placenta to establishment o f cultures in a reduced oxygen 
environment tissues are exposed to atmospheric oxygen. Key events that control CTB
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differentiation may therefore be affected by exposure to high levels o f oxygen before 
the culture conditions are established. Studies by Burton and colleagues suggested 
that first trimester villous tissue are exposed to relatively higher levels o f oxygen and 
oxidative stress than in the in vivo environment as a result o f the collection procedure 
in theatre (Burton et al. 2003). They also showed that the level o f  exposure to oxygen 
and oxidative stress also depends on which area o f the placenta the villous tissue was 
taken from which cannot be deteimined in termination material. Physiological 
adaptations to oxidative stress may pre-dispose expiants to a particular pathway o f 
proliferation or differentiation. In the present study, explants were initially incubated 
in standard culture conditions overnight prior to transfer o f explants to a low oxygen 
environment. Further experiments revealed that the morphological changes seen in 
explants placed directly in a low oxygen environment were similar to those seen in 
explants pre-incubated in standard conditions prior to exposure to low oxygen levels.
8.6.3 C u ltu re  o f CVS explants
W ith regard to the attempt to culture CVS explants, it was hoped that it would be 
possible to study the pregnancies from which these samples were obtained through 
gestation and correlate the outgrowth seen in explant culture with pregnancy outcome. 
Further to this, analysis could be undertaken o f MMP secretion into the culture 
medium from explants cultured in standard and low oxygen conditions.
However almost no outgrowth was observed in any o f the 10 separate CVS 
studied, from which explants were cultured both in normal and in low oxygen tension. 
The CVS obtained were from 10-13 weeks o f gestation while the TOFs used for 
explant culture were from 7-9 weeks o f  gestation. No CVS from earlier in pregnancy 
were available. Wlien a villous explant from a TOP o f the same stage was cultured 
considerably less outgrowth was observed than in the earlier TOPs, suggesting that 
less outgrowth and migration may occur in these later stages o f the first trimester than 
between 7-10 weeks o f  gestation. In addition to the difficulties with the gestations, the 
amount o f villous tissue available from the CVS was very small compared with the 
amount available from the TOP samples. The sampling technique employed in 
obtaining CVS may also damage the tissue. It thus seems likely that explant culture 
with CVS may not be viable in the current situation.
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8.6.4 Conclusions
The development o f  suitable culture models has and will continue to provide tools to 
further enhance our knowledge o f placentation. Although this study does not support 
the findings o f some previous studies on the effects o f oxygen on trophoblast 
differentiation in first trimester explant cultures, a role for oxygen in the regulation o f 
trophoblast differentiation and invasion in normal and pathological pregnancies is not 
excluded. The current study highlights some o f the difficulties that need to be 
addressed, in particular, the importance o f developing protocols to allow comparison 
o f data generated in different laboratories and some o f  the issues in interpreting in 
vitro data.
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Chapter 9: Final Conclusions
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Deficiencies in placentation, in particular in trophoblast invasion and remodelling of 
the maternal spiral arteries, can result in various complications o f pregnancy. Pre­
eclampsia is a common major complication o f human pregnancy and has been studied 
extensively for over 1 0 0  years yet despite this, the fundamental causes o f the disorder 
remain unknown. The generalised maternal endothelial damage characteristic o f the 
disease is thought to be secondary to defective placentation early in pregnancy, 
specifically defective trophoblast invasion and transformation o f the maternal spiral 
arteries. Accumulating evidence supports the hypothesis that pre-eclampsia is a 
complex two-stage process in which defective placentation results in decreased 
placental perfusion, hypoxia/reperfusion injury to the placenta and the secretion o f 
factors into the maternal circulation which result in the clinical presentation o f the 
disease. Further complex feedback interactions cause increasing damage to the 
maternal endothelium.
As discussed in section 1.4, successful placentation and trophoblast invasion 
require regulated secretion o f proteinases, which degrade the ECM  and allow invasion 
to proceed. Several studies have described the importance o f M M Ps in this process, in 
particular the gelatinases MMP-2 and MMP-9. Coupled with the expression o f MMPs 
is the expression o f  their regulatory molecules TIMPs which inhibit the action o f the 
former and the transcription factor HIF which may be responsible for the regulation of 
MMP expression by oxygen tension in the in-u tero environment. Despite the 
evidence for the role o f M MPs and their regulators in placentation, the precise 
temporal and spatial expression o f these molecules is controversial and no reports 
have investigated MMP, TIMP and HIF expression in the same study. One o f the aims 
of this thesis therefore was to study MMP, TIMP and HIF expression in placentae 
throughout gestation using whatever methods were most appropriate.
In section 1.5 the evidence for the role o f oxygen in regulating trophoblast 
invasion is presented. For many years investigators have sought to develop reliable 
models in which to study the effects o f oxygen tension on the parameters of 
trophoblast behaviour and invasion. Several in vitro models o f trophoblast invasion 
are discussed in section 1.3 and the focus o f some o f the work done in this thesis was 
the villous explant culture model developed by Genbacev et al. and widely used by 
many others in recent years. Three aspects o f this model were investigated in the 
course o f the work presented herein; the determination o f the actual oxygen tension 
encountered by cells at the culture interface, the comparison o f  trophoblast behaviour
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in standard compared with low oxygen conditions and the culture o f villous explants 
fi'om CVS.
In vivo studies o f  normal pregnancies in residents at high altitude have also 
allowed study o f the effects o f chronic hypoxia on various parameters o f placentation 
and maternal response (section 1 .6 ). Trophoblast remodelling o f the maternal spiral 
arteries has been reported to be abnormal in high altitude pregnancy and this together 
with the increased incidence o f pre-eclampsia and low birth weight at high altitude 
has led to the speculation that pregnancies at high altitude may be intermediate in 
several aspects between normal pregnancy and pre-eclampsia. The current study 
aimed to compare the concentration o f  CAMs in the maternal circulation as markers 
o f endothelial activation in high and moderate altitude pregnancy. Several CAMs are 
elevated in pre-eclampsia compared to normal pregnancy and other studies have 
shown increased concentrations o f other markers o f endothelial activation in both pre­
eclampsia and high altitude pregnancy. Further to this, immunohistocliemistry was 
used to investigate MMP-9 and MMP-2 expression in term placentae from high, 
moderate and low altitude pregnancy in order to determine whether differential MMP 
expression may be a feature o f placentation in hypoxic conditions.
9.1 M MPs TIMPs and H IF -la
Although a number o f studies have investigated MMP expression at various stages in 
pregnancy, few have compared TIMP and MMP expression in the same study. 
Furthermore, while the transcription factor H IF -la  had been postulated as a regulator 
o f trophoblast invasion and specifically o f MMP-9 expression, few have investigated 
HIF and MMP expression concurrently. Hence this study attempted to provide a 
comprehensive analysis o f the expression and activity o f MMPs and their regulators 
throughout pregnancy.
The results in chapter 3 showed that gelatin zymography was the optimal 
method for determining the activity o f MMPs in placental homogenates. 
Immunohistochemistry was performed to determine in which cells M MP-2, MMP-9, 
TIM P-1, TIMP-2 and H IF - la  were expressed and to semi-quantitatively analyse 
expression o f these proteins from 7-19 weeks o f gestation and at term. The results are 
summarised in table 58.
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Table 58 Summary of MMP, TIMP and HIF analysis
trimester 2"^  trimester Term ZymographicalAnalysis
MMP-9 EVT ^ E V T
Endothelium
(Muscle/Stroma)
Zymography showed 
negative conelation o f 
activity with gestation 
through 1 ®^ trimester 
only
MMP-2 vCTB, EVT, (Stroma)
1 vCTB 
EVT
Endothelium
Endothelium
(Muscle/Stroma)
Zymography showed 
negative correlation o f 
activity with gestation 
through pregnancy and 
activity decreased 
from and from
ist^srd
TIMP-1 EVT, Stroma
ijk Muscle, 
Stroma 
1  EVT
Muscle,
Stroma
TIMP-2
vCTB, EVT, 
(Endothelium, 
Stroma)
. vCTB 
^  EVT
Endothelium
(vCTB), 
Endothelium, 
Muscle, Stroma
H IF -la vCTB, EVT, (Endothelium)
j vCTB 
t  EYX
Endothelium
(vCTB),
Endothelium,
Stroma
Note: W here a cell type is indicated in brackets, only limited staining was present.
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Both immunohistochemistiy and zymography results showed a greater decrease in 
MMP-2 activity with gestation than M MP-9.Immunohistochemical analysis showed 
that MMP-2 was expressed at much higher levels than MMP-9 in the vCTB. vCTB 
expression o f MMP-2 decreased with gestation, as did EVT expression o f both 
proteinases. The expression o f both increased on endothelium and to some extent on 
the villous stroma and muscle surrounding the blood vessels possibly indicating a role 
for M MPs in vascular remodelling and development in the later stages o f pregnancy. 
Expression o f both TIMP molecules on EVT decreased from the first to the third 
trimesters. TIMP-1 increased in muscle and stroma, while TIMP-2 showed a high 
degree o f  co-distribution with MMP-2, declining on vCTB through pregnancy and 
increasing on the endothelium, muscle and stroma. It is possible that the secretion o f 
MMP-2 by vCTB in the first trimester is important in the initial stages o f  placentation 
and is regulated in an autocrine manner by TIMP-2. H IF - la  expression was 
particularly high in the vCTB in the first trimester when no MMP-9 was present in 
these cell types which adds weight to reports by the Caniggia group that MMP-9 
expression is down-regulated by the expression of H IF - la  in response to hypoxia 
early in pregnancy.
The work presented herein is comparable with several published studies as 
discussed previously. Furthermore it proposes a more significant role for MMP-2 in 
placentation than has been suggested in some other studies. Regulation o f expression 
o f MMPs and TIMPs in the EVT and decidua during trophoblast invasion requires 
further investigation in placental bed specimens.
The work herein shows particular similarities to that published by Niu et al. 
(2000) and further to the conclusions presented therein highlights the need to 
investigate the role o f the villous environment in influencing trophoblast behaviour in 
vitro. It would be interesting to determine the secretion profiles o f each o f these 
molecules from cultured trophoblast and from villous explants throughout pregnancy 
to allow comparison between the different culture environments on the secretion of 
these molecules.
The study o f each o f these molecules in pre-eclamptic pregnancy both in vitro 
and in placental sections may also be informative. Pregnancies which end in 
miscarriage may also have defects in trophoblast invasion and immunohistochemical 
study is underway o f MMP expression in these pregnancies.
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9.2 High Altitude Pregnancy
As discussed in section 1.6, high altitude pregnancy has been postulated as a model 
for the development o f pre-eclampsia for several years. Placentas at high altitude are 
subjected to chronic pre-placental hypoxia as opposed to utero-placental or post- 
placental hypoxia, a factor which must be considered when evaluating studies o f this 
type. Various serum markers o f endothelial activation which are increased in the 
disease are also elevated in normal pregnancy at high altitude. Hence the hypothesis 
that CAMs may also be elevated was tested. The hypothesis was not supported and it 
is likely that the increase in CAM concentration in the maternal circulation in pre­
eclampsia is not due to hypoxia per se but rather to a more complex interaction o f  
factors resulting from the oxidative stress in placental tissue in these circumstances. It 
is important to note that hypoxia is not the same as oxidative stress and it may be that 
the hypoxia experienced at high altitude shifts the normal distribution o f  women 
further to the right so that a greater proportion are pre-disposed to the development o f 
pre-eclampsia (figure 68). This may result from reduced trophoblast invasion and 
transformation o f the maternal spiral arteries.
It would be o f interest to determine non-pregnant values o f  circulating CAMs 
at both altitudes to determine if  the reduction in VCAM-1 seen in this study at high 
altitude would also pertain to non-pregnant subjects. Further work is also underway to 
study other markers o f  endothelial activation in the same samples in order to 
determine if  any are altered as a consequence o f hypoxia.
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Figure 68 Proposed model of increased risk of pre-eclampsia in high altitude 
pregnancy
Hypothetical threshold for 
development o f  pre-eclampsia
Low altitude 
pregnancy
High altitude 
pregnancy
Risk of developing disease
The study o f MMP expression in placenta from high altitude provides 
evidence to support the hypothesis that MMP-9 may be differentially regulated in vivo 
in response to hypoxia, a finding which supports previously reported in vitro data on 
MMP-9 regulation by oxygen tension. Particularly interesting was the observation 
that MMP-9 was decreased in the endothelium at high altitude - this may occur in 
response to the lower oxygen in the maternal blood. It is interesting to speculate that a 
similar mechanism may also be responsible for the decreased trophoblast invasion 
seen in normal pregnancies at these altitudes. MMP-2 expression was not altered and 
MMP-9 expression in the stroma was increased suggesting that a variety o f interactive 
factors may be responsible for the final MMP expression and activity present in any 
cell type. Further study to determine MMP expression patterns early in pregnancy at 
high altitude would be o f value.
In conclusion therefore, high altitude pregnancy is providing a novel means o f 
separating the effects o f chronic hypoxia from other more complex issues involved in
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the development o f pre-eclampsia and determining some o f the factors which may 
lead to an increased risk o f  the condition.
9.3 Villous explant culture
The development o f in vitro models to determine the effects o f different oxygen 
concentrations has been important in beginning to understand the processes involved 
in CTB proliferation and differentiation. This aim o f the last section o f this thesis was 
to investigate the widely used villous explant model. Firstly the oxygen concentration 
encountered by the trophoblast cells at the cell culture interface was investigated. The 
findings suggested that the oxygen environment in the incubator is only found in the 
cell culture medium after a time-delay, which is presumably dependent on other 
conditions such as surface to volume ratio. This highlights the need for 
standardisation between different laboratories as to incubation times and measurement 
o f oxygen concentration in the culture medium. Bubbling o f  the culture medium with 
nitrogen gas did reduce oxygen to zero but this reduction was almost completely lost 
during dispensing o f the medium.
Secondly the difference in proliferation and migration between villous 
explants cultured in standard and low oxygen conditions was studied. Previous studies 
have tended to show clear-cut differences between the two conditions. However the 
cuiTcnt study shows a need for caution in interpretation o f results. M any variable 
factors may be responsible for determining the degree o f proliferation/migration in 
any one villous explant. Standardisations between laboratories and investigators may 
help to negate some o f these differences and allow more reliable comparison o f  data.
An attempt to culture CVS villous explants was unsuccessful, possibly due to 
a combination o f  gestation and size o f samples obtained. I f  larger amounts o f villous 
tissue could be obtained from continuing pregnancies earlier in gestation, it would be 
interesting to coiTelate the behaviour o f these explants in various culture conditions 
with the outcome o f pregnancy.
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9.4 Final conclusions
The work in this thesis suggests that the expression o f M MPs and their regulators 
throughout pregnancy require more study before conclusions about the relative 
importance o f  each can be made. The role o f MMP-2 in particular needs to be re­
evaluated. Furthermore the role of autocrine regulation o f these proteinases may be 
important. Accumulating evidence suggests that H IF - la  may be a fundamental 
regulator o f proteinases expression in placental development and this study adds 
further weight to that hypothesis. Elucidating the role o f each o f these individual 
contributors to the complex processes in normal placentation may allow new insights 
to be made into the pathological processes which occur in pre-eclampsia. Only by 
appreciating the normal can we begin to understand the abnonnal.
Models o f placentation and trophoblast invasion have a vital role to play in 
understanding the complexities o f placentation. This thesis has highlighted the care 
required in interpreting results obtained using the villous explant model currently 
favoured by many investigators. Increased standardisation may be required if  results 
between laboratories and between individual experiments are to be comparable. High 
altitude pregnancy as a model for hypoxia in pregnancy and potentially as a model for 
aspects o f the development o f pre-eclampsia is an area which requires further 
validation but whose impact could be significant.
Insights gained from studies o f placental protein expression tlnoughout 
pregnancy and from models o f  placentation and trophoblast invasion will contribute 
to a comprehensive understanding that may ultimately result in improved therapeutic 
interventions in conditions such as pre-eclampsia.
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